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Abstract 
 
Pharmaceutical development and manufacturing of solid dosage forms is witnessing a 
seismic shift in the recent years.  In contrast to the earlier days when drug development 
was empirical, now there is a significant emphasis on a more scientific and structured 
development process, primarily driven by the Quality-by-Design (QbD) initiatives of US 
Food and Drug Administration (US-FDA). Central to such an approach is the enhanced 
understanding of solid materials using the concept of Materials Science Tetrahedron 
(MST) that probes the interplay between four elements, viz., the structure, properties, 
processing, and performance of materials.   In this thesis work, we have investigated the 
relationships between the structure and those properties of pharmaceutical solids that 
influence their processing behavior. In all cases, we have used material-sparing 
approaches to facilitate property assessment using very small sample size of materials, 
which is a pre-requisite in the early stages of drug development when the availability of 
materials, drugs in particular, is limited.   The influence of solid structure, either at the 
molecular or bulk powder levels, on crystal plasticity and powder compaction, powder 
flow, and solid-state amorphization during milling, has been investigated in this study.  
Through such a systematic evaluation, we have captured the involvement of structure-
property correlations within a wide spectrum of relevant processing behaviors of 
pharmaceutical solids.   Such a holistic analysis will be beneficial for addressing both 
regulatory and scientific issues in drug development. 
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Chapter 1. 
 
 
 
Structure-property relationships of solids in 
pharmaceutical processing:  Introduction 
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1.1 Introduction  
The state of formulation development and manufacturing of solid dosage forms is 
witnessing a strategic shift in the recent years.   There is a conscious effort to transform 
the traditional, mostly empirical pharmaceutical development to a more scientific and 
structured process.  Some of the goals of such an effort include streamlined and more 
efficient development steps, minimized risk of batch failure during scale-up, and ensured 
quality built into a drug product at every stage of its manufacture rather than depending 
on quality determination at the end point.   Such a reformed attitude in drug processing 
has, in part, been driven by the Quality-by-Design (QbD) initiatives of US Food and 
Drug Administration (US-FDA).
1, 2
   These efforts are timely and necessitated, especially 
as the drug pipeline is drying up in the recent years, resulting in fewer successful newer 
drug molecule launches, and causing an ever increasing dependence to re-process 
existing molecules into innovative formulations.    
 
Such an approach to drug development involves several key steps, starting with a 
judicious solid form selection
3-5
 with the goal to overcome specific deficiencies in a drug, 
such as poor solubility,
6
 poor physical-chemical stability,
7
 or poor mechanical 
properties.
8
   Once a solid form has been selected, the particulate properties of the drug 
substance may be modified through steps, such as milling to reduce size,
9, 10
 and 
crystallization to modify morphology.
11
   Finally, the drug is formulated with additional 
inert additives and processed through blending, granulation, and powder compaction, to 
manufacture drug products.   At each step, it is essential to correlate the structure and 
properties of the solid materials with their processing performance.  This falls within the 
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scope of an emerging field of research, Pharmaceutical Materials Science.
12
  The ultimate 
goal of such research is to replace product development, enabled through a trial and error 
approach, with that by proper design.   
 
The overall objective of this thesis research work is to correlate the structure of 
molecular organic solids, either in the pure forms or as bulk composites, with the 
properties relevant to their pharmaceutical processing behaviors.   Specifically, the focus 
of this work is on the following aspects of structure-property correlations of solids: 
(a) Relationship between the crystal structure and single crystal mechanical 
 properties, with subsequent impact on bulk powder compaction 
(b)  Relationship of the surface structure of cohesive powders with their flow 
 properties 
(c)  Relationships between the structure of crystals and various aspects of amorphous 
 stability with solid-state amorphization of crystals by milling 
 
Through this work, we have captured the involvement of structure-property 
correlations within a wide spectrum of relevant processing behaviors of pharmaceutical 
solids.   Such a holistic analysis will be beneficial for addressing both regulatory and 
scientific issues in drug development. 
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1.2 Small molecular organic solids  
A significant proportion of pharmaceutical solids, both biologically active drugs and 
inert additives, are small molecular organic materials with molar weights below 1000 
g/mol.   Molecular organic solids can either be crystalline or amorphous, which have 
distinct structures, leading to very different physical-chemical
13, 14
 and mechanical 
properties.
15
   Both crystalline and amorphous solids have important applications in drug 
development.   Crystalline solids are characterized by the presence of three-dimensional 
long range molecular order or periodicity.
16
   Traditionally, crystalline solids have been 
extensively used as drugs due to the advantages in their superior thermodynamic stability, 
normally better chemical stability, and chemical purity.
16
  Crystalline solid forms of a 
drug can either be single component (e.g., polymorphs),
3, 5, 17-19
 or multi component 
systems (e.g., solvates,
20
 hydrates,
21
 salts and cocrystals
22
).    
 
An amorphous solid has higher free energy compared to its crystalline counterparts.
13, 
14, 23
  Contrary to crystals, amorphous lacks the three-dimensional long range molecular 
order, even though, long range order in single dimensions within amorphous glass is 
possible.
24
   The elevated free energy makes the amorphous phase very promising for 
improving the apparent solubility and enhancing the dissolution kinetics of poorly soluble 
drug molecules,
25-28
 which constitute a large fraction of newer drugs due to the greater 
emphasis on biological target-specific lipophilic drug molecules in the recent years.
29, 30
  
Additionally, the random molecular packing in amorphous solids is sometimes also 
advantageous for improving the chemical stability of molecules,
31
 when reactive 
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functional moieties are proximally packed in the crystalline state lowering the chemical 
stability of crystals.
32, 33
   
 
Given the diversity of solid forms of individual drugs, the selection of an optimum 
solid form for drug product development can be daunting, especially if an empirical 
approach is adopted.  On the other hand, it is more efficient if the selection is based on 
well characterized structure-property relationships.   A substantial amount of work has 
already been done to correlate the structure of materials with their physical properties, 
such as solubility and stability, both thermodynamic and chemical.
16
  Factors like the 
strength of lattice packing interactions, enthalpy of fusion, among others, have shown 
promising correlations with the solubility of crystals.
34
  As for physical stability, the 
location of a solid form in the free energy landscape of a material seems to be the major 
determinant.  For instance, the physical stability of different polymorphs of a drug has 
been correlated with their free energy.
17
  Chemical stability is correlated with the packing 
arrangement of reactive functional moieties in a solid.
35
    
 
Such instructive observations support the notion that the material structure directly 
influences its properties.  However, the relationships between the structure of 
pharmaceutical solids and properties relevant to their processing, such as the mechanical 
properties, are still not clearly understood.  Our current work is aimed at addressing this 
specific knowledge deficit in the current state of pharmaceutical drug development for a 
wide range of relevant processes, such as powder compaction, powder flow, and solid-
state crystal → glass transformations by milling. 
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1.3 Materials Science Tetrahedron 
The concept of Materials Science Tetrahedron (MST) is well established in the field 
of materials science,
36
 and routinely applied to metals and ceramics.   According to MST, 
there is significant interplay between four elements of materials, viz., the structure, 
properties, processing, and performance (Figure 1.1).  The application of this concept to 
pharmaceutical materials, however, is relatively new.   The key aspect of MST, relevant 
to this research work, is the structure-property relationship of materials.  A clear 
understanding of this fundamental relationship allows us to adopt optimized processing 
steps to alter the material properties to address performance related problems in 
pharmaceutical manufacture. 
 
 
 
 
 
 
 
 
 
Figure 1.1.  The interplay between structure, properties, processing and performance of 
materials forms the basis of Materials Science Tetrahedron (MST) 
 
The structure-property correlation in the MST framework can be applied at different 
levels, starting from the molecular, to solid particles (crystalline or amorphous), granular 
and bulk powders.  The various structures and properties of interest in pharmaceutical 
solid processing are described below: 
 
Performance 
Structure 
Properties 
Processing 
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Structure: Crystal structure and bonding strength, bonding patterns, amorphous 
 structure (e.g., the surface versus bulk structure of glasses), surface structure of 
 powders, granule structure, tablet structure (e.g., porosity), and chemical 
 composition of molecules. 
Properties from a processing viewpoint:  Mechanical properties (elasticity, plasticity, 
 fragmentation), particulate properties, surface properties, powder tabletability, 
 powder flow and cohesion, and amorphization potential 
 
Even though the terminology of MST is relatively new to pharmaceutical scientists, 
the application of this concept is not.  For instance, a clear correlation was found between 
the chain length of a benzoic acid ester homologous series and the mechanical properties 
of corresponding powders in 1990s.
37, 38
  Around a similar timeframe, investigators 
started to probe the relationship between the mechanical properties with other intrinsic 
properties of drugs, such as their cohesive energy density.
39-42
  Additionally, correlations 
were observed between properties, such as the particle size and surface roughness,
43
 
moisture content,
44
 and crystal brittleness,
45, 46
 with compaction behavior of powders (a 
processing parameter). However, most of these earlier attempts have had limited 
industrial applicability in actual drug development.  A primary reason for this was the 
requirement of a large amount of material to establish such correlations.  In addition, 
often the experimental design for such structure-property correlation studies lacked 
practicality.  For instance, the Hiestand indices, a common set of descriptors to describe  
powder compaction, required specialized equipment to prepare unique shaped donut 
tablets to assess mechanical properties.
46
  In light of these drawbacks, the way forward 
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for pharmaceutical MST is to identify material-sparing approaches that can assess the 
structure-property correlations of pharmaceutical solids with very limited amount of 
sample and using relatively simple experimental design. The knowledge gained through 
such an assessment can be used to design novel functional materials with tailored 
properties and superior processing behavior. 
 
1.4 Incorporating material-sparing approaches within MST framework  
Earlier efforts of building MST correlations have often been limited by the elaborate 
sample size requirements.  To make the MST application more appealing to drug 
development, the requirement of large sample size, or complex sample preparation steps 
must be eliminated.  This is particularly true during the early formulation development 
stages of a new drug, when the average amount of available drug is often less than 5g.  
Therefore, formulations must be developed on a small scale under the constraint of small 
sample size, which will subsequently be tested for their robustness during scale-up when 
more material is available.  The importance of developing the best possible small scale 
formulations cannot be over-emphasized, as any scale-up failure leads to financial losses 
for the industry, in addition to unmet deadlines both in terms of patient administration 
during clinical trials, or delays in filing for regulatory approval.   
 
Therefore, suitable material characterization tools must be identified that can test and 
predict the large-scale processing performance of pharmaceutical solids, using very small 
sample size and preferentially in a non-destructive manner.  Thus, the use of material-
sparing characterization tools is at the heart of the effective implementation of the MST 
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principles in the pharmaceutical industry (Figure 1.2).   Such tools are also necessary to 
address the high attrition rates of new pharmaceutical molecules.   In this thesis work, 
several material-sparing tools have been utilized, tailored to test specific processing-
related properties.  For mechanical properties, we rely on nanoindentation for 
determining single crystal mechanical properties, and powder compaction simulation for 
bulk powder mechanical properties.  Our goal is to correlate single crystal mechanics 
with bulk powder compaction performance, using less than ~2g of material in total.  For 
characterizing powder flow, we utilize shear cell analysis, which is non-destructive to the 
sample, with typical sample weight requirement of less than ~300mg. For solid-state 
amorphization studies, we use a combination of calorimetry and diffractometry 
techniques as the material-sparing tools to predict amorphization potential of crystals.  In 
this case, the sample requirement is less than ~50 mg.  Therefore, all our studies have 
been consistent with the material-sparing approach that we think is critical in this age of 
drug development. 
 
 
 
 
 
 
 
Figure 1.2.  Role of material-sparing characterization tools within the Materials Science 
Tetrahedron framework. 
 
 
Properties 
Processing 
Characterization 
Performance 
Structure 
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1.5 Structure-property relationships 
As mentioned earlier, in this work, we will evaluate the influence of structure-property 
relationships on three key processing behaviors of materials.    
(a) Powder compaction 
(b) Powder flow 
(c) Mechanical amorphization of crystals during milling 
All three factors are intricately involved in the development of solid dosage forms.    
 
1.5.1. Relationship of structure, plasticity and compaction 
Understanding the relationship between crystal packing and the mechanical properties 
of organic crystalline solids is a topic of considerable interest in the fields of solid–state 
chemistry and crystal engineering.
47-52
   The net mechanical strength of tablets depends 
largely on the contact bonding area between particles that is created by powder 
compaction.  During powder compaction, inter–particulate bonding area develops as a 
result of particle rearrangement and their mechanical deformations under stress.
53
   
However, compacts can retain full integrity only if an adequate amount of the inter–
particulate bonding area, thus created, is preserved once the compaction pressure is 
withdrawn during the decompression cycle.   
 
Powder compaction depends on the mechanical deformations of solids.  Mechanical 
deformations have been extensively investigated for inorganic materials, such as metallic 
crystals and glasses.
54-56
    However, such investigations on organic molecular materials 
are relatively few.  The key deformation mechanisms include elastic, plastic, viscoelastic 
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deformation, and fragmentation.  Most pharmaceutical solids are viscoelastic, with both 
elastic and plastic behaviors depending on the strain levels.  The mechanical performance 
of their bulk powders are determined by the relative predominance of elastic and plastic 
deformation components.
54, 57
     Elasticity of a material is its ability to undergo reversible 
deformation under an externally applied stress, such that once the external stress is 
removed, the particles undergo complete recovery and the deformation does not persist.  
Typically, elastic deformations take place in the regime of small displacements under low 
stresses.   For perfect elastically deforming materials (e.g., rubber particles), the contact 
area between particles retained after stress removal during decompression is negligible, 
and these materials, therefore, cannot be made into intact tablets.  For this reason, 
materials with high elasticity, e.g., acetaminophen,
58
 have poor powder compaction 
properties.   Strategies for addressing poor compaction properties of these elastic crystals 
include surface coating with a plastic material to intentionally reduce the elastic response 
of the resultant composite,
59
 and modification of solid–state chemistry to confer adequate 
plasticity for bonding area retention.
50, 60
    
 
The permanent plastic deformation is necessary for sufficient contact area retention 
during decompression phase of powder compaction.  It is a prerequisite for forming intact 
tablets by powder compaction.
53
    Using polymorphs, which are different crystalline 
phases of the same molecule, it has been shown that plasticity depends on crystal packing 
and higher plasticity generally leads to superior compaction properties.
47, 61, 62
   
Recognized mechanisms that promote crystal plasticity include slip of lattice planes,
63, 64
 
dislocation motion,
54, 65
 lattice twinning,
54, 66
 kinking
67
 and perturbation of lattice 
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stability.
54
   Of these mechanisms, the presence of slip planes and twinning are perhaps 
the leading contributors of crystal plasticity of organic materials.    
 
In the slip mechanism, plasticity arises from the motion of dislocations (linear crystal 
defects) through preferential planes in crystals known as slip planes.  The principal slip 
planes are crystallographic planes that have the weakest inter-planar interactions in a 
given crystal. They generally are associated with the highest molecular density and the 
largest separation between adjacent planes.
68
  The presence of flat, un-corrugated slip 
planes in crystals has been used to successfully guide plasticity enhancement, which then 
results in better tabletability of materials.   This has been illustrated with materials, such 
as sulfamerazine and acetaminophen, where the polymorphs with flat slip layers 
(polymorph I in case of sulfamerazine and polymorph II in case of acetaminophen) favor 
compaction.
12
  In the twinning mechanism, successive slip planes are displaced about a 
mirror plane (the twin plane).   This causes the lattice portions above and below the twin 
plane to be mirror images of each other.
69
  Twinning has been shown to cause plasticity 
enhancement of organic materials, such as L-lysine monohydrochloride dihydrate.
69
    
 
In addition to plasticity, fragmentation is another irreversible deformation 
mechanism, where the material structure fails under stress because of the inability to 
accommodate further strains.  The particles formed as a result of brittle fragmentation can 
show two types of behaviors. The fragmented particles can either deform elastically or 
plastically under stress.  Fragments undergoing plastic deformation will lead to improved 
powder compaction. 
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For viscoelastic materials, the mechanical properties that show promising correlations 
with bulk powder tabletability are crystal hardness and elastic modulus.  Crystal hardness 
is a measure of plasticity, a lower value indicating higher plasticity.   Elastic modulus is a 
measure of elastic deformation in materials, a lower modulus indicating higher elasticity 
and stronger bonding.   Higher elasticity, tends to deteriorate tabletability and increase 
lamination tendency on decompression of tablets due to higher elastic recovery.  The 
impact of material hardness on compaction can, however, be complicated.
70
   At very 
high hardness, compaction properties are very poor due to very low plastic deformation 
in materials, leading to little generation of bonding area by compaction.   Similarly, 
materials with very low hardness, also do not necessarily favor compaction, as the 
materials do not impart adequate strength to the tablet matrix.  The best compaction 
profiles are observed in materials with intermediate hardness values (Figure 1.3).
70
    
 
 
 
 
 
 
 
Figure 1.3.  Correlating powder compaction behavior with particle hardness measured by 
Atomic Force Microscopy 
70
 
 
An example to illustrate the importance of flat slip layers to promote material 
plasticity, and hence powder tabletability, is that of acetaminophen. Polymorph I of this 
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molecule has corrugated crystal packing with poor powder compaction properties.  When 
the same molecules are packed into flat layers in polymorph II, the compaction properties 
are significantly enhanced.  This introduction of flat slip layers into a crystal can be 
achieved by forming different polymorph,
12
 cocrystals
71
 and salts.
72
  Figure 1.4 compares 
the compaction properties of Form I acetaminophen with its ionized salt, acetaminophen 
hydrochloride monohydrate.
72
   The ionized form, due to layered packing, shows 
significantly improved tabletability originating from better plasticity of this form.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.   (A) Crystal packing in acetaminophen polymorph I is corrugated, 
herringbone;  (B) Crystal packing in ionized salt of acetaminophen is flat layered; and 
(C)  comparison of compaction properties of the two forms.  The layered structure shows 
much better tabletability
72
 
A 
  
B 
 
C 
Salt with layered 
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Figure 1.5 summarizes the three-level interaction between material structure, 
fundamental mechanical properties (hardness and modulus), and bulk powder compaction 
of materials.   We have probed such correlations in Chapters 2 and 3 of this thesis.    
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. The three-levels of association between crystal structure, crystal mechanics, 
and powder compaction behavior. Three types of powder compaction plots, viz., 
tabletability, compressibility, and compactibility, describe different aspects of powder 
compaction. Tabletability describes the dependence of tablet tensile strength (a property) 
on compaction pressure (a process parameter).  Compressibility describes the dependence 
of tablet porosity (tablet structure) on compaction pressure (a process parameter).   
Compactibility describes the dependence of tensile strength (a tablet property) on 
porosity (tablet structure).   
 
 
1.5.2 Role of surface structure in powder flow 
The next aspect of processing, we are interested in, is powder flow.  Powder flow 
impacts several pharmaceutical unit operations, such as powder compaction, capsule 
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filling, granulation, and blending.  The physics of powder flow involves the interplay 
between two universal forces, inter-particle cohesion (which is mainly van der Waals 
bond) and gravitational force (Figure 1.6).
73-75
  While gravity favors powder flow, 
cohesive force hinders flow by creating inter-particle attraction.  As long as gravity can 
dominate over cohesion, powder flow is spontaneous and generally non-problematic.   
Gravity typically can dominate over cohesion till approximately a critical average particle 
size of ~30 μ.  Powder flow becomes a major issue when cohesion starts dominating over 
gravity.  For this reason, powders constituted of particles < 30 m are very cohesive and 
generally problematic during processing.  The main concerns with poor powder flow 
properties in pharmaceutical manufacturing include highly variable tablet weight, powder 
segregation, and problematic capsule filling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6.  Relative predominance of gravity and cohesion at different particle size 
levels.   The flow problem regime is indicated by dotted box.  The graph is not to scale.   
 
 
20 – 30 μm
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The conventional way to address the flow problem in the pharmaceutical industry is 
to granulate the powders to increase particle size.   However, the size enlargement by 
granulation can often be extremely detrimental to the compaction properties of materials, 
as shown in Figure 1.7 for Avicel PH 101, a phenomenon known as over-granulation that 
is caused by a significant increase in median particle diameter.
76
    
 
                   
 
Figure 1.7.   Negative impact of size enlargement through granulation on powder 
tabletability
76
 
 
Several literature reports have instead suggested using an alternate route to enhance 
powder flow by surface modification of cohesive powders without increasing the particle 
size.   This surface modification concept is based on manipulating the level of cohesive 
interactions, using an understanding of the structural factors affecting powder flow.    
According to Hamaker’s theory,77 the cohesive interaction (F) between adjacent particles 
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(van der Waals interactions), which will limit flow, is inversely proportional to the square 
of their distance of separation, as shown in equation 1.   
 
 
          (1) 
 
Where, A is Hamaker’s constant, D1 and D2 are particle diameters, and d is the distance 
of separation between particle surfaces.  If we assume that the two host particles have 
equal diameters, then the cohesion between adjacent host particles is given by the 
simplified equation 2.
74
 
          (2) 
 
The inverse dependence of cohesion on interparticlulate separation distance suggests 
that, if this separation at the surface can be increased by some physical means, it is 
possible to reduce cohesion and improve powder flow.  The involvement of surface 
structure in powder flow is implicated, for example, in the work of Yang et al,
78
 who 
have shown that the flow properties of cornstarch can be improved significantly by 
coating with silica particles using mechanical coating processes such as magnetic-assisted 
impaction coating (MAIC)  and hybridizer process.
79, 80
   Similarly, by dry coating using 
a plasma downstream reactor, the flow of cohesive lactose particles (d ~ 30.9 m) is 
increased by a factor of 3.1.
73
  Likewise, the flow characteristics of cohesive lactose 
monohydrate powder are modified by intensive dry-coating with magnesium stearate and 
fumed silica through mechanofusion.
81, 82
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All these cases depend on increasing the inter-particle separation in equation 2 to 
overcome flow related problems.  The coating particles act as spacers to increase inter-
substrate separation, thereby reducing cohesion. These illustrate an application of the 
MST principles at the level of powder composite, distinct from the level of single crystals 
in the earlier discussion with powder compaction.  We have probed such structure-
property correlation, related to flow, in Chapter 3 of this thesis by exploring the utility of 
shearing stress to enhance the flow properties of a cohesive cellulose powder. 
 
1.5.3 Solid-state amorphization of crystals 
The final aspects of this thesis (Chapters 5-8) are related to another critical processing 
behavior of crystals, their propensity to undergo processing-induced phase amorphization 
during milling.   Solid-state amorphization of crystals under mechanical stress is a 
transformation from a crystal directly into the higher energy amorphous form, when 
materials are subjected to operations such as milling.
83-86
  Milling-induced amorphization 
has been extensively probed for non-pharmaceutical crystals, such as metal alloys, 
intermetallics, semi-conductors and minerals.
83
  Amorphization in pharmaceutical 
organic crystals has also been observed in several materials, such as indomethacin,
87
 
griseofulvin,
85, 88, 89
 trehalose,
90
 and felodipine.
85
   Any solid-state phase transformation in 
pharmaceutical materials during processing can have serious consequences on drug 
product performance, such as their physicochemical stability, solubility, dissolution 
kinetics, and product appearance,
21, 91
 which are of concern both from product quality and 
regulatory viewpoint.
91, 92
   Preserving the selected solid form of a material during various 
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stages of development and manufacture is critical for ensuring consistent product 
performance and quality.   
 
The amorphous phase of a material can either be generated intentionally or 
unintentionally.  Often, a drug may be intentionally formulated as amorphous due to its 
higher apparent solubility and faster dissolution kinetics compared to corresponding 
crystalline form, with the goal of improving the drug bioavailability
93, 94
   However, since 
the higher solubility is a result of higher free energy of the amorphous solid,
95
 
stabilization strategies must be employed to minimize recrystallization of the amorphous 
phase with time, for instance by using crystallization inhibitors.
93
   When amorphous 
generation is unintentional (e.g., under processing stress), then faster crystallization back 
to the stable form will be the preferred option before the subsequent processing step.     
 
In this work, we have termed the ability of preparing an amorphous phase from a 
crystalline solid as the amorphization potential of the material.  The true mechanism of 
milling-induced amorphization has been under speculation for a long time.
86, 96-98
   Early 
literature suggested localized melt-quenching at the vicinity of the milling, due to 
temperature rise by impact stress, as a possible mechanism for amorphization during 
milling.   However, this mechanism of localized melt-quenching was potentially 
invalidated by the observation of amorphization occurring even under cryogenic milling 
conditions (T<<Tg), where the localized temperature rise is minimum, and insufficient to 
melt the materials due to the liquid nitrogen environment.   Additional results from 
milling experiments on lactose anhydrate were very insightful in abolishing the 
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localized melt-quenching hypothesis during milling.
99
   By using 
13
C-NMR, it was shown 
that pure -anomeric form of lactose existed in the amorphous phase, when created by 
ball milling under a dry nitrogen environment   However, glass generated by any route 
involving a liquid intermediate (such as, melt-quenching, lyophilization or spray drying) 
led to lactose mutarotation, and an equimolar amorphous mixture of  lactose was 
generated.   This shows that milling-induced amorphization purely occurs in the solid-
state that does not involve any liquid intermediate, and is a direct crystal to glass 
transformation. 
 
While making form selection of a drug, a fundamental difficulty in the 
pharmaceutical industry has been the inability to predict a priori whether the drug would 
be a good candidate to develop the amorphous form, by performing a simple assessment 
of its material properties.   Drugs displaying higher amorphization potential during early 
assessment might be superior candidates to develop amorphous drug products.  On the 
contrary, these candidates will also likely create greater challenges if the crystalline form 
is selected for drug development, due to the propensity to undergo processing-induced 
solid-state amorphization during operations such as milling and powder compaction.
100-
102
   
 
In both scenarios, the question at hand is which crystalline materials will undergo 
easy conversion to the amorphous phase.   Unlike some other processing properties that 
we already discussed here, e.g., powder compaction, there is dearth of experimental data 
on the relationship between the structure and the amorphization tendency for molecular 
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organic crystals.  The involvement of crystal lattice structure in amorphization is 
indicated in mathematical theories on the physical mechanism of solid-state 
amorphization, such as the violation of the stability criterion of crystal lattice due to 
anharmonicity of lattice vibrations under mechanical stress,
103, 104
 and the progressive 
generation of crystal dislocations leading to the loss of crystalline order.
86, 102, 105
   
However, very few experimental studies have clearly established that the strength of 
crystal lattice of the starting material influences the amorphization potential.  Crowley 
and Zografi
87
 evaluated the amorphous generation on milling of three indomethacin 
polymorphs and solvates, and showed significant differences in amorphization of the 
various phases.  But no correlation of amorphization with lattice strength of various 
crystalline forms was attempted in that study.  Patterson et al
106
 ball milled 
carbamazepine polymorphs (forms I and III) and found that form I is susceptible to solid-
state transformations during milling, while form III is not.   In polymorph I, molecules 
exist in planar arrangement through the formation of intermolecular hydrogen bonds with 
neighbors.    However, in form III, both inter- and intra-molecular hydrogen bonds are 
formed and dimerization of molecules occurs.   This qualitatively suggests that stronger 
lattice packing can lead to higher resistance to solid-state phase transformations.    
 
In addition to crystal lattice strength, there is one additional aspect in solid-state 
amorphization, i.e., the recrystallization tendency of the amorphous generated by milling.  
Recrystallization will limit the extent of amorphization under processing stress.   The 
impact of amorphous stability, hence recrystallization, on solid-state amorphization has 
been indicated, for instance, by showing that glass transition temperature (Tg) can 
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influence amorphization,
107
 especially in relation to the milling temperature.
100
  For the 
same crystal, milling at temperatures above Tg reduces the amorphization potential, 
compared to when milled below Tg, perhaps due to different amorphous crystallization 
kinetics above and below Tg.  However, as Tg does not necessarily correlate with the 
crystallization tendency of a material, it is hard to imagine that Tg will play a consistent 
role in amorphization when a large number of model compounds are studied.  These 
theoretical and experimental studies indicate that solid-state amorphization of crystals, 
which involves a direct crystal to glass conversion,
108
 is concurrently influenced by two 
sets of factors (Figure 1.8):  
1) Conversion from crystal to amorphous (c→a phase transformation), and  
2) Recrystallization from amorphous to crystal (a→c recrystallization) 
 
 
 
 
 
Figure 1.8.  Schematic illustrating the concurrent effects of crystal lattice strength (LS) 
and amorphous stability (AS) on amorphous generation and elimination, respectively 
 
 
While c→a conversion is expected to depend on crystal structure and crystal lattice 
strength, the a→c conversion depends on recrystallization kinetics and amorphous 
stability of the materials. Therefore, to properly characterize milling-induced 
amorphization, it is necessary to study both factors, which is the focus of chapters 5 and 6 
in this thesis.  In this work, we will systematically investigate the involvement of both 
Influenced by AS
Amorphous
phase
Crystal
Influenced by LS
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crystal structure and amorphous stability of materials in an attempt to better understand 
the structure-property relationships for solid-state amorphization of crystals. 
 
1.6 Crystal and particle engineering  
The application of MST principles should not end simply at the stage of 
understanding the relationships between structure and properties of materials.   The next 
step is to use such knowledge to design and innovate functional materials, with tailored 
properties, by modifying the material structure, once the correlation between structure 
and property is clearly established.
109
   There are broadly two approaches to do this, 
depending on the level at which MST principles are being applied.   If we are interested 
in pure solid form, for instance, a crystalline form, then rational modification of crystal 
packing, either by preserving the chemical composition (e.g., polymorphs) or through 
introduction of additional components in the lattice (e.g., salts, cocrystals, solvates and 
hydrates) is a well tested method to alter material properties.   These approaches fall 
within the scope of crystal engineering.   However, when the MST principles are being 
applied at the bulk powder level, then particulate properties, e.g. morphology, size or 
surface structure, can be manipulated to alter manufacturing performance of materials.  
This latter approach is referred to as particle engineering.  We have already provided an 
example of particle engineering in this discussion, where powder flow is shown to 
improve by coating particle surfaces with dry silica nanoparticles. 
 
Crystal engineering approaches to modify processing behavior of solids is now 
receiving much attention.  The effects of different crystalline solid forms of a material, 
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such as, polymorphs, solvates, salts and cocrystals, on their processing behavior are of 
practical interest both from the development and regulatory viewpoint.  The effect of 
cocrystallization, for instance, on crystal mechanical properties has been studied by 
multiple research groups.
71, 110
   In one of the earlier studies on this topic, the mechanical 
properties of caffeine, a drug with poor compaction properties, were significantly 
enhanced by cocrystallization with coformer methyl gallate.
110
  This cocrystallization 
step introduced flat slip planes in the crystal lattice that promoted the plasticity of the 
material.   Similarly, other solid forms of materials, such as salts, can also lead to 
improved processing of pharmaceutical powders.
72
    
 
Engineering new solid structures to modify their processing performance is an 
attractive option because it allows drug manufacturers an opportunity to tackle the issue 
of patent expiry of blockbuster drug molecules.  A different solid form of the same drug, 
which shows acceptable efficacy and toxicological profiles, can be patented and new 
drug formulations prepared.   With this consideration, in this thesis work, wherever 
appropriate, we have designed new crystal forms of materials to address a processing-
related issue (Chapters 2, 3 and 7).  These attempts also serve to test the structure-
property relationships for various processing behaviors of pharmaceutical solids. 
 
1.7 Thesis organization and hypotheses 
Chapter 2 
The objective of the study in chapter 2 is to provide a mechanistic understanding of the 
relationship between the crystal packing, crystal plasticity, and bulk powder compaction 
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of theophylline, methyl gallate, and their 1:1 cocrystal.   This is the first instance where 
we demonstrated that cocrystallization can, in fact, deteriorate the compaction properties 
of a drug.  We have shown that theophylline anhydrate displays exceptional tabletability 
that is compromised on cocrystal formation due to reduced plasticity corresponding to 
changes in crystal packing. 
 
Hypothesis 1:  Bulk powder tabletability is directly proportional to the plasticity of 
corresponding single crystals 
Hypothesis 2:  Cocrystallization either improves or deteriorates the compaction 
properties of materials, depending on the extent of plastic deformation afforded by 
the crystal packing. 
 
Chapter 3 
In chapter 3, the molecular origin of deteriorated plasticity on cocrystallization of 
molecular organic materials is investigated using nanoindentation.   Using this technique, 
a thorough analysis of the mechanical property landscape of the model system of -
piroxicam, methyl gallate, and their 1:1 cocrystal has been performed.  Nanoindentation 
is an ideally suited material-sparing tool for probing the correlations between crystal 
mechanical properties with bulk powder performance.   The hypotheses of this chapter 
are the same as in chapter 2. 
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Chapter 4 
In chapter 4, we apply the structure-property relationships at the level of bulk powder 
composites to improve the flow properties of poorly flowing, cohesive solids.  By using a 
comilling technique of dry surface nanocoating with silica particles (loading <1.0 wt%), 
we are able to reduce the cohesion of cohesive substrate particles and improve the flow 
factor by almost 5 fold.  Such an approach is attractive because it holds the potential to 
transform poorly flowing materials into direct compression enabled formulations, thereby 
reducing the operating steps and minimizing the number of additional excipients in a 
formulation.   
 
Hypothesis:  Flow properties of cohesive fine particle solids are enhanced when their 
surfaces are dry coated with nanoparticles, which allow increased physical separation 
among adjacent substrates reducing the inter-particulate cohesion. 
 
Chapter 5 
From chapter 5 onwards, the thesis focuses on solid-state amorphization of crystals 
under milling-induced stresses. The extent of solid-state amorphization of crystals, 
contrary to other amorphization routes involving fluid intermediates, is dependent on 
both the lattice strength of the starting crystal and the stability of the generated 
amorphous phase.  In chapter 5, we have investigated the concurrent influence of crystal 
lattice strength and amorphous stability on the rate and extent of amorphization of 
crystals using a large number of model compounds.   Based on such information, an 
amorphization classification map has been developed with drugs categorized into four 
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classes.  Class I materials, with the strongest crystal lattice and very unstable amorphous 
phase, are the best suited for developing the crystalline solid form.   Class IV crystals, 
with the ability to easily convert into kinetically stable amorphous phase within 
timescales of pharmaceutical interest, will be the best suited to develop amorphous drug 
products.   
 
Hypothesis:  The ability of a crystal to amorphize under mechanical stress is inversely 
proportional to its crystal lattice strength, and directly proportional to the stability of 
the corresponding amorphous glass  
 
Chapter 6 
In chapter 6, we have probed the influence of molecular weight of materials on their 
amorphization potential, where low molecular weight materials have lower 
amorphization tendency.  Using calorimetry-based thermodynamic calculations on 
molecular configurations and mobility, we have further correlated the molecular weight 
of compounds with their configurational entropy (i.e., flexibility in the disordered phase), 
which is then correlated to molecular mobility and recrystallization tendency.   Further, 
by fixing the molecular weight using polymorphs of same molecules, we have shown that 
for the same molecular weight, crystal packing difference leads to different 
amorphization propensity, especially when molecular weight is in the intermediate range. 
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Hypothesis 1:   Higher molecular weight materials are easier to amorphize due to 
slower recrystallization, attributed to a larger number of molecular configurations in 
the disordered phase that kinetically slow down the crystallization process  
Hypothesis 2:  For the same molecule, different crystal packing of polymorphs leads 
to different amorphization potential. 
 
 
Chapter 7 
In chapter 7, based on the structure-amorphization correlations established in chapters 5 
and 6, we have employed crystal engineering via cocrystallization to modify the 
amorphization potential of a model drug, sulfamethazine.   Here, we observe that both 
crystal lattice strength as well as the amorphous stability of the cocrystals must be 
considered while attempting to interpret the influence of changing crystal packing on the 
amorphization tendency of a crystal.    
 
Hypothesis:  Forming cocrystals of drugs can either improve or deteriorate the 
amorphization potential of crystals, depending on the relative contributions of crystal 
lattice strength and amorphous stability in the cocrystals 
 
Chapter 8. 
In chapter 8, we focus on how the surface structure of the amorphous glass can influence 
its crystallization behaviors under non-isothermal conditions.   Amorphous glass 
generated by milling can show two modes of crystallization:  unimodal and bimodal.   In 
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this work, we probe the factors, such as faster surface mobility and the presence of seed 
nuclei on the manifestation of different modes of non-isothermal crystallization. 
 
Hypothesis 1:   Faster surface crystallization of glass below Tg leads to the appearance 
of bimodal crystallization events under non-isothermal conditions. 
Hypothesis 2:   It is possible to flip the crystallization modes of glasses by altering 
crystallization kinetic factors, such as heating rate, surface area, and seed 
concentration. 
 
1.8 Conclusions 
With the advent of more stringent guidelines governing pharmaceutical drug 
development and manufacture, the principles of Materials Science Tetrahedron are 
invaluable to pharmaceutical development scientists.   Our focus is primarily on the 
structure-property relationships of pharmaceutical materials, both crystalline and 
amorphous solids, to modulate their processing behaviors.   Such an understanding is the 
stepping stone towards designing functional materials with tailored processing behaviors.  
We have focused in this dissertation on three aspects of processing of crystals, viz., 
powder compaction, powder flow, and amorphization during milling.  For each of these 
key parameters, we have probed the relationships between material structure and 
properties, such as, plasticity, elasticity, flow, lattice strength, and amorphous stability.   
A holistic and systematic study of these parameters is expected to benefit the drug 
development process well into the future. 
 
  31 
Chapter 2. 
 
 
Cocrystallization-induced decline in plasticity and powder 
compaction:  Part 1.   Crystal structure contributions  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based on the following published research article: Chattoraj et al., 
Crystal Engineering Communications, 12, 2466–2472, 2010.  
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The purpose of this study was to probe the effect of changing crystal structure of drugs by 
co-crystallization, on their plasticity and powder compaction.   For the model system of 
1:1 cocrystal formed between theophylline and methyl gallate, significant deterioration in 
powder compaction is observed relative to the parent drug, theophylline, even though 
compaction is improved compared to the other co-former, methyl gallate.  We 
demonstrate that these differences in the bulk powder compaction originate from 
different crystal plasticity of the materials, probed with single crystal nanoindentation.   
The rank orders of bulk powder compaction and single crystal plasticity are identical in 
this case:  theophylline > cocrystal >> methyl gallate.  Unique molecular packing features 
in the respective crystal lattices drive the plasticity differences.  The presence of an 
extremely dense three-dimensional hydrogen bonded network structure lowers the plastic 
deformation in methyl gallate crystal, leading to its poor compaction.  In contrast, the 
cocrystal exhibits a two-dimensional hydrogen bonded layered structure, which improves 
its plasticity and compaction properties relative to methyl gallate by facilitating slip.  
Theophylline undergoes the highest plastic deformation (indicated by the lowest crystal 
hardness), due to multiple slip layers conferred by hydrogen bonded columns.  The 
extremely high plasticity of theophylline is essentially insensitive to significant alteration 
in particle morphology or size distribution. This work clearly demonstrates the 
relationship between structure, plasticity and powder compaction for organic molecular 
solids, consistent with the principles of Materials Science Tetrahedron. 
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2.1 INTRODUCTION 
 Organic crystals can be readily modified through crystal engineering to address 
key challenges in the formulation and manufacture of drugs, such as low solubility and 
dissolution rate,
1, 2
 physicochemical instability,
3
 and poor tablet compaction.
4, 5
  In 
addition to the more traditional crystal engineering approaches, such as salts, polymorphs 
and solvates,
6
 cocrystallization has shown considerable promise in overcoming many 
processing deficiencies in drug molecules.
3, 4, 7-9
   Cocrystals are solid phases where two 
or more non-volatile components crystallize in stoichiometric ratios within the same 
crystal lattice, and may be distinguished from salts in having at least one of the 
components neutral, irrespective of the temperature.  Using a wide range of structurally 
diverse co-former molecules, cocrystallization can significantly improve the probability 
of successful solid form selection of drugs with desired solid-state properties.
3, 10, 11
  
 
Understanding the relationship between crystal structure and material properties is 
important for the effective application of crystal engineering to attain the desired product 
performance.
3, 8
  In this work, we have examined the relationship between crystal 
structure, crystal plasticity, and powder compaction behavior.  Plasticity is the ability of a 
material to undergo permanent, irreversible deformation upon the application of stress, 
and is one of the most critical material properties that directly influences powder 
tabletability.
12, 13
  Plasticity is affected by several features of crystal packing, such as 
slip,
4, 14
 dislocation motion,
15, 16
 twinning,
16, 17
 kinking,
18
 and perturbation of lattice 
stability.
16
  Motion of dislocations along specific slip planes leads to crystal plasticity. 
Slip planes are crystallographic planes that have the weakest inter-planar interactions in a 
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given crystal,  and are associated with the highest molecular density and the largest 
separation between adjacent planes.
19
  Thus, introducing more slip planes in a crystal is a 
valid strategy for plasticity enhancement, which facilitates the compaction of powders 
with poor tabletability.
4, 5
   
 
However, in the current work, we have found that forming cocrystals between 
theophylline anhydrate (Figure 2.1a) and methyl gallate (Figure 2.1b) can not only 
improve the plasticity and tabletability of methyl gallate, but also significantly 
compromise that of theophylline. To our knowledge, this is the first report where 
cocrystallization has resulted in deterioration of the tableting behavior of a material. 
Thus, this model system provides an opportunity to holistically examine the effects of 
cocrystallization on crystal mechanical properties.  Further, using this system, we can get 
a more clear insight into how a crystal’s mechanical properties such as plasticity and 
tabletability get influenced by changes in crystal packing features. 
 
 
   
 
 
 
 
 
 
   (a)                 (b) 
 
Figure 2.1. Molecular structures of (a) theophylline anhydrate and (b) methyl gallate 
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2.2 MATERIALS AND METHODS 
2.2.1 Preparation of bulk cocrystal powder 
Bulk powder of the 1:1 cocrystal between theophylline (purity > 99%, Acros 
Organics, NJ) and methyl gallate (purity > 98%, Fluka Chemicals Corp., Milwaukee, WI) 
was prepared by solvent mediated transformation in ethanol, using controlled slurry 
agitation.  Theophylline (5.04 g) and methyl gallate (5.16 g), 0.028 moles each, were 
suspended in 500 ml of ethanol in a conical flask. The slurry was continuously stirred 
magnetically to maintain a stable vortex.  The conversion to the cocrystal was verified by 
powder X-ray diffractometry (PXRD, Bruker AXS D5005, Madison, WI).  The 
suspension was subsequently filtered and vacuum dried.  For powder XRD studies, a Cu 
X-ray source (45 kV, 40 mA) providing CuKα1 emission of 1.5414 Ǻ was used. Data 
were collected at 5 - 40
o
 2θ at a step size of 0.01o with a dwell time of 1s at each step. 
 
2.2.2 Physical characterization of powders 
Melting points of bulk cocrystal and starting materials were measured using 
differential scanning calorimetry (model 2920, TA Instruments, New Castle, DE) 
operated in standard mode.  Samples were placed in hermetically sealed aluminum pans 
having pinholes, and heated at 10 
o
C/min to 20 
o
C beyond the melting point, under a 
nitrogen purge of 50 ml/min. Temperature and cell constant were calibrated using indium 
standard after performing baseline calibration.  The room temperature true densities of 
the powders were measured using a helium pycnometer (Ultrapycnometer 1000e, Version 
4.00, Quantachrome, Boynton Beach, FL).  The true density can also be calculated from 
the crystal structure.  However the crystal structure solutions at room temperature are not 
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available for methyl gallate and the cocrystal, necessitating the true density 
measurements.  Particle size distributions were obtained using a light scattering particle 
size analyzer (Helos H1588, Sympatec, Germany, dry powder dispersion, 2.0 bar 
dispersion air pressure).   
 
2.2.3 Compaction behavior of powders 
The tabletability of the bulk powders (theophylline, methyl gallate, and cocrystal) 
was determined using Zwick Materials Testing Instrument (Zwick-Roell MaterialPrufung 
1485, Germany) over a compaction pressure range of 50 to 400 MPa at increments of 50 
MPa using 8 mm round, flat-faced punches.  The in-die elastic recovery of the compacts 
was calculated using the tablet thickness values at peak compaction pressure, and at the 
end of the decompression cycle, as previously described.
4
  Tablets were stored for 48 
hours in an ambient atmosphere to allow for the relaxation of residual stress.  Radial 
breaking strength of each tablet was obtained using a Texture Analyzer (TA-XT2i, 
Texture Technologies Corp., NY, 30 Kg load cell, test speed of 0.01 mm/s with a trigger 
force of 5 gm).  The tablet tensile strength was calculated based on the tablet dimensions 
and the breaking force.
20
  
 
2.2.4 Crystal growth and structure solution 
The single crystals of theophylline, methyl gallate and their 1:1 cocrystal were 
prepared by slow evaporation of the respective ethanolic saturated solutions at room 
temperature. The crystal structures of methyl gallate and the cocrystal were solved using 
single crystal X-ray diffractometry (Siemens SMART platform CCD diffractometer, NY) 
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at 173 K.  The crystal structure of methyl gallate at 100 K has already been published,
21
 
and we report a new determination at 173K.  The crystal structure of theophylline has 
been obtained from the literature through CCDC.
22
 
 
2.2.5 Mechanical properties of single crystals 
The elastic modulus and indentation hardness values of the predominant faces of  
single crystals of theophylline, methyl gallate, and the cocrystal were obtained using 
nanoindentation (NanoXP, MTS-Nano Instruments, Oak Ridge, TN) with a Berkovich 
diamond tip.
23
  During the indentation experiment, the indenter tip was pressed into the 
crystal surface at a constant rate of 5 nm/s.  Once the maximum penetration depth of 
1000 nm was reached, the indenter was held for 10s before being withdrawn to allow 
time for stress relaxation of plastic materials.  For all of the three crystals, the Poisson 
ratios were assigned a value of 0.3.
24
  Indentation data between the penetration depth of 
600 and 900 nm were analyzed to derive the indentation hardness and elastic modulus 
values.
23
  
 
2.2.6 Crystal slip planes and Burgers vector  
The principal slip plane in each crystal was identified both by direct visualization 
of the crystal packing and attachment energy calculations, as described previously 
(Materials Studio, v5.0, Accelrys, San Diego, CA).
19
  A Dreiding 2.21 force field was 
employed in the attachment energy calculations because it has been frequently applied to 
small organic molecules.
19
  The direction of slip were computed from the Miller indices 
(h k l) of the identified slip plane.
16
  Slip system is composed of slip plane (h k l) and slip 
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vector <u v w>, which is any vector parallel to the slip direction.   The magnitude of the 
Burgers vector, b, was determined for each crystal based on the identified slip system and 
lattice spacing in slip direction.   
 
2.3 RESULTS AND DISCUSSION 
2.3.1 Characterization of powders 
The PXRD profile of the bulk cocrystal powder was distinct from either that of 
theophylline or methyl gallate (Figure 2.2).  Also, both the melting point and true density 
of the cocrystal were different from those of the starting materials (Table 2.1). These data 
confirmed that the cocrystal was structurally singular from the starting materials. 
                  
 
Figure 2.2. Powder X-ray diffraction profiles of theophylline, methyl gallate, and 
cocrystal  
 
 
2.3.2 Compaction behavior of powders 
On evaluating the powder compaction properties of different materials, 
theophylline was found to demonstrate the highest tabletability, while methyl gallate’s 
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tabletability was extremely poor.  Tabletability plots show the dependence of tablet 
tensile strength on the compaction pressure used to prepare the tablets.  The bulk powder 
tabletability decreased in the order of theophylline > cocrystal >> methyl gallate (Figure 
2.3).   
 
 
Figure 2.3. Bulk powder tabletability of theophylline, cocrystal, and methyl gallate over 
compaction pressure range of 50-400 MPa.  No intact tablets could be formed for methyl 
gallate at pressures exceeding 300 MPa.   Error bars represent one standard deviation of 
measurements (n = 3). 
 
 
Because of the poor tabletability, methyl gallate did not form intact tablets easily 
and many tablets laminated after ejection from die.  Those tablets were discarded because 
they could not be used for testing tablet tensile strength.   In contrast, the cocrystal 
powder formed intact tablets over the entire range of compaction pressures, indicating 
significant improvement in the tabletability compared to that of methyl gallate.  At any 
given compaction pressure, the tablet tensile strength of the cocrystal was always much 
higher than methyl gallate.  This is similar to our earlier observations with the methyl 
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gallate-caffeine 1:1 cocrystal system.
4
  However, the tabletability of theophylline was 
compromised on cocrystal formation.  
 
Powder compaction can also be assessed using compactibility plots, which show 
the dependence of tablet tensile strength on tablet porosity (i.e., the dependence on solid 
fraction).   From the compactibility plots (Figure 2.4), the tablet tensile strength 
extrapolated to zero porosity (σ0) was found to be the highest for theophylline (Table 
2.1).  σ0 is routinely used to assess the powder compaction properties of materials, and is 
a property intrinsic to the material devoid of any contribution from porosity.  The 
compactibility of theophylline is exceptionally high, because σ0 values for most 
pharmaceutical powders generally range between 0.1-10 MPa.
26
 Both tabletability and 
compactibility plots indicate that theophylline has exceptionally good powder 
compaction properties.  
 
Figure 2.4. Compactibility (dependence of tablet tensile strength on compaction 
pressure) of theophylline, methyl gallate, and cocrystal.  Error bars represent one 
standard deviation of measurements (n = 3). 
  41 
 
 
 
 
 
Table 2.1. Properties of theophylline, methyl gallate, and cocrystal relevant for assessing plasticity and compaction. 
Data presented as mean ± one standard deviation of measurements (n = 3). 
 
 
Materials 
Bulk powder properties 
 
Crystal properties 
 
Melting 
point (
o
C) 
 
True 
density 
(g/cc) 
[n=10] 
 
D50 
(µm) 
Tensile 
strength at 
zero porosity 
(MPa) 
Indentation 
Hardness 
(GPa) 
(n ≥ 10) 
Elastic 
modulus 
(GPa) 
(n ≥ 10) 
Dislocation 
density 
×10
16
 (m
-2
) 
Theophylline 272.19 
1.481 ± 
0.0003 
128.98 9.98 ± 0.36 0.28 ± 0.01 11.59 ± 0.27 27.3 
Methyl gallate 194.48 
1.481 ± 
0.001 
55.86 NA 0.78 ± 0.14 9.38 ± 0.67 3.5 
Cocrystal 242.76 
1.548 ± 
0.0009 
6.28 8.81 ± 0.24 0.48 ± 0.05 15.09 ± 0.92 4.0 
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2.3.3. Particle size and morphology effects on theophylline compactibility  
For many plastic materials, smaller particles lead to higher compactibility due to 
the larger area available for bonding during compression.
27
   However, it was found that 
in spite of having a much larger particle size compared to the other two materials (Table 
2.1), theophylline displayed the best compaction behavior.  To examine the effect of 
particle size and morphology on the compaction behavior of theophylline, we compared 
the compactibility of three batches of theophylline having very different particle size and 
morphology.  Batch 1 was commercial theophylline anhydrate powder with prism-shaped 
crystals (Figure 2.5, Batch 1). Batch 2 was prepared from commercial theophylline by 
cryomilling the powder under liquid nitrogen at 77K (SPEX SamplePrep 6750 
Freezer/Mill, Metuchen, NJ).  We verified that the samples, immediately after 
cryomilling, did not show reduction in crystallinity, based on DSC and PXRD data.  For 
Batch 2, the powdered material was not subjected to any further treatment, and the 
compactibility was measured directly. The prism-shaped crystals of commercial 
theophylline were converted to more iso-dimensional crystals in Batch 2.  For Batch 3, 
after following a similar cryomilling protocol as in Batch 2, the sample was suspended in 
ethanol with continuous stirring, using magnetic stirrer in a sealed round bottom flask. 
This treatment produced crystals of prism morphology, similar to commercial 
theophylline, but with significantly reduced average particle size. 
 
Even with such drastic changes in particle size or morphology, the compactibility 
of theophylline was not significantly altered (Figure 2.6).  A 50-fold reduction in particle 
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size only slightly altered the compactibility of theophylline, as expected due to larger 
available bonding area for fine particles.  
 
 
 
 
 
 
 
 
 
 
Figure 2.5. SEM images of the three batches of theophylline produced by particle 
engineering strategies, such as milling and recrystallization. 
 
 
Figure 2.6. Compactibility of three batches of theophylline with engineered particle size 
and morphologies 
 
 
Alteration of 
morphology 
Reduction of 
particle size 
Batch 1 
Batch 2 
Batch 3 
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The insensitivity of compaction to particle size/morphology can only occur if the 
intermolecular interaction strength at the bonding surface of a material is the same as that 
within the crystal.  The fracture plane, then, can run through individual particles when a 
tablet breaks under an applied tensile stress.
21
  Due to this factor, the tablet strength of 
theophylline is essentially unaffected by size and morphology of the initial theophylline 
particles.  Thus, due to its higher plasticity, analogous to plastic metals, pressure-induced 
bonding between particles of theophylline can readily occur on application of stress.  In 
addition, theophylline particles yield under stress during tablet breaking (tablet tensile 
strength determination), which further obscures the differences in pore distribution 
caused by different particle size and morphology.   Due to the above reasons, the superior 
plasticity and hence, the tabletability of theophylline can be regarded as property intrinsic 
to this material, and not artifacts of extrinsic factors like particle shape and morphology. 
 
2.3.4 Mechanical properties of crystals 
The differences in tableting performance of the three materials can be interpreted 
based on the different mechanical properties of the corresponding crystals.  During 
compaction, plastic materials can undergo permanent and irreversible deformation that is 
necessary to form inter-particulate bonding.
27
  The indentation hardness is an indicator of 
material plasticity, a lower hardness corresponding to higher plasticity.  Of the three 
crystals, the indentation hardness of theophylline was approximately half of that of the 
cocrystal and one third of methyl gallate (Table 2.1). The theophylline crystals are 
therefore the most plastic, while methyl gallate crystals are the least plastic.  Overall, the 
rank orders of plasticity and powder tabletability are the same (theophylline > cocrystal > 
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methyl gallate), indicating a positive correlation between single crystal plasticity and 
powder tableting performance.  
 
Crystal plasticity can also be qualitatively assessed from load-displacement 
curves during nanoindentation tests (Figure 2.7).  For the same indenter that penetrates 
crystals to the same depth, a higher load corresponds to higher crystal hardness, and 
hence lower plasticity.
28
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7. Load-displacement nanoindentation curves of theophylline, methyl gallate, 
and cocrystal.  Arrows indicate some selected pop-in events. 
 
 
From Figure 2.7, it can be observed that the maximum load follows the order of 
methyl gallate > cocrysal > theophylline, again confirming the lowest plasticity of methyl 
gallate.  Moreover, breaks in the nanoindentation loading curves or “pop-in events” can 
be seen for both theophylline and cocrystal at low loads (Figure 2.7). These pop-in events 
are characteristic of slip between crystal slip planes under applied load.
29
  Pop-in events 
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occurred at a lower frequency for theophylline than for the cocrystal.  This observation is 
consistent with the presence of multiple slip mechanisms in theophylline crystal 
(discussed later), which facilitates easier stress dissipation in this lattice.  The enhanced 
stress dissipation reduces the need of frequent “pop-in” events in theophylline, compared 
to the cocrystal, for which slip between flat layers is the only mode of plastic 
deformation.  Methyl gallate also showed pop-in events.  However, these events occurred 
at higher loads compared to the other two crystals, consistent with its lowest plasticity. 
Considering the rigid three-dimensional hydrogen bonded structure and lack of slip 
planes in methyl gallate crystal (discussed later), these events were probably caused by 
micro-cracking near the site of indentation.   
 
Besides plasticity, important insights into tabletability may also be obtained from 
the crystal elasticity, which can be represented either as the elastic modulus of crystal or 
the elastic recovery of tablets during decompression.
30
  The elastic modulus of crystals 
was found to decrease in the order of cocrystal > theophylline > methyl gallate (Table 
2.1), a lower value of elastic modulus indicating higher elasticity.  Based on this rank 
order, methyl gallate would exhibit the largest elastic strain under the same applied stress, 
and the highest elastic recovery after stress removal.  This agrees well with the highest 
elastic recovery of methyl gallate tablets during decompression (Figure 2.8). A high 
elastic recovery during bulk powder compaction can break inter-particulate bonding sites 
and thus, leads to deterioration in the powder compaction properties.  Thus, both low 
plasticity and high elasticity of methyl gallate contribute to its extremely poor tableting 
performance.   
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Figure 2.8. In-die elastic recovery during compaction of bulk powders of theophylline, 
cocrystal, and methyl gallate. 
 
 
The in-die elastic recovery of theophylline bulk powder was lower than that of the 
cocrystal at moderate to high compaction pressures (Figure 2.8).  This means that, despite 
the lower elastic modulus of theophylline crystal, the apparent elastic modulus of 
theophylline tablet is higher than that of the cocrystal, under the same compaction 
pressure.  This may be explained by considering the difference in the crystal hardness of 
theophylline and cocrystal.  Under the same applied pressure, the net area of a plane 
perpendicular to the loading axis during stress application is larger for softer 
theophylline. The larger area leads to a higher apparent modulus of theophylline tablet, 
even though the elastic modulus of the corresponding crystal is lower than that of the 
cocrystal.  It is also possible that the rank order of elastic modulus measured on the 
predominant crystal face by nanoindentation may slightly differ from that of the bulk 
powder because of the anisotropy of mechanical properties of organic crystals.
16
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2.3.5 Identification of slip systems 
        To properly understand the plasticity differences, it is important to describe the 
slip systems and dislocations for each of the three crystals.  Attachment energy (Eatt) 
calculations have been extensively used in literature to assist the identification of slip 
planes.
19
   Slip planes, among all planes in a crystal, possess the lowest absolute Eatt, 
which is defined as the energy released on attaching a new layer (slice) of molecules to a 
growing crystal face.
19
  The accuracy of Eatt prediction is dependent on the choice of the 
force field.  Although the Dreiding force field performs better than many other force 
fields for organic crystals, it does not always yield a correct prediction.
19, 31
  In such 
cases, direct visualization of crystal packing using Materials Studio software results in a 
more accurate identification of predominant slip plane.   
The predominant slip plane in the theophylline crystal was identified as (1 0 0) 
both by Eatt calculations and direct visualization of crystal packing.  The corresponding 
slip vector for theophylline was <0 1 0>.  For the cocrystal, slip plane identified by Eatt 
calculations was (1 0 0), while that by visualization was (3 0 -2).  The (3 0 -2) plane was 
used as the slip plane, because slip along (1 0 0) required traversing hydrogen bonded 
layers of molecules, which is not energetically favorable.
22
  It should be pointed out that 
in addition to the principal slip plane, potential secondary slip planes in a crystal may 
become activated under favorable external stress conditions.
16
  However, the principal 
slip planes can be considered to be more influential to crystal plasticity.
16, 19
  The slip 
plane in methyl gallate could not be easily identified by visualization of crystal packing 
due to the unique molecular arrangement in its lattice.  Eatt calculations identified (1 1 0) 
as the slip plane, with <0 0 1> as slip vector. 
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2.3.6 Qualitative assessment of crystal packing effects on mechanical properties 
The differences in plasticity of the three crystals can be interpreted based on their 
different crystal structures.  In the theophylline crystal, molecules form stacking layers 
(Figure 2.9a and b), within which, these molecules are arranged in hydrogen bonded V-
shaped rigid columns (Figure 2.9c). These columns can undergo facile relative motion 
when stressed.  In adjacent layers, these columns are oriented at obtuse angles of 111.61
o
, 
each layer accommodating stress at a different orientation, increasing the resolved shear 
stress beyond the critical yield stress needed for plastic deformation.  The columnar 
arrangement of theophylline molecules in the flat layers offers additional lattice 
flexibility over flat slip planes.  Compared to the slipping of rigid sheets of molecules in 
the cocrystal (Figure 2.10), there is also a lower energy barrier for the columns to move 
with respect to each other when stressed.  This results in easier dislocation motion in 
theophylline crystals, thereby enhancing its plasticity.  In addition, these composite layers 
of columns can still slip relative to each other, similar to that between rigid slip planes. 
The dual mechanisms for slipping correlate well with the superior plasticity of 
theophylline crystals.  
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                        (a)                           (b)                         
 
(c) 
Figure 2.9.  Theophylline crystal packing (a) unit cell viewed along b-axis, showing 
predicted slip plane, (b) unit cell viewed along c-axis, and (c) stacking V-shaped columns 
within a flat layer  
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The cocrystal, on the other hand, exhibits extensively hydrogen bonded flat-layers 
(Figure 2.10).  This type of layered structure, analogous to the structure of graphite, is 
expected to enhance crystal plasticity by permitting easy slip between layers.  However, 
the plasticity resulted from slip of flat-layers alone is less effective than that from 
structures similar to theophylline, which have multiple slip mechanisms.  
 
 
          (a) 
 
         (b) 
Figure 2.10. (a) Hydrogen bonded flat layers of cocrystal molecules showing slip plane 
along (1 0 0) predicted by attachment energy calculations, and (b) slip plane along (3 0 -
2) predicted by direct visualization of lattice 
 
 
Lastly, the crystal lattice of methyl gallate is characterized by an extensively 
hydrogen bonded three-dimensional network structure (Figure 2.11a and b).  Such a 
  52 
network makes this crystal extremely difficult to deform plastically, because of the 
absence of potential slip planes.  In fact, the existence of such a hydrogen bonded 
network in methyl gallate crystal was predicted on the basis of its poor tabletability, even 
before its structure was solved.
4
   This is consistent with the view that mechanical 
properties of crystalline materials are closely related to their crystal structures.  Hence, a 
proper understanding of the molecular packing in crystals provides a clear interpretation 
of the mechanical behavior of materials.   
 
     
           
 
 
 
 
 
 
 
            (a)                         (b) 
 
Figure 2.11. (a) The unit cell of methyl gallate, and (b) three-dimensional hydrogen 
bonded network in methyl gallate lattice 
 
 
2.3.6 Correlation between crystal dislocations and plasticity 
 An additional interpretation of plasticity difference between the crystals can be 
provided by calculating dislocation density.
14, 16, 32, 33
 All crystals have a certain number 
of intrinsic dislocations arising from imperfect crystal growth, whose motions under 
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stress contribute to crystal plasticity.
16, 34
  New dislocations may additionally be created 
during plastic deformation.
16, 33
  Irrespective of the origin, crystal dislocations generally 
weaken lattice and facilitate plastic deformation, neglecting work hardening. In work 
hardening, plasticity is reduced due to entanglement of dislocations at very high 
dislocation concentrations. However, work hardening is not important in this study 
because the extent of plastic deformation, and thus, dislocation generation, is limited 
during powder compaction in a die.    
 
Each crystal dislocation possesses an associated stress field, which has two 
primary components – an inner inelastic core, and an outer region where the theories of 
linear elasticity hold.
16 
An appropriate measure of the inelastic core is 5b, which can be 
considered as a characteristic distance parameter (d) of dislocations.
16,35,35
  Essentially, 
this is also the minimum distance of separation between two adjacent dislocations, with 
allowance for stress field overlap.  Based on this distance, a limiting dislocation density 
(ρd) for each crystal, defined as the length of dislocation line (L) per unit volume of core 
(d
2
L), can be calculated using the equation (1).
16
  
2
1
d
d     (1) 
Here, we have defined ρd in a way that it quantifies the dislocation density at the 
minimum possible separation between two dislocations in a crystal.  We note that ρd 
(with a unit of m
-2
) is different from the total number of dislocations within a unit volume 
of lattice (i.e. the concentration of dislocations in lattice, with a unit of m
-3
).  
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A higher ρd for a crystal indicates that the crystal lattice can accommodate adjacent 
dislocations to a smaller effective distance of separation (d).  This should facilitate easier 
plastic deformation due to the increased potential of dislocation motion at the same strain 
rate and temperature,
14, 16, 33, 34
  without considering work hardening.
34, 36
  Theophylline 
has the smallest Burgers vector magnitude, b = 0.383 nm, so the smallest d compared to 
the other two crystals.  ρd of theophylline is 6 to 7-fold higher than the other two crystals 
(Table 2.1).  The highest ρd for theophylline explains its highest plasticity.  The cocrystal, 
on the other hand, possesses a significantly longer d (Burgers vector magnitude, b = 
1.012 nm) compared to theophylline.  The resultant ρd of cocrystal is much lower than 
theophylline (Table 2.1).  Corresponding to its lowest plasticity, methyl gallate shows the 
lowest ρd with the largest d (Burgers vector magnitude b = 1.060 nm).   The rank order of 
crystal plasticity (theophylline > cocrystal > methyl gallate) correlates with that of the 
limiting ρd (theophylline > cocrystal > methyl gallate).  Thus, the dislocation density 
model of plasticity provides an additional quantitative interpretation for the lower 
plasticity of the cocrystal compared to theophylline.   
 
2.4 CONCLUSIONS 
The different mechanical properties of theophylline, methyl gallate, and their 1:1 
cocrystal originate from differences in crystal packing.  Methyl gallate crystals, which 
contain three-dimensional hydrogen bonded networks, exhibit low plasticity and high 
resistance to deformation.  The cocrystals, containing hydrogen-bonded two dimensional 
flat slip planes exhibit higher plasticity.  The highest crystal plasticity of theophylline is 
due to flat slip planes composed of hydrogen bonded columns, which provides additional 
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flexibility for slip leading to a more effective mechanism for plastic deformation.  Thus, 
it is not surprising that cocrystallization can reduce the crystal plasticity and deteriorate 
tableting performance of materials such as theophylline, while improving the mechanical 
properties of other materials such as methyl gallate.  These results show that a holistic 
understanding of the relationship between crystal structure and mechanical properties is 
essential for effectively implementing crystal engineering to address pharmaceutical 
challenges.   
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Chapter 3. 
 
 
Cocrystallization-induced decline in plasticity and powder 
compaction: Part 2.   Quantitative assessment of plasticity   
of molecular organic crystals with nanoindentation 
 
 
 
 
 
 
 
 
 
 
 
 
 
  57 
 
Following on the qualitative assessment of crystal structure contribution in material 
plasticity and compaction properties in Chapter 2, in this chapter, the objective is to 
quantitatively investigate using nanoindentation the origin of deteriorated plasticity of 
cocrystals based on an analysis of crystal mechanical deformations. The mechanical 
properties of the materials have been studied at two levels:  bulk powders and single 
crystals.  The bulk mechanical properties of the cocrystal and co–formers have been 
assessed by studying their compaction properties over 10–300 MPa compaction pressure.  
The compact tensile strength of the cocrystal was lower than both the co–formers, as well 
as to their 1:1 physical mixture.  The inferior mechanical performance of the bulk 
cocrystal powder stems from a sharp increase in crystal hardness after cocrystallization, 
resulting in high resistance towards plastic deformation.   The rank order of bulk powder 
compaction (saccharin > piroxicam > cocrystal) was identical to that of crystal plasticity 
(probed with nanoindentation). Using multiple load–displacement cycling at small 
strains, mechanical properties such as the yield strength (σys) were quantified for each 
material, which proved that the cocrystal has the highest resistance to plastic deformation 
onset.  This work clearly demonstrates that altering crystal packing of solids may lead to 
worsened mechanical properties, which in turn will affect their processability.   Further, 
nanoindentation, a material–sparing technique, can successfully elucidate, and in 
principle predict, the bulk mechanical behavior of materials by quantifying their 
mechanical property landscape at a sub–micron level. 
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3.1 INTRODUCTION  
The design of molecular packing in crystals for tailored physicochemical and 
mechanical properties is a topic of fundamental importance for organic materials with 
pharmaceutical,
1
 food,
2
 optical 
3
 and magnetic applications.
4
   Crystal engineering,
5
 the 
technique for intentionally modifying the solid–state chemistry of crystals, is receiving 
substantial interest in materials research.   Some of the key forms of molecular organic 
crystals, relevant for product development, are polymorphs,
6
 salts,
7
 solvates,
8
 and 
cocrystals.
9
   Cocrystals, in particular, have been under immense scrutiny over the past 
decade, especially for innovative pharmaceutical applications.
10
  Cocrystallization, a 
process by which two or more non-volatile molecules in unionized or zwitterionic forms 
11
 pack together within the same crystalline lattice through non–ionic interactions,12, 13 
offers several advantages for drug development, such as improved physical 
14
 and 
chemical stability,
15
 enhanced thermodynamic solubility and faster dissolution kinetics,
16
 
chiral resolution,
17
 and opportunity for intellectual property.
18
  The focus of this work is 
on an aspect of cocrystal research that has, thus far, received only limited attention, i.e., 
the impact of changing crystal composition and packing by cocrystallization on the 
mechanical properties of molecular crystals.   
 
The mechanical properties and deformation mechanisms have been extensively 
investigated for inorganic materials, such as metallic crystals and glasses.
19-21
  However, 
such investigations on organic molecular materials are few.  The mechanical properties of 
organic crystals, as with any material, govern their deformation behaviors under 
mechanical stress.  The key deformation mechanisms include elastic, plastic, viscoelastic 
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deformation, and fragmentation.  Elasticity is the ability of a material to undergo 
reversible deformation under an externally applied stress, with no residual deformation 
once stress is removed.
22
   At molecular level, elastic deformation is a consequence of 
reversible stretching of bonds, and therefore limited to deformations under small loads.
22
    
Plastic deformation, on the contrary, is a permanent deformation caused by gliding of 
molecular layers under stress and dislocation motion.
19
  Viscoelastic deformation is 
controlled by the relative predominance of elastic and plastic deformations.
23
     
Fragmentation or fracture of a material results when the rearrangement of molecules 
under stress cannot accommodate the strain. In this study, we have confined our 
investigations to the viscoelastic deformation region of organic crystals by operating 
within small strains without causing fragmentation or cracking. 
Depending on the crystal packing, plasticity of a cocrystal can either improve 
24, 25
 or 
deteriorate 
26
 relative to parent cocrystal formers (co–formers).   The goal of this study is 
to investigate the origin of cocrystallization–induced deterioration of mechanical 
properties (especially plasticity), using the model system of a 1:1 cocrystal formed 
between piroxicam and saccharin 
11
 shown in Figure 3.1.     
 
Figure 3.1.  Molecular structures of piroxicam and saccharin.  Piroxicam exists in zwitterionic 
form in the cocrystal.  The cocrystal is stabilized through N-H
...
O
-
 hydrogen bonds. 
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Piroxicam is a drug molecule with anti–inflammatory properties and saccharin is an 
artificial sweetener used in foods and pharmaceuticals.   We have probed the mechanical 
properties of the materials at two levels:  bulk powders (by assessing powder compaction 
properties) and single crystals by nanoindentation.  Nanoindentation can probe the 
mechanical deformation landscape of materials by initially inducing reversible elastic 
deformation at low loads and then irreversible plastic deformation by increasing the load 
to exceed the elastic–plastic limit.  If strain is sufficiently large, crystal fragmentation or 
cracking may result.  Because the mechanical properties of a molecular crystal is 
dependent on its chemistry and crystal packing,
26
 nanoindentation is an indirect probe of 
crystal packing stability and strength of lattice interactions.   Therefore, we have used this 
technique to investigate the origin of deteriorated material plasticity upon 
cocrystallization.  
 
3.2 MATERIALS AND METHODS 
3.2.1 Materials and crystallization strategies 
Both piroxicam (β–polymorph) and saccharin were purchased from Sigma-Aldrich (St. 
Louis, Missouri, USA).  The cocrystal is formed between saccharin and zwitterionic 
piroxicam (Figure 3.1), which is stabilized by N–H...O– hydrogen bond interactions.   
Bulk cocrystal powder was prepared by suspending equi–molar quantities (~0.02 moles) 
of piroxicam (6.627g) and saccharin (3.664g) in ~30 ml of 1:1 (v:v) mixture of ethanol 
and ethyl acetate.  The suspension was stirred for 48 hrs at room temperature prior to 
filtration under vacuum for one hour.   
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Single crystals for both the cocrystal and co–formers were obtained by slow solvent 
evaporation under ambient conditions.   β–piroxicam crystals were grown from benzene, 
while saccharin crystals were grown from 1:1 mixture of ethanol and ethyl acetate.  
Single crystals of the cocrystal were generated by evaporating a 1:1 mixture of ethanol 
and ethyl acetate containing equi–molar quantities of piroxicam and saccharin.   
 
3.2.2 Phase purity of bulk powders 
The phase purity of bulk powders (API, coformer and cocrystal) was analyzed by 
obtaining their powder X-ray diffraction patterns (Siemens DIFFRAC plus 5000 powder 
diffractometer with Cu-Kα radiation, 1.54056 Å) at room temperature and overlaying 
them with calculated diffraction patterns obtained from CSD (Conquest ver 1.13, 
Cambridge Crystal Database Center, Cambridge, UK).  The tube voltage and amperage 
were set at 40 kV and 40 mA, respectively.  The sample stage was spun at 30 rpm.  The 
divergence slit and antiscattering slit settings were variable for illumination on the 20 mm 
area on the sample.   Each sample was scanned between 5 and 40 °2θ, with a step size of 
0.05° at 1 step/sec.  The instrument was pre-calibrated using silicon standard.   
 
3.2.3 Mechanical properties of crystals  
Crystal hardness, H (a measure of plasticity) and elastic modulus, E (a measure of 
elasticity) were quantified using a nanoindenter (TriboIndenter TI-900, Hysitron Inc., 
MN, USA) fitted with a standard pyramidal Berkovich diamond indenter tip (tip radius 
approximately 100nm, total included angle of 142.3°, and half angle of 65.3°) under 
ambient conditions (~21°C, ~38% relative humidity).   The area function of the tip was 
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derived using a series of indentations on fused quartz standard (modulus of 69.6 GPa).  
Nanoindentation experiments were performed under displacement–controlled mode, 
which is more sensitive than load–controlled mode.20   The loading and unloading rates 
were both 100 nm/s.  Once the maximum penetration depth of 500 nm was reached, a 10s 
holding time was applied to allow for stress relaxation.  During nanoindentation, force 
and displacement were recorded simultaneously with resolutions of ~1 nN and ~0.2 nm, 
respectively.  A total of 12 - 15 indentations were performed on each sample.   Based on 
the standard methods of analyzing indentation data,
27
 the elastic modulus and hardness of 
each material was obtained from the unloading portion of the load-displacement 
nanoindentation curves.  The reduced elastic modulus (Er), i.e., modulus of the sample 
taking into consideration the effects of elastic deformation of the indenter material, was 
then computed for each material.   The yield strength of materials, defined as the limit of 
elastic deformation beyond which plastic deformation onsets, was determined by partial 
loading and unloading experiments 
28
 at low deformations (up to 50 nm displacement into 
crystal surface at rate of ~2nm/s).    
To select crystals suitable for nanoindentation, crystals were first washed with 
silicone oil to remove fine crystallites and other extraneous adherents from the crystal 
surfaces.   The washed and dried crystals were observed under an optical microscope 
(10X, Wild M32, Heerbrugg, Switzerland).  Crystals with large flat surfaces were 
selected for indentation studies.  The phase nature of single crystals was verified by unit 
cell parameters, determined with single crystal X-ray diffraction (SMART diffractometer, 
Bruker AXS, equipped with an APEX II CCD detector).   The selected crystals were face 
indexed using single crystal X–ray diffraction.  Under optical microscope, the crystals 
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were then carefully affixed on glass disks using epoxy (setting time ~5 min) ensuring that 
the selected crystal faces were parallel to the horizontal plane.  The samples were stored 
under ambient conditions for ~24 hours before indentation to ensure that epoxy was 
firmly set to fix crystals in position during indentation.  Finally, crystal surfaces were 
imaged by scanning tip (resolution ~1nm) to measure the surface roughness.  Only 
surfaces with low roughness (<10 nm) were indented.   
 
3.2.4 Mechanical properties of bulk powders  
The mechanical properties of bulk powders were assessed by quantifying their 
tabletability, which describes the variation in compact tensile strength with changing 
compaction pressure.
29
   A Materials Testing Machine (Zwick-Roell MaterialPrufung 
1485, Germany) was used to compress powders into flat-faced round tablets (8 mm 
diameter) at a speed of 1 mm/min.  Approximately 200–250 mg of each powder was 
compressed at pressures ranging between10 - 300 MPa (at ~23°C and ~34% relative 
humidity).   Before compaction, the powders were mildly ground and sieved to obtain 
similar particle size fractions for all three powders.  Particle size was estimated by digital 
microscopy (AD413T Dino-Lite Pro2, Hsinchu, Taiwan).   Phase purity of the milled 
powders was verified with powder X-ray diffraction to eliminate the possibility of 
milling-induced loss in crystallinity of crystals.
30
 
Compacts were stored for ~48 hr at ambient conditions to allow for relaxation of any 
residual stress after tablet ejection.  Compact tensile strength (σ) was calculated using Eq. 
1, by measuring the compact diametrical breaking force with a texture analyzer (TA-
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XT2i, Texture Technology Corps, NY, 30 Kg load cell, test speed of 0.01 mm/s with a 
trigger force of 5 g).     
)1(
2
tD
F
     
where F is tablet breaking force, D and t are tablet diameter and thickness, respectively.    
The elastic behavior of the bulk powders was assessed from the in–die elastic recovery 
(ER) calculated using Eq. 2.  
)2(100
0
0
h
hh
ER     
where h and h0 are respectively the tablet thickness at peak compaction pressure and 
when the pressure reaches zero at the end of the decompression.   ER is related to the 
elastic energy stored in the material during compaction, which is released during 
decompression.   
 
3.2.5. Molecular properties of crystal lattice 
The principal slip plane in each crystal was identified by attachment energy 
calculations using molecular modeling of crystal packing (Materials Studio, v5.0, 
Accelrys, San Diego, CA), the slip plane being the crystal plane having the lowest 
attachment energy.  A Dreiding 2.21 force field was employed in the attachment energy 
calculations because it has been frequently applied to small organic molecules.  The 
magnitude of the Burgers vector, b, was determined for each crystal based on the 
identified slip system and lattice spacing in the direction of slip.   
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3.3 RESULTS 
3.3.1 Phase purity of bulk powders 
Powder X-ray diffraction patterns, before and after grinding, are compared with 
calculated patterns from single crystal structures in Figure 3.2.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.  Powder X-ray diffraction profiles of unmilled and milled β-piroxicam, 
saccharin, and PiroSac cocrystal, compared with respective calculated diffraction patterns 
from single crystal structures, to confirm phase purity of milled powders 
 
All milled powders retained crystallinity after grinding, due to the very mild grinding 
stress.  Slight changes in intensity of some peaks are attributed to preferred orientation 
differences. 
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3.3.2 Mechanical properties of bulk powders 
The tabletability of the three powders (piroxicam, saccharin and cocrystal), along 
with that of an equi-molar physical mixture of piroxicam and saccharin, is shown in 
Figure 3.3a.    The average particle size of the powders used for compaction were in the 
comparable range (~17µm for piroxicam, ~24µm for saccharin, and ~27µm for the 
cocrystal).  The tabletability for piroxicam and the cocrystal were extremely poor and no 
intact compacts were formed at compaction pressures exceeding 100 MPa.    On the 
contrary, saccharin demonstrated the best tabletability among the three materials, and 
formed intact compacts over the entire compaction pressure range explored.  Overall, the 
tabletability of the powders decreased in the order of saccharin > physical mixture > 
piroxicam > cocrystal.   Figure 3.3b shows the in–die elastic recovery (ER), as a function 
of compaction pressure, which decreased in the order of cocrystal > saccharin > physical 
mixture > piroxicam.      
 
The tensile strength of compacts (σ) displayed an exponential relationship with tablet 
porosity (Figure 3.3c), which can be described using Eq. 3, the compactibility of 
materials.
32
 
)3(0
be  
where b is a fitting constant, σ0 is tensile strength extrapolated to zero porosity, and is 
compact porosity calculated using Eq. 4.   
)4(1
true
compact
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In Eq. 4, tab and true are the compact density and powder true density, respectively.  
True densities of different powders (Table 3.1) were measured using helium pycnometry 
under ambient conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.  Powder compaction properties of saccharin, piroxicam, 1:1 cocrystal and 1:1 
(molar ratio) physical mixture: (a) tabletability, (b) in-die elastic recovery and (c) 
compactibility.  Error bars represent one standard deviation of measurements (n=3).   
 
 
Although σ0 may be obtained by extrapolating the compactibility plot (Figure 3.3c) to 
zero porosity, large errors may result in such extrapolations especially if the tensile 
strengths of only highly porous compacts are experimentally accessible.
33
  For instance, 
piroxicam and cocrystal powders could not be compacted below ~20% porosity, and 
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extrapolated tensile strength at zero porosity would likely have large errors.  To minimize 
such errors, the tensile strength at 20% porosity, σ20, was used to rank order the 
mechanical performance of the three powders (Table 3.1).   
 
Table 3.1.  Relevant physico-mechanical properties of piroxicam, saccharin and 
cocrystal at room temperature.   
 
Material 
True density 
of powder, 
ρtrue  (g/mL) † 
Crystal 
density,     
ρcrys  (g/mL) ‡ 
Water 
content 
(%w/w) ↑ 
Tensile strength 
at 20% porosity, 
σ20 (MPa) 
β-piroxicam 1.499±0.0003 1.481 0.167 0.254 
Saccharin 1.585±0.0005 1.603 0.055 0.632 
Cocrystal 1.525±0.0005 1.548 0.228 0.199 
  
† Helium pycnometer (Ultrapycnometer 1000e, Version 4.00, Quantachrome, Boynton Beach, 
FL,  n=10).  ‡ Single crystal X-ray diffraction.  ↑ Weight loss of powders when heated to 110°C 
uner dry nitrogen purge by thermogravimetry (Q500 TA Instruments, DE) at 10°C/min heating 
rate. 
 
3.3.3 Mechanical properties of crystals 
Crystal surface roughness and crystal orientation are two key factors affecting 
nanoindentation results.
34-36
    Table 3.2 summarizes these and key mechanical properties 
of the three crystals.  The average surface roughness ( ) of the crystal surfaces indented 
in this study was less than 10nm.   
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Table 3.2.  Summary of mechanical properties of crystals measured by nanoindentation.   
 
Material 
Crystal 
face 
indented 
Surface 
Roughness 
α (nm) 
Crystal 
hardness 
H (GPa) 
 
Reduced 
elastic 
modulus 
Er (GPa) 
 
Yield 
Strength 
σy (MPa) 
 
Zone of 
plastic 
deformation 
at Lmax† 
ψ (nm) 
-piroxicam [100] 0.54 - 4.2 0.47±0.03 6.50±0.2 749.57 1081.7 
Saccharin [100] 0.98 - 5.7 0.33±0.04 4.23±0.1 446.35 1175.9 
Cocrystal [001] 0.92 - 5.9 0.74±0.06 19.6±1.0 1864.23 929.71 
 
† Lmax= load at maximum displacement 
 
Figure 3.4 shows the representative load–displacement curves for the three materials.  
At any fixed displacement on this plot, the load necessary to create the corresponding 
displacement into the crystal decreased in the order of cocrystal > piroxicam > saccharin.  
Also, the loading portions of the indentation curves showed distinct excursions or ‘drop–
in’ at constant displacements.  The same event is termed as 'pop–in' for load–controlled 
indentation, where it involves change in displacement at constant load.
26
  Based on the 
load–displacement curves, various mechanical properties of the three materials can be 
estimated (Table 3.2).  Hardness decreased in the order of cocrystal > piroxicam > 
saccharin, which is consistent with the hierarchy of the load–displacement curves shown 
in Figure 3.4.  The reduced elastic modulus also followed the same order of cocrystal > 
piroxicam > saccharin. 
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Figure 3.4.   Load–displacement nanoindentation curves of β-piroxicam, saccharin and 
cocrystal.  Arrows indicate some drop-in events. 
 
Nanoindentation may provide a direct measurement of the yield strength by 
performing multiple loading and unloading cycles (Figure 3.5a) until the yield point is 
exceeded, which is typically at a small strain (<50nm).  Below the yield point, the 
indenter loads produce purely elastic response and no hysteresis between the loading and 
unloading curves is observed (Figure 3.5b).  Beyond the yield point, hysteresis between 
the loading and unloading curves is clearly visible due to the occurrence of irreversible 
deformation in the samples.  The yield point corresponds to the maximum shear stress 
( max) necessary to nucleate a single dislocation under indenter stress, which is given by 
Eq. 5.
37
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where, L is the load on sample, Er is the reduced elastic modulus, R is the indenter tip 
radius, and  is the penetration depth into the sample.    
 
 
 
 
 
 
 
Figure 3.5. (a)  Partial loading-unloading profiles used for yield strength estimation.  (b) 
Overlays of the load-displacement profiles with a partial unload to assess elasticity-
plasticity transition.  The initial elastic loading segment has been fitted with Hertz 
equation. 
 
 
The yield strength, calculated using equation 5, decreased in the order of cocrystal > 
piroxicam > saccharin (Table 3.2).  The corresponding contact radii (a) at the yield point, 
calculated using equation 6 following the classical Hertzian model of elastic contact 
mechanics,
37
 were ~57.0 nm (cocrystal), ~60.4 nm (piroxicam) and ~55.2 nm (saccharin).   
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Figure 3.6.  (a)  2D images of indents of saccharin, β-piroxicam and cocrystal.   The 
loads at maximum displacement decrease in the order of cocrystal > piroxicam > 
saccharin.  (b)  Corresponding 3D plots showing pile up and residual indent after 
withdrawal of indenter tip. 
 
Under indenter load, a zone of plastic deformation (ψ) is created surrounding the contact 
region between the indenter tip and the material being indented.   Using Hill's theory of 
elastic–plastic contact mechanics,38 ψ can be calculated using Eq. 7.   
)7(
2
3
ys
L  
a
Saccharin Load ~1292 µN Piroxicam Load ~1836 µN Cocrystal Load ~3863 µN
 
Piroxicam
Saccharin
Cocrystal
b 
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Saccharin and the cocrystal have the largest and the smallest ψ, respectively (Table 3.2). 
Figure 3.6a shows the 2D images of the surfaces after indentation.  The loads 
corresponding to the maximum displacements of ~500nm are noted for each material on 
the 2D plots.  The corresponding 3D images of the indented surfaces (Figure 3.6b) show 
clear pile–up 27 and residual indent after withdrawal of the indenter tip.   
 
3.3.4. Molecular properties of crystals 
The molecular properties of crystals, determined by molecular modeling of crystal 
structures of the three materials, are summarized in Table 3.3.  Crystal lattice enthalpy, 
which indicates the strength of lattice interactions, follow the order of saccharin < 
piroxicam < cocrystal, even though the values are comparable.  A higher lattice enthalpy 
indicates stronger lattice.  The slip planes are identified based on attachment energy (Eatt) 
calculations.  Eatt is defined in equation 8, where EL is lattice enthalpy and Eg is the 
enthalpy required to add a slice of molecules from a growing crystal face.  Slip plane in a 
crystal has the lowest Eatt value. 
)8(glatt EEE  
 
Burgers vector, which quantifies the extent of lattice mismatch in a crystal caused by 
dislocation, is the largest for the cocrystal. 
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Table 3.3.  Summary of molecular properties quantified by molecular modeling based on 
crystal structure data collected at room temperature 
 
 
Slip system 
[hkl] (uvw) 
Material 
Lattice 
enthalpy 
(kcal/mol) Based on attachment energy 
calculations 
Burgers 
vector  
b (nm) 
β-piroxicam 
-208.45 [020] (100) 0.713 
Saccharin 
-199.62 [100] (010) 0.691 
Cocrystal 
-209.63 [001] (010) 1.046 
 
 
 
3.4 DISCUSSION 
Understanding the relationship between crystal packing and the mechanical properties of 
organic crystalline solids is a topic of considerable interest in the fields of solid–state 
chemistry and crystal engineering.
9, 26, 39-42
   
 
3.4.1 Mechanical properties of crystals 
Nanoindentation of crystalline samples has been widely used to characterize the 
mechanical properties of materials at sub–micron scale based on the principles of contact 
mechanics.
27, 43
   The progression of indentation as a function of load
38
 is schematically 
represented in Figure 3.7.     
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Figure 3.7.  Stages of indentation:  1.  Indenter tip touching the surface of the material;  
2. at σ < σys, purely elastic deformation; 3. at yield point (σ = σys), elastic-plastic 
transition, plastic region completely surrounded by elastic medium; and 4. at σ > σys, 
load-dependent regional distribution of elastic and plastic deformations under indenter 
tip. 
 
At relatively small strains corresponding to a few nanometers in displacement, the 
deformation of a crystal is purely elastic, and the load–displacement plot approximately 
follows a Hertzian relationship.   At the yield point, there is the onset of plastic 
deformation, with the plastic zone relatively small and fully contained within the 
surrounding elastically deforming continuum.  Consistent with the previous results,
44
 the 
yield point for all three crystals in this study is associated with a displacement excursion 
with approximately the magnitude of one Burgers vector (Table 3.3).  Burgers vector is a 
measure of the lattice mismatch caused by the nucleated dislocation,
19
   As the load on 
crystal is further increased, the plastic zone grows in dimension.  The plastic zone 
diameter (ψ) is a measure of the ease of nucleation of crystal dislocations or linear 
defects, whose motion along slip planes is one of the primary mechanisms of plastic 
 
PE E
P
Material surface
Material deformations at increasing indenter loads
Isoline σ = σys
E
P – elastic-plastic region
Pile-up
1 2 3
E
4
E – elastic continuum
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deformation.
19
    ψ represents the extent of plastic deformation occurring in the crystals as 
a result of the applied load.  In the current system, ψ is the highest for saccharin and the 
lowest for the cocrystal when evaluated at the same maximum penetration depth of 500 
nm under maximum indenter load.    
 
At loads exceeding the yield strength of a material, the plastic zone has radial stress 
and strain symmetry,
38
 which pushes a portion of the material up along the sides of the 
indenter tip by plastic flow, a phenomenon known as pile–up.  Pile-up is observed for all 
three materials (Figure 3.6).  The extent of pile–up at either the same load or depth of 
penetration has been used in the past as a measure of plasticity.  However, the extent of 
pile–up depends on the indenter load applied.  In this study where the maximum 
penetration depth of 500 nm was used, both the maximum load and the extent of pile–up 
are the highest for the cocrystal even though it is the least plastic (highest H).  Once we 
normalize the extent of pile–up with the load applied, we obtain similar values of 
normalized pile–up for the three crystals.  This indicates that even though pile–up is a 
consequence of plastic flow of materials, the extent of pile-up alone is not a reliable 
descriptor of material plasticity.  
 
Beyond the yield strength, multiple 'drop–in' events are visible in the loading portions 
of the indentation curves (Figure 3.4).  The dimensions of these excursions are the largest 
for the cocrystal and the smallest for saccharin.  The appearance of multiple excursions 
corresponds to bursts of dislocations under applied load.
44
   The size of these excursion 
events are typically in integral multiples of Burgers vector.   Consistent with this idea, 
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excursions are the largest for the cocrystal, which has the largest Burgers vector (Table 
3.3), and the smallest for saccharin.  The importance of Burgers vector in the excursion 
events can be understood based on the stress field configuration of dislocations.  A 
crystal dislocation has a stress field composed of two components—an inner inelastic 
core and an outer region where the theories of linear elasticity hold.  No two adjacent 
dislocations can approach each other to a distance closer than the inelastic core, which 
has a size ~3 to 5 times the Burgers vector for a material.
19
 Therefore, the dimensions of 
these 'drop–in' events, which are bursts of multiple dislocations, have to be integral 
multiples of 3 -5b.  For crystals in this study, most of these excursions are ~2 – 8 times 
5b depending on load.    
 
Insights into material deformations can also be gained by analyzing indent images 
after indenter withdrawal (Figure 3.6).  The residual indent depth after indenter 
withdrawal, for instance, is material specific, even though the same maximum indentation 
displacement was used for all three materials.  This depth is the smallest for saccharin 
and the largest for cocrystal.   The difference in depth is attributed to the differences in 
elastic recovery of the three materials.  Saccharin crystal surface likely undergoes more 
elastic deformation to accommodate for the stress applied by the indenter tip, leaving a 
shallower residual impression upon withdrawal of the indenter tip.   This is consistent 
with the lowest Er of saccharin.   A similar mechanism explains the differences in 
residual indent angles, which is the smallest for the most elastic saccharin and the largest 
for the least elastic cocrystal.  The similar residual indent angles between saccharin and 
piroxicam also agree with their similar Er.  Finally, high lattice enthalpy of the cocrystal 
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(Table 3.3) seems to correlate with its low deformability, which is manifested as high E 
and H.     
 
3.4.2 Correlation between powder compaction and crystal mechanical properties 
Mechanical performance of bulk powders of viscoelastic materials are determined by 
the relative predominance of elastic and plastic deformation components.
10, 19
   Inter–
particulate bonding area develops as a result of rearrangement and deformations of 
particles under mechanical stress during powder compaction.
23
   However, compacts 
retain integrity only if an adequate amount of the inter–particulate bonding area is 
preserved once the compaction pressure is withdrawn.  Therefore, permanent plastic 
deformation is a prerequisite for forming intact tablets by powder compaction.
23
  For this 
reason, materials with low plasticity, e.g., acetaminophen,
45
 have poor powder 
compaction properties.  Strategies for addressing poor compaction properties of these 
crystals include surface coating with a plastic material 
46
 and modification of solid–state 
chemistry to render adequate plasticity for bonding area retention.
25, 41
   Using 
polymorphs, it has also been shown that plasticity is crystal packing dependent and 
higher plasticity generally leads to superior compaction properties.
39, 47, 48
 
 
It has been proposed that the minimum tensile strength of ~2 MPa is required for the 
successful commercial tableting.
49
   By this measure, both piroxicam and the cocrystal 
exhibit very poor tabletability (Figure 3.3a).  This is also supported by the very low σ20 
values for these materials (Table 3.1).  In comparison, the compaction properties of 
saccharin are much superior, with tensile strength exceeding 2 MPa at pressures >150 
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MPa.  Using 1:1 (mole ratio) physical mixture of piroxicam and saccharin as a control, 
we show that the mechanical properties of the cocrystal were far inferior to that of the 
physical mixture, indicating that the worsened mechanical properties of the cocrystal are 
a consequence of its unique crystal packing features. 
 
 The differences in powder mechanical properties may be well explained based on 
their different mechanical properties of the three crystals.   The contribution of elasticity 
and plasticity on the compaction behavior is of special interest.  Saccharin is the most 
plastic among the three crystals, indicated by its lowest hardness and lowest yield 
strength determined using nanoindentation (Table 3.2).   A lower hardness indicates the 
greater ability of a material to undergo plastic deformation under mechanical stress. 
Based on our experience, organic materials with either very low (<0.2 GPa) or very high 
(>0.7 GPa) hardness are prone to suffer from poor tabletability.  Within the intermediate 
hardness range, tabletability generally increases with decreasing hardness.  The cocrystal 
has a much higher hardness compared to both the co–formers and therefore smaller 
bonding area retention and inferior tabletability.    
 
In addition to plasticity, important insight into tabletability is also provided by 
elasticity, which can be characterized either by elastic modulus (Er) of a crystal or the 
elastic recovery (ER) of compacts during the process of decompression (withdrawal of 
compaction pressure).  A lower value of Er (Table 3.2) or higher value of ER (Figure 
3.3b) indicates higher elasticity.   High degree of elastic recovery can break inter–
particulate bonding sites and deteriorate tabletability.  In this work, the cocrystal shows 
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the highest degree of elastic recovery of compacts (Figure 3.3b).   Saccharin has high 
plasticity but also low Er, (Table 3.2) which leads to large elastic recovery.  This high 
elasticity of saccharin compacts may be one reason for the high degree of variability seen 
in the saccharin tabletability data.   
 
The mismatch between the rank orders of Er for the crystals and ER for their 
compacts may be explained by the porous nature of the compacts ( >20%).  ER of a 
compact is determined by the mechanical property of the crystal–air composite confined 
in a die, rather than the Er of the crystal.  It has been known that the elastic modulus of a 
compact generally decays exponentially with increasing porosity.
50
  Although Er of the 
cocrystal is the highest among the three crystals, its compact is also more porous at the 
same compaction pressure.  Consequently, the apparent elastic modulus of its compact is 
low, which leads to high ER.  Similar mismatch in rank orders of the two parameters 
have previously been reported for other materials.
26
 
 
3.5 CONCLUSIONS 
We have shown that cocrystallization between saccharin and piroxicam leads to reduced 
plasticity and compromised tableting behavior.  The mechanism of the deteriorated 
mechanical performance of the cocrystal has been investigated by probing the mechanical 
properties of the cocrystal and the co–formers using nanoindentation, which is supported 
by an analysis of crystal packing.  The multi-scale investigation reveals that much 
reduced cocrystal plasticity (or higher hardness) is responsible for the poor tableting 
behavior of its bulk powder.  Moreover, high lattice enthalpy of the cocrystal seems to 
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correlate with its low deformability, which is manifested as high E and H.    Our efforts 
of probing the mechanical properties and deformations of molecular organic materials 
cater to a long-lasting need of systematically studying such properties in these classes of 
molecular organic materials at sub-micron and bulk levels. 
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Chapter 4. 
 
 
Modifying surface structure of microcrystalline cellulose 
by dry mechanical coating to improve powder flow 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based on the following published research article: Chattoraj et al., 
Journal of Pharmaceutical Sciences, 100, 4943-4952, 2011.   The article has been 
reproduced with permission from John Wiley and Sons. 
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The objective of this chapter is to apply the concept of Materials Science Tetrahedron at 
the level of bulk powder to modify the surface structure of powders to address the 
problem of poor powder flow.  Poor flow properties hinder the easy handling of powders 
during industrial scale processing.  In this work, we show that powder flow can be 
substantially improved by reducing the cohesion of powders through coating them with 
nano-sized guest particles, by the application of shear stress with comilling of guest and 
host particles.  We have systematically investigated the effects of total number of 
comilling cycles (varied between 1 to 70 cycles) and silica loading (varied between 0 to 
1.0 wt%) on the flow behavior of a highly cohesive and poorly flowing grade of 
microcrystalline cellulose powder (Avicel PH105).  Optimum flow enhancement has 
been achieved with 1.0 wt% silica loading at 40 comilling cycles.  The flow properties of 
nanocoated Avicel PH105 are comparable with those of Avicel PH102, which exhibits 
adequate flowability for processing on a high speed tablet press.  Comilling is fast and 
suitable for continuous processing.  It holds potential for addressing industrial powder 
handling problems caused by poor powder flow properties.   
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4.1 INTRODUCTION  
Adequate powder flow is a necessary prerequisite for the successful 
pharmaceutical manufacturing using unit operations such as powder compaction and 
encapsulation.
1-3
   Manufacturing problems, arising from poor powder flow properties, 
are regularly encountered during the industrial handling of bulk powders.
1, 2, 4, 5
   Flow-
related problems are expected for fine powders (d50 < 30 m), which are generally highly 
cohesive and poorly flowing.
1, 4, 6, 7
  A common approach adopted in the industry for 
improving powder flow is particle size enlargement through granulation.   Despite recent 
technological advancements, granulation can often lead to processing problems, such as 
deteriorated powder tabletability and poor drug release behavior.
8-11
  Tabletability suffers 
due to size enlargement of particles during granulation.   Moreover, granulation 
invariably lengthens the manufacturing process, and results in higher production costs.  
Thus, it would be extremely useful to develop an alternate technique for flow 
improvement of cohesive powders without the requirement of granulation.  Such a 
technique should also be economical, easy to set-up, and suitable for industrial scale 
powder processing.  
 
An attractive alternate way to improve the flow properties of fine powders, 
without the need of granulating, is dry particle coating of the cohesive powder surfaces, 
which facilitates the physical separation of adjacent substrate particles, thereby reducing 
cohesion.  For example, Yang et al 
12
 have shown that the flow properties of cornstarch 
can be improved significantly by coating with silica using mechanical coating processes, 
such as magnetic-assisted impaction coating (MAIC)  and hybridizer process.
13, 14
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Coating using fine guest particles tends to produce better flow of cohesive powders.   
Similarly, by dry coating using a plasma downstream reactor, the flow of cohesive 
lactose particles (d ~ 30.9 m) is increased by a factor of 3.1.
6
  Likewise, the flow 
characteristics of cohesive lactose monohydrate powder are modified by intensive dry-
coating with magnesium stearate and fumed silica through mechanofusion.
16, 17
   
 
Even though these techniques can improve powder flow, they invariably require 
specialized instruments that are not commonly available in manufacturing plants.  In 
addition, most of these processes involve intense mechanical impact that significantly 
alters particle properties, such as particle size and shape and can induce mechanical 
amorphization in crystals.  Potential chemical degradation of the material due to impact 
during powder processing is another serious problem.
18
  Finally, scaling up these 
processes is generally difficult and costly.  Thus, there is a need of finding a cost-
effective and scalable dry surface coating (nanocoating) technique for improving the flow 
of cohesive powders that will not suffer from these deficits.  Herein, we show that 
comilling is a process that successfully meets these criteria.  In this process, a powder is 
subjected to only shear stresses (no impact) when it is pushed through a screen by a 
rotating impeller, and thereby avoids most of the problems in the earlier processes arising 
from impact stress on materials.  The comilling process is fast and suitable for continuous 
operation, which makes it ideal for industrial scale powder nanocoating. 
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4.2. MECHANISM OF NANOCOATING 
The physics behind the beneficial role of nanocoating on powder flow has been 
well explained in the literature.
19
  Briefly, flow improvement by nanocoating can be 
easily understood by considering the interplay between two universal forces affecting 
powder flow, i.e., inter-particle cohesion (mainly van der Waals forces) and gravitational 
force.
6, 15, 19
  Let us consider a container with a small opening at the bottom, assuming 
that 1) the particles at the air-powder interface on the bottom opening are influenced 
mainly by gravity and cohesion, and 2) the opening is sufficiently large so that particle 
jamming is avoided during flow.  While gravity favors powder flow by pulling particles 
downward, cohesive force hinders flow by inter-particle attraction. As long as gravity 
dominates over cohesion, powder flow is spontaneous.  Conversely, powder flow is 
problematic when cohesion dominates over gravity.  According to Hamaker’s theory,20 
the cohesive interaction (F) between adjacent particles (van der Waals interactions) is 
inversely proportional to the square of the distance of separation, as shown in equation 1.   
 
          (1) 
 
Where, A is Hamaker’s constant, D1 and D2 are particle diameters, and d is the distance 
of separation between particle surfaces.  If we assume that the two host particles have 
equal diameters, then the cohesion between adjacent host particles is given by the 
simplified equation 2.
19
 
          (2) 
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Nanocoating helps to increase the distance of separation (d) between adjacent host 
particles and hence reduces cohesion, sometimes by several orders of magnitude 
6, 19
.  
The substantially reduced cohesion, in turn, leads to profoundly improved powder flow as 
gravity is allowed to outplay cohesion.  As a secondary mechanism, the guest 
nanoparticles can act as ball bearings to further improve powder flow by reducing the 
friction between host particles.  It should be noted that, for optimum flow improvement, 
nanoparticle coating must be discrete.  A continuous layer of guest nanoparticles on the 
host particles slightly increases the diameter (D) of the host particles.  When such 
particles are in contact, the d is very small while D is slightly larger than before coating.  
Thus, the cohesion remains high according to equation 2.  Alternatively, this may be 
understood by considering the scenario where two host particles are initially separated by 
a single guest nanoparticle.  In this situation, cohesion is significantly lower than if the 
two host particles are in contact because of the larger d.  If the surfaces of both host 
particles are progressively covered with more guest particles, the attraction force between 
the host particles increases because of the increased mass.  When a continuous coating 
layer is achieved, the attraction force is the highest.     
 
4.3 MATERIALS AND METHODS 
4.3.1 Materials 
Microcrystalline cellulose (Avicel PH105, Batch: 50843C, FMC Biopolymer, 
Philadelphia, PA) was selected as the cohesive host (substrate).  Avicel PH105 is well 
known for exhibiting exceptional tabletability, but very poor flow properties.
4
  Colloidal 
silica (grade M-5P, ~14 nm, Cab-o-sil, Cabot Corp., Boston, MA) was selected as the 
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coating material (guest).  Before comilling, both powders were first vacuum dried for 24 
hrs at room temperature and then exposed to ambient conditions for approximately 1 hr 
before coating operations by comilling.  The moisture contents of coated and uncoated 
powders were found to be similar by thermogravimetric analysis.  Avicel PH102 (Batch: 
P208819629, FMC Biopolymer, Philadelphia, PA) was utilized as a reference powder to 
assess, by way of comparison, whether the coated powders exhibited adequate flowability 
for successful high speed tableting.
1
 
 
4.3.2 Nanocoating procedure 
Nanocoating was performed by comilling Avicel PH105 and silica (Comil
®
, 
Model U3, Quadro Engineering Corp., Waterloo, OT, Canada).  Avicel PH105 and silica 
powders were mixed by geometric dilution and passed through a standard sieve with 
150 m opening before the comilling operation.  The pre-sieving step improved the 
nanocoating efficiency by breaking large silica agglomerates, which otherwise tended to 
‘float’ on the top of the powder bed and did not easily pass through the comilling screen.  
The pre-sieved powder mixture was then placed within the comill powder-receiving 
chamber fitted with a stainless steel screen (round holes of 0.9905 mm, or 0.039", 
diameter, part number: 7B039R03125).  The lowest speed (2200 rpm) of the impeller 
(150 Grit round impeller with square arms) was used to minimize mechanical stress on 
the powders.  SEM data, particle size data, and powder XRD data showed no evidence 
that suggested any change in particulate properties or crystallinity of MCC particles after 
comilling.  Factors such as the total number of comilling cycles, silica loading, type of 
screen used (mesh size), impeller speed, and impeller type can all potentially influence 
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the efficiency of the nanocoating process.  However, in this study, we focused on 
evaluating the effects of the number of comilling cycles and silica loading, while fixing 
the other variables.  The effect of comilling cycles (0 to 70 at increments of 10 cycles) on 
flow was evaluated at a constant silica loading of 1.0% (wt%).  The effect of silica 
loading (0 – 1.0%) on flow was assessed by fixing the total number of comilling cycles at 
40, which corresponds to optimum flow enhancement (discussed later).  A constant batch 
size of 100 g was used throughout our study.  Fewer cycles are expected to achieve the 
same degree of flow improvement if industrial scale comilling is used for nanocoating the 
powders.   Due to the high efficiency of this process, it took only a few seconds to 
process 100 g of powder by comilling.   
 
4.3.3 Particle size distribution 
Particle size distributions (PSD) of uncoated and nanocoated MCC were 
measured in triplicates using a laser scattering particle sizer (Mastersizer 2000 with a 
Scirocco dry module, Malvern Instruments Ltd., UK) operated at an inlet air pressure of 1 
bar and feed-rate of 30%.   
 
4.3.4 Specific surface area 
The speciﬁc surface areas (SSA) of powders were measured by Brunauer, 
Emmett, and Teller (BET) nitrogen gas adsorption method (Tristar, Micromeritics, 
Norcross, GA). Before each measurement, the sample was purged with a continuous 
stream of nitrogen gas at 30 °C for at least 1 h.  Nitrogen adsorption was measured at 
multiple partial pressures (P/P0) ranging from 0.05 to 0.2. 
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4.3.5 Ring shear cell measurement of powder flow  
Powder flow properties were measured using a ring shear cell tester (RST-XS, 
Dietmar Schulze, Wolfenbuttel, Germany).
4, 21, 22
  Before flow measurement, the 
performance of the instrument was verified using limestone standard.  For shear cell 
measurements, powders were first over-filled into a ring-shaped cell (approximately 30 
mL in volume). The excess powder was then gently scraped off to produce a flat surface, 
which was coplanar with the top edges of the cell.  Care was taken while adding powder 
to the shear cell to avoid the formation of large air pockets within the powder bed.  Four 
pre-shear normal stresses, 1, 3, 6, and 9 kPa were used in shear cell study.  Under each 
pre-shear normal stress, shear tests were conducted at a total of five progressively 
increasing normal stresses equally spaced between zero and the corresponding pre-shear 
normal stress.  The sixth shear test was carried out at the stress conditions identical to the 
first shear test (the lowest normal stress).  Any change in properties of constituting 
particles was deemed negligible when the flow difference between the first and sixth 
measurement was less than 5%, which was approximately the relative standard deviation 
in our typical shear cell measurements.  According to this criterion, none of the powders 
tested for this study showed any change in properties during shear cell testing.  
 
A yield locus was constructed by connecting the neighboring points on the plot of 
maximum shear stress versus normal stress during each shear test.
22
  The average shear 
stress from the two shear tests at the lowest normal stress was used for plotting.  The 
lowest portion of the yield locus was obtained by extending to y-axis (shear axis) the 
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segment defined by the points at the two lowest normal shear stresses (straight section 
method of data analysis).  From each yield locus, unconfined yield strength, fc, and the 
corresponding major principal stress, n, were obtained by drawing two Mohr’s circles by 
the following criteria: 1) one circle passing through origin and tangent to the yield locus, 
and 2) the second circle passing through the pre-shear point and tangent to the yield 
locus.  Flow function of a powder was obtained by plotting fc against n, derived from 
different yield loci.  At a given n, a lower fc indicates easier initiation of powder flow.   
Another way to represent the shear cell data is to calculate flow factor, ff, which is 
defined as n/fc. 
22
  All shear cell experiments in this study were performed at 23.5 ± 1.5 
°C and 30 ± 3% RH.    
 
4.3.6 Compaction studies 
Powder tabletability properties were tested using a compaction simulator 
(Presster, Metropolitan Computing Company, East Hanover, NJ) simulating a Korsch 
XL100 (10 station) tablet press (production speed of 61600 tablets/hr, corresponding to a 
press speed of 102.7 rpm, dwell time of 20 ms). Round (9.5 mm in diameter) flat-faced 
punches were used for tableting.  Tablet breaking forces were measured using Texture 
Analyzer (TA-XT2i, Texture Technologies Corp., NY, 50 kg load cell, test speed of 0.01 
mm/s with a trigger force of 5g).  Tablet radial tensile strength was calculated using the 
tablet breaking force, thickness, and diameter which were measured using digital caliper 
(Electron Microscopy Sciences, Hatfield, PA).
23
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4.3.7 Scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS) 
A thermally activated field emission gun type scanning electron microscope 
(FEG-SEM, JEOL 6500F, Tokyo, Japan) was used to obtain information on particle size 
and surface topography of uncoated and nanocoated powders (1% silica, 40 comilling 
cycles).  Before SEM analysis, a thin layer of platinum (thickness ~50 Ǻ) was deposited 
on the particle surfaces. The SEM sample chamber was maintained with a high vacuum 
(10
-4
 to 10
-5
 Pa) during the imaging process.  Point scanning energy dispersive spectra 
were collected for both the coated and uncoated samples.  This showed the relative 
proportions of different elements in the scanned spectra generated using Noran System 6 
software (Thermo Fischer Scientific, West Palm Beach, FL).    
 
4.3.9 Statistical analysis 
Statistical analysis on data was performed using software package Arc XLISP-PLUS 
version 3.04 (R. D. Cook & S. Weisberg, University of Minnesota).  At 95% confidence 
level, p<0.05 was considered significant. 
 
 
4.4 RESULTS AND DISCUSSION 
4.4.1 Particle size distribution and specific surface area 
 The very small particle size of Avicel PH105 (d10 = 6.8 ± 0.1 m and d50 = 20.9 ± 
0.1 m, and d90 = 45.7 ± 0.5 m, n = 3) is consistent with its high cohesiveness and poor 
flow properties.  The particle size increases very slightly for Avicel PH105 after being 
coated with 1% silica after 40 comilling cycles, which can be attributed to the deposition 
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of nanoparticles on the surfaces of Avicel PH105 (Figure 4.1).  Silica nanoparticle 
coating also helps to increase the specific surface area (SSA) of powder significantly 
(p=1.5×10
-6
) with SSA= 1.999 ± 0.004 m
2
/g for Avicel PH105 as received, and 6.171 ± 
0.009 m
2
/g for Avicel PH105 coated with 1.0% silica at 40 comilling cycles.   
 
 
 
 
 
 
 
 
Figure 4.1.  Cumulative particle size distribution (n = 3) of Avicel PH105, both uncoated 
and coated with 1% silica (40 comilling cycles).   
 
 
 
4.4.2 Effect of comilling cycles on powder flow 
At 1.0% silica loading, powder flow properties show considerable improvement 
with repeated comilling up to a total of 40 cycles, as shown by the lowering of the flow 
function line with increasing number of milling cycles (Figures 4.2).  The reduction in 
slope of the flow function is statistically significant (p=4.4×10
-5
), with the slope 
decreasing from 0.269 (for uncoated Avicel PH105) to 0.086 (for nanocoated with 1% 
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silica, 40 comilling cycles).  However, repeated milling beyond 40 comilling cycles leads 
to no further flow improvement.   
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Figure 4.2.  Effect of number of comilling cycles on flow functions of Avicel PH105 at 
silica loading of 1.0%.  Numbers on the plots represent the corresponding comilling 
cycles employed.  Error bars represent one standard deviation of the measurements (n = 
3). 
 
 
Jenike 
24
 has developed a scheme for classifying powder flow properties, based on 
flow factor (ff), defined above.  A powder is considered unable to flow when ff<1, very 
cohesive when 1<ff < 2, cohesive when 2 < ff < 4, easy-flowing when 4 < ff < 10, and 
free-flowing when ff > 10.
22, 24-26
  It must be noted that Jenike’s flow classification is 
based on flow characterization using a translation shear cell, and not the ring shear cell 
used in this study.  It is possible that the exact numerical ranges of the classification may 
  95 
not be valid for our studies.  It is, nevertheless, a useful classification system to gain 
insight into the powder flow behavior.  According to this classification, uncoated Avicel 
PH105 falls within the cohesive region (Figure 4.2).  However, after nanocoating with 
1.0% silica using only 20 comilling cycles, the flow function of the powder is moved into 
the easy-flowing zone (4<ff<10), at major principal stresses ≥ 3 kPa.    
 
 
 
 
 
 
 
 
Figure 4.3. Variation of flow factor, ff, of Avicel PH105 with total number of comilling 
cycles with 1.0% silica loading at 3 kPa normal stress.  Error bars represent one standard 
deviation of the measurements (n = 3). 
 
 
The relationship between flow factor (ff) at a fixed normal stress of 3 kPa, and the 
number of comilling cycles is shown in Figure 4.3.  40 comilling cycles (at 2200 rpm 
comilling speed) correspond to optimum flow improvement for 1.0 wt% silica loading in 
this model system.  For this batch, the flow is significantly improved (p=0.0007) 
compared to uncoated Avicel PH105.  The lack of flow improvement after 40 cycles, 
shown by decreasing ff, suggests that at this stage, sufficient surface coverage of host 
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particles has been achieved so that two adjacent hosts, at random orientations, are always 
separated by nanoparticles.    
 
4.4.3. Effect of silica loading on flow   
The effect of silica loading on flow factor, ff, at 40 comilling cycles is shown in 
Figure 4.4.  Silica loading has been varied from 0% (uncoated Avicel PH105) to 1.0% 
silica at increments of 0.2%.  At normal stresses ≥ 3 kPa, the powders behave as non-
cohesive (ff>4) at all silica loadings of ≥ 0.2%.   Nanocoating with a silica loading of 
1.0%, at 40 comilling cycles, produces a mean flow factor that is not statistically different 
(p=0.81) from flow factor of a free flowing product (ff=10).  Thus, it appears that with 
this level of silica nanocoating, it is sufficient to transform the otherwise cohesive Avicel 
PH105 powder into a free-flowing product at preshear normal stresses ≥ 9 kPa.   
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Figure 4.4. Effect of silica loading on flow factors of Avicel PH105 with 40 comilling 
cycles.  Error bars represent one standard deviation of the measurements (n = 3). 
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In this context, it must be mentioned that colloidal silica has been commonly used 
in the pharmaceutical industry with the intention to enhance powder flow of formulated 
powders.  Thus, to clarify that the flow enhancement of Avicel PH105 observed in this 
work can be attributed to comilling and not simply to the presence of silica, we have 
compared the flow properties of nanocoated Avicel PH105 (using a comill, 1% silica) 
and a blend prepared using a common V-shaped laboratory blender (Blend Master, 
Patterson-Kelley, PA, 10 min, 1.0% silica).    
 
As shown in Figure 4.5, comilling leads to significantly improved flow properties 
(p=0.002) compared to standard blending at same silica loading. While the comilled 
sample flows easily, the powder after 10 min of simple blending and sieving remains 
cohesive and exhibits flow properties that are statistically similar to the starting Avicel 
PH105 (p=0.21).  Clearly, ordinary blending process does not provide sufficient amount 
of shear stress necessary for effective de-agglomeration of silica particles and subsequent 
coating of host particles.   
 
4.4.4. Flow comparisons with Avicel PH102 
Avicel PH102 has recently been established as a reference material that lies near 
the boundary between zones of acceptable and unacceptable flow properties during high 
speed tableting.
1
   By this measure, Avicel PH105 is clearly not suitable for high speed 
tableting because it exhibits much poorer flowability than Avicel PH102 (Figure 4.5).  In 
contrast, Avicel PH105 comilled with 1.0% silica after 40 comilling cycles display flow 
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properties that are statistically similar (p= 0.65) to Avicel PH102 (Figure 4.5). Thus, due 
to its much improved flow properties, the nanocoated Avicel PH105 is expected to be 
acceptable for use on a high speed tablet press.   
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Figure 4.5.   Flow factor difference of powders at 9 kPa normal stress.   The nanocoated 
batch of Avicel PH105 was processed with 1% silica at 40 comilling cycles.  Error bars 
represent one standard deviation of the measurements (n = 3). 
 
 
4.4.5. Compaction studies 
To examine the impact of nanocoating on the compaction properties of Avicel 
PH105, we have tested the tabletability (dependence of tablet tensile strength on 
compaction pressure) of uncoated and optimized nanocoated Avicel PH105 (1% silica, 40 
comilling cycles) and Avicel PH102, which is commonly used in pharmaceutical tablet 
products (Figure 4.6).   
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Figure 4.6.  Tabletability of uncoated Avicel PH105, nanocoated Avicel PH105 and 
uncoated Avicel PH102. The broken line indicates the minimum tablet tensile strength, 2 
MPa, for pharmaceutical tablets 
3, 8
. 
 
Uncoated Avicel PH105 shows exceptionally high tabletability and forms hard 
tablets.  Tablets compressed at compaction pressures higher than 220 MPa exceeded the 
limit of the load cell (50 kg) on the texture analyzer and could not be broken.  However, 
as expected based on its poor flow, it was extremely difficult to reproducibly fill the die 
with Avicel PH105 from a hopper.  The tabletability of nanocoated Avicel PH105 (1% 
silica, 40 comilling cycles) is inferior to the uncoated powder.  We attribute this reduction 
in tabletability on nanocoating to the reduced bonding areas between microcrystalline 
cellulose (MCC) particles, since bonding strength between MCC and silica is expected to 
be much lower compared to MCC-MCC particles.  The bonding between silica particles 
is negligible because they do not undergo appreciable amount of plastic deformation 
during compaction, so that tabletability of silica is essentially zero.
27
  Despite the 
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reduction, the tabletability of nanocoated Avicel PH105 is still superior to that of Avicel 
PH102.  Importantly, the nanocoated Avicel PH105 exhibits good flow behavior and is 
readily filled into the die from a hopper without any problem.     
 
4.4.6. SEM studies on coated particles 
After comilling, the discrete nanoparticle coating can be easily discerned on the 
surfaces of the Avicel PH105 particles using SEM (Figure 4.7).  We have identified these 
nanoparticles as silica by analyzing the EDS spectra of the coated particles (Figure 4.8).  
When these nanoparticles are surveyed by SEM-EDS analysis, a peak corresponding to 
silicon (Si) is always present in the resulting spectra.  When the nanoparticles are not 
included, the silicon peak is always absent.  A few clusters of silica particles can be 
observed in the SEM pictures.  The presence of some silica clusters is expected because 
of the cohesive nature of nanoparticles, which tend to agglomerate.  
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Figure 4.7.   SEM images of Avicel PH105 uncoated (left) and coated (right) with 1.0% 
silica loading at 40 comilling cycles at different magnifications.       
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Figure 4.8.  Energy dispersive spectra (EDS) of uncoated and 1.0% silica nanocoated 
Avicel PH105 (at 40 comilling cycles). The y-axis shows the counts of the number of 
photons received and processed by the EDS detector at different energy levels (x-axis). 
 
 
4.4.7. Rationale for using comilling process and colloidal silica 
Our results show that powder flow properties can be much improved through 
surface coating of cohesive cellulose with nanosized silica particles by comilling.  There 
are several motivations for using the comilling process in this study: 1) no additional 
capital investment is necessary for adopting this flow improvement technique because 
comills are commonly available in pharmaceutical industries; 2) the comilling process 
provides mostly shear stress, which effectively de-agglomerates nano-sized guest 
particles and facilitate coating onto host particles.  There is generally no significant 
temperature rise during comilling because of an absence of significant conversion of 
mechanical energy to heat through impact; 3) the comilling process is fast, continuous, 
and scalable.  Hence, it can be readily adopted during both development and 
manufacturing of pharmaceutical products. 
 
After showing that this simple, but elegant, process works, it is worth exploring 
why comilling has not been applied for improving powder flow before, when both the 
Coated with 1% silica 
Uncoated  
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problem of poor flow 
1, 13, 14, 28, 29
 and the comilling technique are prevalent in the recent 
decades.  Traditionally, comilling has mainly been used to de-agglomerate powders for 
particle size reduction.  Without a fundamental understanding of the physics of flow 
enhancement by nanocoating (described under the mechanism section), it is not intuitive 
to connect flow enhancement with the comilling process.  Based on our understanding of 
materials science tetrahedron (MST),
30
 performance related problems are tackled using 
the relationship between structure and property of a material.  Thereafter, a suitable 
engineering process is developed to overcome the performance problems by modifying 
structure and, thus, the properties of the material.  In essence, MST necessitates the 
seamless integration of materials science and engineering to tackle problems in material 
performance.  In this work, the performance-related problem was poor powder flow 
properties.  Based on the materials science portion of the problem in hand (i.e., surface 
nanocoated particles lead to flow improvement of cohesive powders), we searched for an 
engineering strategy that would solve the performance problem of poor flow on an 
industrial scale without subjecting the powders to large impact stresses.  Realizing the 
critical role of shear stress in nanocoating subsequently led us to identify the comilling 
process for achieving the desired goal.     
 
4.5. CONCLUSIONS 
We have shown that the simple, economical, and efficient comilling process can 
be successfully used to coat the surfaces of Avicel PH105 particles with nano-sized silica.  
Nanocoating results in profound improvement in the flow properties of the host powder 
without substantially compromising its tableting properties.  Thus, it is expected to be an 
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excellent tool for enabling the direct compression process in tablet manufacturing.  
Comilling is fast and amenable to continuous operation, which makes this process 
attractive for ready implementation in manufacturing plants to address unmet challenges 
related to poor powder flow.   
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Chapter 5. 
 
 
Assessing amorphization potential of crystals: Part 1.  
Concurrent influence of lattice strength and amorphous 
stability 
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From this chapter, we start our investigations on the involvement of structure-property 
relationships involved in solid-state amorphization of crystals under mechanical stress.  
The objective of this work is to develop a classification system for assessing the solid-
state amorphization of crystalline pharmaceuticals based on their structural and 
thermodynamic properties.   Amorphization of crystals is influenced both by crystal 
lattice strength (LS), which governs amorphous generation (crystal→amorphous), and 
amorphous stability (AS), which governs amorphous elimination (amorphous → 
crystalline).  In this study, LS has been assessed by quantifying volume expansivity of 
single crystals by variable temperature single crystal-XRD, and lattice fusion enthalpy of 
bulk powders measured by DSC.  AS is assessed using configurational entropy as a 
thermodynamic measure and activation energy of crystallization as a kinetic measure of 
stability.   Four classes of materials have been distinguished based on LS and AS:  I (high 
LS, low AS), II (low LS, low AS), III (high LS, high AS), and IV (low LS, high AS).  
Amorphous phase of classes I and II materials are highly unstable and tend to undergo 
fast recrystallization.  Materials in these two classes, therefore, have low propensity to 
undergo processing-induced amorphization due to rapid amorphous elimination.   On the 
contrary, materials in class IV are more suitable for amorphization, both due to weaker 
lattice favoring amorphous generation, and better amorphous stability than other classes.   
This knowledge of different amorphization classes of crystals is expected to facilitate the 
drug development process by an early identification of 1) the suitability of drugs for 
developing stable amorphous product, or 2) potential problems of unexpected processing-
induced amorphization if the crystalline phase is used for development. 
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5.1 INTRODUCTION 
Selection of an appropriate solid form of a drug is a critical step for developing a high 
quality drug product,
1, 2
 which is characterized by optimum product properties, such as 
aqueous solubility and dissolution kinetics,
3
 physical-chemical stability
4-6
 and mechanical 
properties.
7, 8
  Solids can either be crystalline or amorphous.  Traditionally, crystalline 
phases have been preferred for drug development due to their superior thermodynamic 
stability, superior chemical stability, high chemical purity, and the ease of 
processability.
2, 5
   Contrary to crystals, amorphous phase of a drug has higher free 
energy, which leads to the improved apparent solubility and dissolution kinetics of 
drugs.
9-12
  This is an advantage in drug delivery because an increasing fraction of newer 
drugs are poorly soluble due to the recent emphasis on biological target-specific 
lipophilic drug molecules.
13, 14
  Amorphous solids are characterized by the absence of 
three-dimensional long range molecular order and higher number of molecular 
configurations compared to crystals.
15-17
 However, long range order along single 
dimensions is still possible in glasses.
18
 Additionally, the more random molecular 
packing in amorphous solids can sometimes lead to improved chemical stability of 
drugs.
19
  This happens when reactive functional moieties are proximally packed in the 
crystalline state, which lowers the chemical stability of crystals.
20, 21
   
 
A key challenge with the selection of amorphous form for product development has 
been the tendency of amorphous to recrystallize during manufacturing or storage, which 
negates the solubility advantage conferred by the amorphous phase.  Ideally, the 
suitability of the amorphous phase of a drug for development must be accurately 
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predicted a priori from its material properties that are readily accessible.   If such an 
assessment is feasible, then an informed judgment can be made whether the crystalline or 
amorphous form of solid is preferred for further development.  Drugs displaying higher 
amorphization potential will be superior candidates for developing amorphous products.  
Such drugs will, however, also be prone to processing-induced solid-state amorphization 
if the crystal form is selected for development,
22-24
 which may lead to compromised 
product quality, such as variable dissolution, stability, and manufacturability.
25, 26
  
 
Contrary to amorphous preparation routes that involve a liquid or vapor intermediate 
phase, solid-state amorphization of crystals, which involves a direct crystal to glass 
conversion,
27
 is influenced both by (a) the ability of the starting crystal to resist the 
generation of disorder by mechanical stresses, and (b) the stability of the corresponding 
amorphous phase.   Solid-state amorphization by mechanical activation 
28
 during milling 
has been observed for a large number of crystals, both pharmaceutical,
22, 24, 29, 30
 and non-
pharmaceutical.
31-33
  Several theories have been proposed to explain the phenomenon of 
solid-state amorphization, including 1) the violation of the stability criterion of crystal 
lattice due to anharmonicity of lattice vibrations or phonons under mechanical stress,
34, 35
 
and 2) progressive generation of crystal dislocations leading to loss of crystalline order.
24, 
36, 37
   These theories, however, cannot be easily used to predict the amorphization 
potential of a candidate drug.  From a more practical viewpoint for drug development, it 
is highly desirable to predict the amorphization propensity using easily accessible 
material properties.  However, progress along this line has been limited, despite 
significant efforts in the recent years to correlate amorphization with properties of 
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crystals and glasses.   For instance, Tg has shown some influence on amorphization,
29
 
especially in relation to milling temperature,
22
 perhaps by affecting amorphous 
crystallization kinetics.   However, this study will demonstrate that crystal amorphization 
can be more reliably predicted using more fundamental structural and thermodynamic 
properties of organic materials. Most of the earlier efforts have been limited to 
phenomenological approaches,
29
 i.e., they only considered whether or not amorphization 
had taken place after milling.  A more quantitative approach to the phenomenon is clearly 
necessary to gain the insight needed for making reliable predictions. 
 
According to the principles of Materials Science Tetrahedron (MST),
38
 the 
performance of materials during processing is directly influenced by their structure and 
material properties.   As such, it is a reasonable expectation that the phenomenon of 
crystal amorphization has its structural and molecular origins.    The purpose of this work 
is to develop a classification system to readily assess the amorphization potential of 
crystals in the solid-state.  This is achieved through a thorough understanding of the two 
factors that control crystal amorphization (Figure 5.1): a) crystal lattice strength (LS), 
which affects amorphization generation, and b) amorphous stability (AS), which affect 
elimination of any generated amorphous phase.  
 
 
 
 
Figure 5.1.  Schematic illustrating the concurrent effects of crystal lattice strength (LS) 
and amorphous stability (AS) on amorphous generation and elimination, respectively 
Influenced by AS
Amorphous
phase
Crystal
Influenced by LS
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A large set of structurally diverse model compounds have been used in this study to 
develop the classification.  We have also adopted a material-sparing approach (<20mg) to 
predict amorphization, as the amounts of available materials are very limited during early 
stages of drug development.  Such a generic classification of the amorphization potential 
of crystals is expected to facilitate the drug development process by an early 
identification of 1) potential problems of unexpected processing-induced amorphization, 
and 2) the suitability of drugs for developing stable amorphous forms. 
 
5.2 MATERIALS AND METHODS  
5.2.1 Materials 
Amorphization propensity of a large number of structurally diverse model pharmaceutical 
crystals was investigated in this study. Acetaminophen, griseofulvin, 
hydrochlorothiazide, indomethacin, piroxicam, sulfacetamide, terfenadine, sulfamerazine, 
sulfisoxazole, sulfadiazine, sulfadoxin, sulfamethoxazole, aspirin, phenacetin, 
sulfanilamide, ibuprofen, and sucrose were commercially obtained from Sigma–Aldrich, 
Inc. (St. Louis, MO, USA).  Felodipine, nifedipine and simvastatin were obtained from 
A.K. Scientific, Inc. (Union City, CA, USA).  Danazol was purchased from Spectrum 
Pharmaceuticals, Inc. (Irvine, CA, USA).  Ketoconazole was obtained from Hawkins, 
Inc. (Minneapolis, MN, USA).  All crystalline materials were used for various studies 
without further purification.  Table 5.1 summarizes some key molecular properties of 
different model compounds. 
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Table 5.1.  Basic information on some relevant molecular properties of the model compounds.   Data presented as mean ± one 
standard deviation of measurements (n = 3). 
 
Compound 
Molecular 
Weight 
Mw /g-mol
-1 
Molar 
volume 
Mv/cc-mol
-1
 
† 
Melting 
point 
Tm  /K 
Melting 
enthalpy 
Hm/KJ-mol
-1 
Glass 
transition 
Tg  /K 
ΔCp at Tg 
J-g
-1
K
-1
 ‡ 
Kinetic 
fragility 
Tg/Tm 
Acetaminophen-I (ACM-I) 151.2 116.9 439.3±0.2 26.7±1.1 296.7±0.3 0.42±0.16 0.6754 
Acetaminophen-II (ACM-II) 151.2 116.9 430.4±0.1 32.1±0.6 296.7±0.3 0.42±0.16 0.6895 
Phenacetin (PHE) 179.2 146.3 405.9±0.2 19.7±1.1 - - - 
Aspirin (ASP) 180.2 128.5 401.8±1.2 29.7±4.2 - - - 
Sulfacetamide (SCT) 214.2 148.6 453.1±0.1 17.1±1.7 303.5±0.5 0.42±0.03 0.6698 
Sulfadiazine (SDZ) 250.3 165.4 526.1±0.4 55.5±1.4 390.9±0.7 0.26±0.04 0.7430 
Sulfamethoxazole (SMET) 253.3 171.4 439.5±0.3 38.8±2.1 302.8±0.9 0.38±0.08 0.6889 
Sulfamerazine-I (SMZ-I) 264.3 196.2 505.4±0.2 40.4±1.1 334.1±2.4 0.43±0.04 0.6611 
Sulfamerazine-II (SMZ-II) 264.3 184.8 483.7±0.8 27.9±2.8 334.1±2.4 0.43±0.04 0.6907 
Sulfamethazine (SMT) 278.3 188.6 470.0±1.1 60.5±4.5 348.6±0.6 0.46±0.06 0.7417 
Hydrochlorothiazide (HCT) 297.7 178.1 534.8±0.2 34.3±1.0 391.9±1.2 0.34±0.02 0.7362 
Sulfadoxin (SDOX) 310.3 211.4 465.8±0.1 44.2±3.8 330.7±0.2 0.47±0.01 0.7097 
-piroxicam (PRX) 331.3 224.6 473.9±0.1 36.0±1.8 336.0±0.2 0.41±0.01 0.7091 
Danazol (DNZ) 337.5 273.3 494.8±1.3 39.0±1.9 345.6±0.7 0.46±0.01 0.6984 
Sucrose (SUC) 342.3 215.2 Decomp - 347.2 0.54±0.02 - 
Nifedipine (NFD) 346.3 251.3 443.1±0.5 40.6±4.1 318.9±0.2 0.36±0.02 0.7197 
Griseofulvin (GRF) 352.8 240.7 493.4±0.1 39.2±0.7 363.9±0.8 0.37±0.04 0.7375 
-Indomethacin (IMC) 357.8 260.8 433.2±0.6 39.1±3.5 318.9±1.0 0.37±0.05 0.7361 
Felodipine (FLD) 384.3 264.9 411.5±0.2 30.6±0.7 319.7±0.2 0.30±0.03 0.7769 
Terfenadine (TFD) 471.6 336.9 419.6±0.3 55.4±2.1 332.6±0.3 0.56±0.19 0.7927 
Dipyridamole (DPD) 504.5 374.3 434.5±0.1 31.6±0.7 311.5±0.4 0.28±0.04 0.7169 
Ketoconazole (KNZ) 531.4 379.6 419.4±0.3 57.4±1.7 317.6±0.4 0.46±0.06 0.7573 
†  Calculated based on single crystal X-ray density of crystals at room temperature (283-303K) 
‡   Calculated using reversing Cp signal in DSC 
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5.2.2 Solid-state amorphization by cryomilling 
Approximately 2g of crystalline powder for each material was cryomilled in a liquid 
nitrogen bath at ~77K (6750 Freezer Mill, SPEX CertiPrep, Metuchen, NJ) for up to 2 
hours, with intermittent sample withdrawal at both short (10 min) and long (>30 min) 
milling times.  Samples were milled under the impact of a magnetically-driven 
cylindrical stainless-steel milling bar on to two stainless-steel lids of a polycarbonate tube 
containing the samples.  After the sample was loaded and prior to milling, the milling 
assembly was pre-cooled at liquid nitrogen temperature (~77K) for 2 minutes.  Milling 
was conducted at a rate of 10 impacts per second.  A 2 min cooling period was employed 
after each 2min of milling.   Cryomilled samples were withdrawn inside a glove box 
purged with dry nitrogen and stored in desiccator containing anhydrous calcium sulfate 
(Dreirite
®
, W.A. Hammond Dreirite Co. Ltd., OH).  Freshly milled samples were 
characterized typically within 5-10 minutes after sample withdrawal.   Water content of 
milled samples was <0.5 wt% up to 100 
o
C by thermogravimetric analysis (TGA Q500, 
TA Instruments, New Castle, DE). 
 
5.2.3 Characterization of milled samples 
Thermal studies:  The milled samples were studied using Differential Scanning 
Calorimetry (DSC Q1000 and Q2000, TA Instruments, New Castle, DE) to assess their 
crystallinity after milling.  Universal Analysis (Version 4.1D, TA Instruments) was used 
for DSC data analysis.  The baseline of DSC was calibrated using empty cell, followed 
by sapphire discs.  Temperature and enthalpy calibrations were done using high purity 
indium (standard mode, ramp rate of 10 K/min).  The DSC cell was purged with nitrogen 
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at a rate of 50 mL/min.  Hermetically sealed aluminum pans without pinholes were used 
for all studies.  To enhance thermal contact with samples, aluminum pans were 
hermetically sealed by crimping the pan lids upside down to minimize headspace within 
the sealed pans.  For standard DSC runs, a ramp rate of 10K/min was used.  For 
temperature-modulated DSC (MDSC), a sinusoidal modulation of ±1K was employed 
every 100 seconds, with a ramp rate of 2K/min.  For DSC runs, average sample weight 
was approximately 4 – 8 mg.    Glass transition temperatures (Tg) are reported as the mid-
points of the glass transition events determined from the reversing heat capacity (rev Cp) 
signal.  Crystallization and melting temperatures are the extrapolated onset temperatures 
of the corresponding thermal events.   Enthalpies of crystallization and fusion events 
were obtained by integrating the peaks using sigmoidal baseline.     
 
Powder X-ray diffraction studies:  A powder X-ray diffractometer (D8 Advance, Bruker 
AXS, Madison, WI) with CuK  radiation and scintillation counter detector was used to 
examine changes in crystallinity of the samples after milling.  The diffractometer was 
calibrated using corundum standard (SRM 674b, NIST) at d = 2.0852Ǻ.  Diffraction data 
were collected over 5 - 35º 2θ with step size of 0.05º and dwell time of 1s.  Milled 
samples were packed into the sample holder without further treatment.  Melt-quenched 
glasses were mildly ground using mortar and pestle before being packed for PXRD 
studies.  All samples were packed into the sample holder by top filling method.  PXRD 
data were collected using the Diffrac Plus XRD commander software (Bruker, AXS).  
Data analysis was performed using JADE (version 8, Materials Data Inc., Livermore, 
CA). 
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5.2.4 Quantification of amorphous content  
Amorphous content can be quantified by several analytical techniques, such as 
calorimetry, powder X-ray diffractometry, molecular spectroscopy, and moisture 
sorption.
39
  Although solution calorimetry or moisture sorption can potentially have 
superior limits of quantitation for amorphous, they are not suitable for rapid routine 
amorphous quantitation because they require either special sample preparation or are time 
intensive.   We adopted the DSC method in this study for amorphous quantitation 
because of the large number of samples that needed to be analyzed, due to several 
compounds each with multiple milling time points.  An advantage of DSC method is that 
quantification on freshly milled samples can be performed with no sample exposure to 
the ambient environment with minimal sample preparation requirements (samples 
crimped in humidity controlled glove box).  The amorphous content (φ) of the milled 
samples was quantified using the enthalpies of crystallization (Hc) and melting (Hm) 
measured using DSC in non-isothermal mode (10K/min).   Hm was corrected for the 
difference over the temperatures between crystallization and fusion   (equation 1).      
)1(
)( cm
c
pm
c
TTCH
H

  
 
In this expression, ΔCp
l-c
 is the difference in heat capacities between the liquid and 
crystalline phases.  The corrected Hm is the total enthalpy required to “melt” the crystal at 
the temperature of crystallization, which is equal to the heat of crystallization for a pure 
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amorphous phase.  This heat capacity correction is necessary to account for the thermal 
dependence of enthalpy of a material.   
 
Amorphization potential of crystals was quantified using their rate constants (ka) of 
solid-state amorphization during a given milling duration (t), which was calculated using 
equation 2.  This treatment is based on the observation that amorphization generally 
follows first-order kinetics of transformation.
31, 40
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5.2.5 Heat capacity measurements  
Heat capacity at constant pressure (Cp) was measured using modulated differential 
scanning calorimetry (Q1000, TA Instruments, New Castle, DE) equipped with a 
refrigerated cooling system.  DSC heat capacity was calibrated using crystalline sucrose, 
where the heat capacity constants (ratio of theoretical to actual Cp) were 0.988 for the 
direct signal and 1.049 for the reversing signal (acceptable Cp constant range:  0.9 - 1.1).     
Several factors can lead to erroneous heat capacity measurements even when the 
calorimeter is properly calibrated, such as sample size, thermal contact, type and flow 
rate of purge gas, pan crimping, moisture, and amplitude and frequency of modulation 
employed.
41
   A low purge flow rate of nitrogen (~5 mL/min) was used to improve the 
accuracy of heat capacity measurements by minimizing thermal fluctuations.  With 
helium as purging medium, the purge flow rate can be further reduced to ~1mL/min.  A 
sinusoidal modulation of ±1K was employed every 100 seconds, with a ramp rate of 
  116 
2K/min.   Sample weights for heat capacity measurements were on average ~15 mg.  To 
maximize thermal contact of the sample, powders were mildly pressed into thin compacts 
to fit inside the bottom of DSC pans. Extra care was taken during sample packing to 
ensure that samples covered only the bottom of the aluminum DSC pans, with no sample 
residues sticking to the sides of the pans.  Hermetically sealed aluminum pans with 
pinholes were used.  Samples were first isothermally held at 110°C for 10 min to 
eliminate residual moisture before commencing with the heat capacity measurements for 
100% crystalline drugs.  
 
5.2.6 Estimation of lattice strength of crystals 
Lattice strength of crystal was quantified by measuring volume expansivity of 
crystals
42
 of different materials using variable temperature-single crystal X-ray 
diffractometry (VT-SXRD).   Expansivity, VT, defined as the relative thermal dilation in a 
crystal at the ambient pressure, is mathematically expressed in equation 3.
42
  
)3(pT
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In the literature, crystal lattice strength has often been characterized using parameters 
such as lattice energy calculated by computational modeling of crystal structure,
43
 or 
hydrogen bond strength calculations using molecular spectroscopy, which are, at best, 
indirect evidence of the actual lattice strength of crystals.
44, 45
   However, VT-SXRD is 
advantageous as it directly probes lattice strength (through expansivity) as function of 
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temperature and provides a wealth of structural information on the packing strength of 
crystals at a molecular level.    VT-SXRD data were collected over 123-298 K 
temperature range using Bruker SMART diffractometer (Bruker AXS, operated at 40 kV 
and 50 mA) equipped with an APEX II CCD detector.   A Mo-K  radiation source was 
employed (0.71073 Å) for X-rays and the radiations filtered with a graphite 
monochromator.   For collecting diffraction data, a single crystal was glued to the 
goniometer glass fiber tip using epoxy adhesive.  Data were collected between 5º≤ θ≤75º 
using and scans with 0.5º scan width. Beam exposure times varied between 5 to 30 
s depending on the nature and quality of crystals.    To eliminate variations in diffraction 
data due to different crystal quality, the same crystal was used for each material at all 
temperatures.  Temperature was controlled with a temperature controller (Cryostream 
Controller 600, Oxford) fitted with CFT-25 refrigerated recirculator (set at 9 psig) to 
deliver liquid nitrogen.  After the data collection at a temperature was completed, the 
temperature was increased at a ramp rate of 6 K/min to the next higher target temperature 
and held at the target temperature for 10-15 minutes before data acquisition to ensure 
thermal equilibrium of the molecules.   
 
5.2.7 Configurational amorphous stability  
Thermodynamic stability of amorphous phase, prepared by in situ melt-quenching in 
DSC, for each compound was assessed using the configurational entropy using heat 
capacity (Cp,conf) as a function of temperature.  Cp,conf is defined as the difference in the 
measured heat capacities between the amorphous and the crystalline phases (equation 4).   
Figure 5.2A shows a representative plot of the difference of heat capacities of crystalline 
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and amorphous solid for griseofulvin.  The corresponding Cp,conf in the vicinity of the 
glass transition is plotted in Figure 5.2B. 
)4(crystalpamorphouspconfp CCC  
 
The configurational entropy of crystallization, i.e., the entropy difference between the 
amorphous and the crystal (∆Sconf) was then computed by integrating the Cp,conf over a 
range of temperature of interest (Origin 8.6) and using fusion enthalpy, ∆Hmelt of each 
material (equation 5). 
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For sucrose, because of the decomposition on fusion, melt-quenching was not feasible.  
So, freeze dried amorphous sucrose was used to measure the configurational entropy.  
∆Sconf was compared for different materials at room temperature (298K), which is the 
temperature of interest concerning amorphous stability in this work.   For materials that 
crystallized during melt-quenching, configurational entropy was calculated by 
extrapolating the heat capacity of the liquidus phase prior to crystallization, and 
calculating the configurational parameters between extrapolated liquid and crystal 
(Figure 5.2C). 
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Figure 5.2.  Various quenching behaviors of melts in situ in differential scanning 
calorimeter:  (A)  Heat capacities of crystalline and amorphous griseofulvin, (B) 
configurational heat capacity in the vicinity of Tg of griseofulvin; and (C) crystallization 
during melt-quenching of phenacetin using the 'jump' function in DS Q2000. 
 
 
5.2.8 Crystallization activation energy of glass 
Activation energy of non-isothermal crystallization (in DSC) of melt-quenched glass was 
quantified by fitting Avrami-Erofeev model
46-48
 of the third order to a modified Coats-
Redfern equation
49, 50
 (equation 6).    
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In this expression, β is the linear heating rate, g( ) is the crystallization model in the 
integral from, Ea is the activation energy, A is frequency factor of Arrhenius equation, R 
is the gas constant, and T is the temperature in Kelvin.   Activation energy was obtained 
from the slope of the linear plot between )(.ln g  and 
T
1
.   Avrami-Erofeev model of 
the third order was found to provide the best statistical fit to the crystallization data 
between 25 - 75% of conversion, consistent with previous literature.
51
  At very low and 
high extents of crystallization, the fit deviated from linearity and data from these portions 
were not used for calculating Ea by model-fitting. 
 
5.2.9 Statistical modeling 
Statistical analysis of data and development of regression models for amorphization 
prediction were performed using Arc statistical software (v1.06, Department of Statistics, 
University of Minnesota, 2004).   Further details are provided in the Appendix I. 
 
5.3 RESULTS AND DISCUSSIONS 
5.3.1 Amorphization behaviors of crystals 
The amorphization potential of the crystalline materials is summarized in Table 
5.2.  Some materials are resistant to amorphization under mechanical stress during 
cryomilling.  No detectable amorphous content is observed in these cryomilled crystals, 
either by DSC and PXRD, up to two hours of cryomilling.  Acetaminophen polymorph I 
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is a good example of this kind of behavior. The non-isothermal DSC profiles of 
cryomilled acetaminophen are shown in Figure 5.3A. No glass transition or 
crystallization event is observed when the cryomilled samples are heated, indicating that 
the samples are crystalline after milling.  PXRD also shows no evidence of detectable 
amorphous phase or formation of a different crystalline phase in the milled samples 
(Figure 5.3B).  Therefore, this crystal is either intrinsically resistant to amorphization by 
milling or its amorphous phase crystallizes extremely quickly after sample withdrawal 
from cryomill.  The latter mechanism is confirmed by data that will be discussed in a 
subsequent section. 
Table 5.2.  Amorphization behaviors of model crystals.  Data presented as mean ± one 
standard deviation of measurements (n = 3). 
  
Compound 
Amorphized up to 2 
hrs of cryomilling 
Amorphous 
content after 2 
hr cryomilling 
φ (%) 
Post-onset 
amorphization 
rate constant 
ka (min
-1
) 
DSC PXRD 
Acetaminophen-I (ACM-I) No No 0 0.00 
Acetaminophen-II (ACM-II) No No 0 0.00 
Phenacetin (PHE) No No 0 0.00 
Aspirin (ASP) No No 0 0.00 
Sulfacetamide (SCT) No No 0 0.00 
Sulfadiazine (SDZ) No No 0 0.00 
Sulfamethoxazole (SMET) No No 0 0.00 
Sulfamerazine-I (SMZ-I) Yes Yes 79.58 ± 4.98 0.0103 ± 0.002 
Sulfamerazine-II (SMZ-II) No No 0 0.00 
Sulfamethazine (SMT) Yes Yes 73.47 ± 4.36 0.0100 ± 0.002 
Hydrochlorothiazide (HCT) Yes Yes 73.85 ± 5.61 0.0124 ± 0.001 
Sulfadoxin (SDOX) Yes Yes 61.74 ± 4.56 0.0081 ± 0.003 
-piroxicam (PRX) Yes Yes 54.54 ± 5.12 0.0073 ± 0.001 
Danazol (DNZ) Yes Yes 61.11 ± 9.13 0.0086 ± 0.002 
Sucrose (SUC) Yes Yes 63.24 ± 4.21 0.0080 ± 0.005 
Nifedipine (NFD) Yes Yes 49.23 ± 3.03 0.0068 ± 0.001 
Griseofulvin (GRF) Yes Yes 79.65 ± 4.51 0.0100 ± 0.001 
-Indomethacin (IMC) Yes Yes 72.36 ± 2.54 0.0137 ± 0.003 
Felodipine (FLD) Yes Yes 69.52 ± 2.47 0.0110 ± 0.001 
Terfenadine (TFD) Yes Yes 98.63 ± 3.31 0.0379 ± 0.012 
Dipyridamole (DPD) Yes Yes 88.68 ± 7.45 0.0184 ± 0.002 
Ketoconazole (KNZ) Yes Yes 80.21 ± 4.60 0.0098 ± 0.001 
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Figure 5.3.  (A) DSC (standard, 10K/min) and (B) Powder XRD profiles of cryomilled 
(CM) acetaminophen (polymorph I).   While the melt-quenched sample is clearly 
amorphous, showing amorphous signatures such as Tg and crystallization exotherm, the 
milled samples stay crystalline till 2 hours of cryomilling. 
 
An analysis of amorphous conversion data (Table 5.2) suggests that up to 2 hours of 
cryomilling led to partial amorphization of the crystals in many cases.  This kind of 
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behavior is illustrated by -indomethacin.  The DSC profiles of milled indomethacin are 
shown in Figure 5.4A.   Ramping up the milled samples produces Tg at ~ 44°C (from rev 
Cp), followed by crystallization, both events indicating the presence of amorphous 
domains in the milled samples.  The crystallization onset is depressed compared to melt-
quenched glass, due to the presence of residual indomethacin nuclei in milled samples 
(PXRD, Figure 5.4B).  The residual  polymorph nuclei also facilitate preferential 
crystallization of milled samples into the polymorph, while melt-quenched glass 
crystallizes into a mixture of  (melting point of ~151ºC) and polymorphs (melting 
point ~161ºC).  Similar effects on crystallization by seed nuclei have been observed for 
all model systems that amorphized on applying mechanical stress.
23
 
 
 
 
 
 
 
 
 
Figure 5.4.  (A) DSC (standard, 10K/min) and (B) PXRD profiles of cryomilled (CM) 
indomethacin (polymorph ).   Cryomilling leads to amorphization in this case, even 
though amorphization is not complete as crystalline peaks are still visible. 
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The time course of solid-state amorphous transformation can be described by first 
order kinetics as shown by the representative plot in Figure 5.5 for felodipine.  This is 
consistent with previous observations on non-pharmaceutical crystals,
31, 40
 which agrees 
with the assumption that two events, amorphous generation and elimination through 
crystallization, are involved in the bulk amorphization by milling.  Compounds differ in 
their onset times for amorphization.  For instance, felodipine, the first evidence of 
amorphization is observed after 10 min of milling, which is taken as the onset time of 
amorphization under cryomilling conditions.  The first order rate constants for 
amorphization beyond the onset (ka) are summarized in Table 5.2, along with the extent 
amorphized in 2 hours of cryomilling, calculated using equation 1.   
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.  An illustration of sample amorphization kinetics for the model drug 
felodipine.  In this crystal, amorphization is first observed after 10 min of cryomilling.  
Post onset, solid-state amorphization follows first-order kinetics of transformation with 
amorphization rate constant ka.  Data are presented as mean ± one standard deviation of 
DSC measurements (n = 3). 
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5.3.2 Identification of amorphization correlators 
The wide differences in the amorphization behaviors observed for the model compounds 
under identical milling conditions raises the fundamental question as to what factor(s) 
lead to such differences.   As a starting point, we screened for the influence of several 
fundamental molecular factors on the amorphization propensity of materials using linear 
regression analysis.  The factors tested related to two broad categories:  (a) crystal lattice 
strength, including volume expansivity, fusion enthalpy, melting point, and molar 
volume; and (b) amorphous stability, including configurational entropy, Tg, and kinetic 
fragility of glass.  Using statistical regression modeling following the process of forward 
parameter selection
52
 (see Appendix I), volume expansivity, configurational entropy and 
molecular weight were identified as particularly influential in the amorphization process.   
The final predictive regression model for amorphization rate constant (ka, min
-1
) is given 
by equation 7. 
)7(001.0,9.10;01.0).108.2().107.2().103.5( 555 pFMVSk wTca
 
In this expression, ΔSc is configurational entropy (J/mol-K), VT is volume expansivity 
(×10
-6
 K
-1
) and Mw is molecular weight (g/mol).   The large F and p < 0.05 at 95% 
confidence level indicates a statistically significant model.  The influence of volume 
expansivity and configurational entropy on amorphization potential of materials indicates 
that mechanical amorphization is influenced by both the lattice strength of the crystal and 
the stability of the generated amorphous phase.   These effects will be discussed in detail 
in this chapter, while the role of molecular weight will be discussed in Chapter 6. 
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5.3.3 Concurrent influence of crystal lattice strength and amorphous stability 
The ability of materials to form stable amorphous phase has often been analyzed in terms 
of their glass forming ability (GFA) and amorphous stability (AS).
53-55
    GFA is normally 
assessed  by quantifying the critical cooling rate from liquid required to avoid nucleation 
and initiate vitrification.
56, 57
   However, for solid-state amorphization that avoids the 
liquid intermediate, GFA is essentially determined by the crystal lattice strength (LS).   
Stronger crystal lattice will resist amorphization, while weaker lattices will favor 
amorphization.   Volume expansivity is used in this work as a measure of LS, and 
therefore quantifies the GFA of materials.   A higher expansivity corresponds to weaker 
lattice and presumably a higher GFA.   In general, we observe that materials with higher 
expansivity (>150 × 10
-6
 K
-1
) tend to amorphize more readily under mechanical stress 
(Table 5.3).  However, there are exceptions.  Sucrose has a low expansivity owing to a 
dense three-dimensional hydrogen bonded molecular packing, but still amorphizes when 
milled beyond 30 min under cryogenic conditions.  We, however, have not observed 
amorphous generation in sucrose at shorter milling times (<10 min).  Phenacetin and 
aspirin also are exceptions.  They have high expansivity (weak lattice) but do not show 
amorphous conversion after milling. 
 
These exceptions are not unexpected.  As evident based on the linear regression 
model, amorphization is a multi-factorial problem and no single predictor is sufficient to 
describe the process fully across all compounds.   It is also necessary to consider the 
other critical factor in this transformation, i.e., the amorphous elimination step that is 
controlled by amorphous stability.   Amorphous stability has been characterized by 
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several parameters in the literature,
58, 59
 such as thermodynamic configurational 
parameters,
60, 61
 molecular mobility
58
 and activation energy of crystallization.
62
   While 
all these parameters have their own merits, in this work we probed the fundamental 
thermodynamic barrier to crystallization from glass, which is governed by the 
configurational flexibility of the molecules in the disordered phase, i.e., their 
configurational entropy (Table 5.3).   Molecules with higher configurational entropy have 
a larger number of possible configurations in the disordered phase, which has been 
speculated to lead to greater difficulty for the amorphous phase to crystallize.
60
   
However, such a correlation between configurational parameters and ease of 
crystallization has not yet been established for a large set of compounds.  Figure 5.6 
shows the correlation between configurational entropy and activation energy of 
crystallization.  Since higher activation energy corresponds to a higher kinetic barrier to 
crystallization, this plot shows that higher entropy does correspond to slower 
crystallization, as previously speculated.  
 
Going back to the case studies on sucrose, phenacetin, and aspirin that were 
exceptions in the volume expansivity rank order, their amorphization behaviors can be 
well explained when we consider the amorphous stability aspect.  Sucrose has a large 
configurational entropy (Table 5.3) and high activation energy of crystallization, which 
indicates that any amorphous phase generated by milling is kinetically stable. Therefore, 
even though it resists amorphization at short milling duration, longer cryomilling duration 
(>30min) eventually produces detectable amorphous phase.     Phenacetin and aspirin on 
the contrary have low configurational entropy and crystallize fast.  Therefore, despite 
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having weak crystal lattice that can readily be disrupted, their amorphous phase 
crystallizes rapidly during sample withdrawal.  This interaction effect between the lattice 
strength and amorphous stability on the amorphization process is clearly demonstrated by 
the amorphization behaviors of these apparent exception cases.   Amorphization occurs 
most easily for materials having simultaneously high expansivity (weak lattice) and high 
configurational entropy (slow recrystallization).  Terfenadine is an example of such a 
material that undergoes almost 100% amorphous conversion after 2 hr cryomilling. 
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Figure 5.6.  Correlation between configurational entropy and activation energy of 
crystallization measured by the model fitting of non-isothermal crystallization data to 
Avrami-Erofeev kinetic model.   Molecules with higher configurational entropy, i.e. 
those with more number of configurations in the disordered phase, have lower 
recrystallization tendency, indicated by higher activation energy barrier to crystallization.  
Data are presented as mean ± one standard deviation of DSC measurements (n = 3).  
Correlation equation:  57.0;6.534.0
2RSE confa  
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5.3.4 Amorphization Classification System (ACS) maps 
Based on the understanding of the dual influential factors on amorphization of crystals, 
an Amorphization Classification System (ACS) can be constructed for solid-state 
amorphization by cryomilling.   Figure 5.7 shows an illustration of one such quantitative 
map plotted using expansivity on Y axis (i.e., lattice strength) and configurational 
entropy on X axis (i.e., amorphous stability).   The map is divided into four regions:  I 
(high LS, low AS), II (low LS, low AS), III (high LS, high AS), and IV (low LS, high AS).   
The location of various model compounds in this study is also marked on this map (also 
indicated in Table 5.3).   Classes I and II materials will be better for developing their 
crystalline solid form because of their lack of amorphization tendency, attributed to fast 
recrystallization.   Class IV materials will likely be the well suited for amorphous 
preparation.  Figure 5.8 shows a generic version of the map indicating various classes and 
decision arrows to guide solid form selection in terms of phase stability. 
 
The delineation between different classes is based on the criterion described with 
Table 3.  This criterion has been developed based on the experimental observations of the 
milling-induced amorphization behaviors of different compounds by DSC and PXRD 
studies.   Materials with lattice expansivity >150 × 10
-6
 K
-1
 and configurational entropy 
>25 J mol
-1
K
-1
 always formed stable amorphous by 2 hr cryomilling.  These materials are 
clubbed together in Class IV, which will likely be the best suited to develop stable 
amorphous phase.   
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Figure 5.7.  Quantitative map for Amorphization Classification System (ACS) showing 
the spatial distribution of various molecules in this study.   Data are presented as mean ± 
one standard deviation of measurements (n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8.   Generic map for Amorphization Classification System (ACS) plotted 
considering crystal lattice strength (Y axis) against amorphous stability (X axis).  
Predicted order for solid-state amorphization potential is IV >> III >> II > I. 
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Table 5.3.  Volume expansivity, configurational entropy and amorphization classification 
of model compounds.  Both expansivity and configurational entropy are calculated at 
298K.  Data presented as mean ± one standard deviation of measurements (n = 3). 
 
    Classification criterion:   I - VT <150×10
-6
 K
-1
, Sc <25 J mol
-1
 K
-1
 
    II - VT >150×10
-6
 K
-1
, Sc <25 J mol
-1
 K
-1
 
    III - VT <150×10
-6
 K
-1
, Sc >25 J mol
-1
 K
-1
 
    IV - VT >150×10
-6
 K
-1
, Sc >25 J mol
-1
 K
-1 
 
 
5.3.5 Differentiating Class I and II materials by milling in presence of a polymer 
The lack of amorphization in classes I and II, up to 2 hours of cryomilling,  may be for 
two possible reasons:  a) either amorphous is not generated at all, or b) any generated 
amorphous phase is eliminated by rapid crystallization.   The difference between Class I 
and II crystals, however, is in the strength of crystal lattice, while materials in both these 
classes have low amorphous stability and fast recrystallization tendency (illustrated by 
Compound 
Volume 
expansivity, VT  
Configurational 
entropy, Sc Amorphization 
Class x10
-6
 (K
-1
) at 
25°C 
(J mol
-1
 K
-1
) at 25°C 
Acetaminophen-I (ACM-I) 150.54 ± 4.36 21.9 ± 2.7 II 
Acetaminophen-II (ACM-II) 173.67 ± 4.29 24.3 ± 1.7 II 
Phenacetin (PHE) 195.44 ± 7.42 23.6 ± 3.9 II 
Aspirin (ASP) 274.09 ± 4.41 19.9 ± 2.3 II 
Sulfacetamide (SCT) 100.13 ± 1.21 24.3 ± 2.1 I 
Sulfadiazine (SDZ) 131.85 ± 4.63 28.3 ± 3.2 III 
Sulfamethoxazole (SMET) 148.55 ± 3.71 30.9 ± 4.8 III 
Sulfamerazine-II (SMZ-II) 95.66 ± 4.24 14.3 ± 2.2 I 
Sulfamerazine-I (SMZ-I) 152.09 ± 4.18 45.8 ± 5.8 IV 
Sulfamethazine (SMT) 166.40 ± 2.01 36.3 ± 2.0 IV 
Hydrochlorothiazide (HCT) 283.16 ± 3.96 30.2 ± 1.1 IV 
Sulfadoxin (SDOX) 168.32 ± 4.04 43.2 ± 2.2 IV 
β-piroxicam (PRX) 267.89 ± 6.86 55.3 ± 5.7 IV 
Danazol (DNZ) 202.07 ± 7.36 36.7 ± 5.2 IV 
Sucrose (SUC) 88.91 ± 2.61 56.2 ± 4.7 III 
Nifedipine (NFD) 166.99 ± 5.84 37.3 ± 3.1 IV 
Griseofulvin (GRF) 171.62 ± 4.69 52.4 ± 6.1 IV 
γ-indomethacin (IMC) 156.78 ± 2.88 52.3 ± 2.1 IV 
Felodipine (FLD) 186.05 ± 4.76 41.0 ± 0.6 IV 
Terfenadine (TFD) 243.36 ± 6.69 57.7 ± 5.1 IV 
Dipyridamole (DPD) 113.36 ± 3.36 50.4 ± 2.4 III 
Ketoconazole (KNZ) 179.87 ± 7.36 65.8 ± 7.1 IV 
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their lower configurational entropy and lower activation energy of crystallization).   Class 
II crystals have weaker lattice, as demonstrated by significantly higher volume 
expansivity than Class I crystals.   Therefore, the two classes can be distinguished if 
recrystallization of generated amorphous phase in Class II is delayed.  This can be probed 
by co-cryomilling class II crystals in presence of a crystallization inhibitors (polymer).    
 
To test this, two representative drug candidates were selected, one from each class, 
(acetaminophen-I, a class II crystal) and (sulfamerazine-II, a class I crystal).   A polymer 
(polyvinylpyrrolidone vinyl acetate, Kollidon
®
) film was initially prepared with 
supersaturated drug loading (~97.5 wt%) by film casting method from methanol.   The 
films were initially dried at 60°C in a tray oven for 2 h, followed by vacuum drying for 1 
h, and then equilibrated in a humidity controlled glove box purged with dry nitrogen.  
The polymer film was then mixed with acetaminophen crystals and milled.  The 
intentional supersaturation of films with drug crystals at room temperature (verified by 
birefringence in polarized light microscopy) eliminates the possibility of the dissolution 
of acetaminophen into the polymer during cryomilling.
63
 Therefore, any amorphization of 
acetaminophen crystal is due to the milling. 
 
Figure 5.9 shows the powder XRD results of the drug-polymer co-cryomilling 
experiments.   Unmilled drug-polymer film composite appears crystalline and the halo of 
the amorphous polymer is barely observable.  On cryomilling the drug-polymer 
composite, we clearly observe amorphization of the drug crystals in case of 
acetaminophen-I only, while sulfamerazine-II sample shows no sign of amorphization 
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during co-cryomilling.  This suggests that the observed lack of milling-induced 
amorphization for pure aceteminophen (class II) is due to fast recrystallization, while for 
sulfamerazine-II (class I) is due to the lack of amorphous generation due to strong lattice.   
Longer milling may help to commence the amorphization process of sulfamerazine-II (or 
any materials belonging to Class I).   This is in fact observed for glucose, a class I 
material, which can indeed amorphize if milled for a long duration, which allows 
sufficient mechanical stress to overcome the lattice strength of the material.
22
 
 
5.3.6 Differentiating Class III and IV materials by short duration milling  
Both Class III and IV materials can potentially generate amorphous due to high 
amorphous stability.   However, the distinction between Class III and IV is in the lattice 
strength of crystals, where Class III materials have high lattice strength (low expansivity).  
To better distinguish between Class III and IV materials, we probed their amorphization 
behaviors at short milling times.  The guiding hypothesis here is that materials with 
stronger lattice will have a delayed onset of amorphization, i.e., they would require 
longer duration milling for the amorphization process to commence.  Materials in Class 
III with lower expansivity (higher lattice strength) do not amorphize at short milling 
times (typically require at least 30 min of cryomilling to start amorphization), contrary to 
materials in Class IV where amorphization starts at <10 min milling.   Thus, Class IV 
materials will be the most prone to solid-state amorphization during processing, and also 
have the greatest potential to develop kinetically stable amorphous phases.   
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Figure 5.9.  Distinction between Sulfamerazine-II (Class I) and Acetaminophen-I (Class 
II) illustrated by co-cryomilling in presence of crystallization inhibitor - polymer 
PVPVA.  While Class II crystal actually amorphizes during milling, class I crystal is 
resistant to amorphous generation. 
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5.3.7 Fast DSC screen of amorphization potential 
The classification system developed in this work for amorphization potential depends on 
lattice strength information obtained from VT-SXRD.   However, VT-SXRD experiments 
involve significant sample preparation and experimental complexity.   It is not always 
possible to have crystals available during early stages of drug development.  In addition, 
SXRD facility is not readily available at all academic and industrial locations, and 
operating it at several temperatures can be time consuming and inefficient.    
 
To address these practical issues, we attempted to identify a bulk powder surrogate 
property to volume expansivity that can more readily be quantified.   The lattice strength 
of crystals using bulk powder has been estimated here using the “lattice enthalpy of 
fusion” of crystals extrapolated to the temperature of milling ( KfH
77
) by performing a 
heat capacity correction between liquid and crystal (Origin 8.6) assuming linear 
dependence of heat capacity difference on temperature below Tg (equation 8). 
)8(
77
77 dTCHH
mT
K
xl
pf
K
f  
 
where, Tm is the melting temperature of the crystal in Kelvin.  
K
fH
77
 is the energy 
required to covert the crystal to a disordered phase at 77 K.   For crystals with very 
different melting points, the enthalpy of fusion at the melting temperature cannot be 
reliably used to measure the lattice strength because the heat capacity is temperature and 
material dependent.   The hypothetical “fusion enthalpy” at a fixed temperature, 
described here, is a more appropriate parameter to compare the lattice strength of 
  136 
different crystals.  The temperature should be relevant to the process of interest where 
amorphous is generated, which is 77 K in this study. 
 
 
 
 
 
 
 
 
 
 
Figure 5.10.  Correlation between volume expansivity of crystals measured by variable 
temperature single crystal X-ray diffraction and lattice enthalpy of crystalline powders at 
77K measured by differential scanning calorimetry.   
 
Figure 5.10 shows a correlation between expansivity and lattice enthalpy for a few 
compounds.  A lower value of expansivity corresponds to higher 
K
fH
77
, and hence 
stronger lattice.  Using 
K
fH
77
, the amorphization classification map can be reconstructed, 
which allows to assess the amorphization potential of a material based on a single 
instrumental technique, DSC, using a total sample weight of <20mg of powder, making 
this approach material-sparing.  This is potentially very attractive to scientists during 
early stages of drug development and will aid in early solid form selection. 
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5.3.8 Comment on ACS classification when fluid intermediates are involved 
The amorphization classification developed in this work is for solid-state amorphization, 
where both the lattice strength of the crystal and amorphous glass stability must be 
considered.  However, when amorphous is generated from melt (e.g. melt-quenching), 
solution (e.g. freeze drying) or vapor (e.g. vapor deposition),
15
 the classification is 
simplified, as the crystal lattice history is no longer relevant.  For such cases, 
amorphization potential of a material will be primarily a function of the amorphous 
stability parameters.   It must be noted that even though lattice strength is no longer an 
issue, the concept of glass forming ability (GFA)
54
 still is valid when amorphous is 
produced from fluids, for instance  GFA is routinely quantified using the critical cooling 
rate necessary to form glass by quenching melts.  
 
5.4 CONCLUSIONS 
In this study, we have designed a scheme for the fast assessment of amorphization 
potential of pharmaceutical crystals using structural and thermodynamic material 
properties.   DSC and XRD have been used to create amorphization classification maps 
by incorporating two factors influencing solid-state amorphization:  crystal lattice 
strength and amorphous stability.   Four amorphization classes of materials have been 
distinguished based various combinations of lattice strength and amorphous stability.   
Materials in class I and II, due to fast recrystallization tendency of amorphous phase, are 
suitable for crystalline development.  Class II materials can form amorphous if 
crystallization is delayed by using polymer dopants.  Materials belonging to class IV are 
best suited for preparing stable amorphous forms.   This knowledge of the amorphization 
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potential of materials is expected to greatly streamline the early identification of 
candidate materials with (a) better suitability for developing stable amorphous form 
(Class IV), or (b) potential problems of unexpected processing-induced amorphization 
(Class III, IV). 
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Chapter 6. 
 
 
 
Assessing amorphization potential of crystals: Part 2.  
Higher molecular weight favors formation of stable 
amorphous phase  
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The objective of this chapter is to elucidate the influence of molecular weight (MW) on 
mechanical amorphization of small molecular organic crystals from both kinetic and 
thermodynamic viewpoint.   Results based on 21 model compounds show that crystals of 
compounds with MW <260 g/mol do not form stable amorphous phase under mechanical 
stress.  The amorphous phases of lower MW compounds have greater propensity to 
crystallize, as shown by their lower activation energies during non-isothermal 
crystallization.  The influence of molecular weight on crystallization appears to be 
connected to the excess configurational entropy (ΔSconf) in the amorphous phase.  A 
positive correlation is observed between MW and ΔSconf in this set of structurally diverse 
molecules.  This suggests that molecular flexibility in the amorphous phase, measured by 
ΔSconf, plays a role in the observed differences in amorphization behaviors of crystals.  To 
gain further insight, mean structural relaxation times ( calc) have been calculated for 
different molecules based on the temperature dependence of ΔSconf in supercooled liquid 
phase using Adam-Gibbs theory.  Significantly shorter calc values are obtained for 
materials with lower MW, indicating higher global molecular mobility and faster 
recrystallization. These conclusions are further supported by glass relaxation studies 
performed below Tg using isothermal microcalorimetry.   In summary, the lack of 
observable amorphization of low MW crystals is a result of fast elimination of 
amorphous phase at ambient conditions prior to sample characterization.      
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6.1 INTRODUCTION 
Solid-state phase transformations of pharmaceutical materials during processing can 
significantly affect their physicochemical stability, solubility, and dissolution kinetics, 
which can lead to serious consequences on drug product performance.
1, 2
  An early 
prediction of such potential phase transformations is important for designing high quality 
products, maintaining product quality, facilitating regulatory approval, and ensuring 
batch-to-batch consistency.    Solid-state amorphization, a type of phase transformation 
that involves direct crystal to glass transition, has been observed frequently for a large 
fraction of pharmaceutical crystals during milling.
3-8
   Amorphous phase, which lacks the 
three-dimensional long range molecular order present in crystalline materials, is the 
higher free energy solid form with the tendency to revert to the crystalline counterparts.
9
  
Amorphous solids are sometimes generated intentionally to improve drug properties,
9-11
 
for instance, to enhance the dissolution kinetics of poorly soluble drugs,
12-15
 and 
occasionally improve the chemical stability of materials.
16
  However, when amorphous 
phase is unintentionally introduced during processing, detrimental effects on the physical 
stability (i.e., recrystallization tendency), chemical stability (i.e., degradation), and 
dissolution kinetics of the material may result.   This usually leads to catastrophic 
consequences in development and manufacturing of solid dosage forms.  If amorphous is 
the intended solid form, then crystallization has to be avoided.  On the other hand, if 
amorphous phase is generated unintentionally, faster crystallization back to the stable 
form before the final step of manufacturing will be preferred.    
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The ability of preparing an amorphous phase from a crystalline solid is termed the 
amorphization potential of the material in this work.  The physical stability of the 
amorphous form plays an important role in the amorphization potential of a crystal.  Our 
earlier studies have shown that solid-state amorphization of crystals is affected both by 
the lattice strength of the starting crystalline form, and the stability of the generated 
amorphous phase, which encompass the amorphous phase generation and elimination 
steps, respectively.  Materials with weaker lattice and lower amorphous crystallization 
tendency were able to form stable amorphous phase by milling.  For any material, 
recrystallization from milled samples is generally easier because of facilitated 
heterogeneous nucleation, the larger surface area, and the presence of crystal nuclei. 
Therefore, an earlier crystallization onset is usually observed in mechanically activated 
glasses.
6, 17
  This two step process of amorphization, i.e., generation and elimination, is 
also indicated in crystal to crystal polymorphic phase transformations that involve an 
amorphous intermediate.
18
 
 
Even though the phenomenon of amorphization has been extensively reported in the 
pharmaceutical literature, it is still not feasible to predict the amorphization of a crystal 
based on an assessment of its material properties.  Recently, there have been attempts to 
correlate structural features of crystals with their amorphization propensity.  For instance, 
the ability to amorphize has been correlated to the ease of generation of dislocations in a 
crystal under stress, which is then correlated to the free energy difference between 
amorphous and crystal.
4, 5, 19
   Such an approach, however, is unrealistic, because it relies 
on properties not readily amenable to experimental characterization, such as the burgers 
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vector of an organic crystal.   Other easily accessible material properties, such as Tg and 
molar volume, have also been used to predict the amorphization potential of crystals with 
some success.
5
   For example, the influence of milling temperature relative to Tg on 
mechanical amorphization has been investigated.
3
  For the same crystal, milling at 
temperatures above Tg reduces the amorphization potential, compared to when milled 
below Tg. 
 
The focus of this work is to probe the role of molecular weight in the ability of 
materials to form kinetically stable amorphous phase within timescales of pharmaceutical 
interest.  In this work, we have only considered materials belonging to Amorphization 
Classes II and IV (see Chapter 5).  These materials have weak lattice (expansivity > 
150×10
-6
 K
-1
) and can amorphize by milling.  However, the difference between Class II 
and IV is in amorphous stability, where class II materials are fast crystallizers (entropy < 
25 J/mol-K) but class IV materials are not. Here, we have explored the relationship 
between molecular weight and configurational flexibility of molecules in the disordered 
phase, and the amorphous stability of various materials has been used to explain the 
observed differences in the processing-induced amorphization behaviors of their crystals.   
 
6.2 MATERIALS AND METHODS 
6.2.1 Materials 
Small molecular organic materials with a wide range of molecular weights (150 - 
600 g/mol) were probed in this study.  Acetaminophen, griseofulvin, hydrochlorothiazide, 
indomethacin, piroxicam, terfenadine, sulfamerazine, sulfisoxazole, sulfadoxin, 
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sulfamethoxazole, aspirin, phenacetin and sulfanilamide were obtained from Sigma–
Aldrich, Inc. (St. Louis, MO, USA).  Felodipine, nifedipine and simvastatin were 
obtained from A.K. Scientific, Inc. (Union City, CA, USA).  Danazol was purchased 
from Spectrum Pharmaceuticals, Inc. (Irvine, CA, USA).  Ketoconazole was obtained 
from Hawkins, Inc. (Minneapolis, MN, USA). 
 
6.2.2 Solid-state amorphization  
Approximately 2g of crystalline powder for each material was cryomilled in a liquid 
nitrogen bath at ~77K (6750 Freezer Mill, SPEX CertiPrep, Metuchen, NJ) for up to 2 
hours, with intermittent sample withdrawal at both short (10 min) and long (>30 min) 
milling times.  Samples were milled under the impact of a magnetically-driven 
cylindrical stainless-steel milling bar on to two stainless-steel lids of a polycarbonate tube 
containing the samples.  After the sample was loaded and prior to milling, the milling 
assembly was pre-cooled at liquid nitrogen temperature (~77K) for 2 minutes.  Milling 
was conducted at a rate of 10 impacts per second.  A 2 min cooling period was employed 
after each 2min of milling.   Cryomilled samples were withdrawn inside a glove box 
purged with dry nitrogen and stored in desiccator containing anhydrous calcium sulfate 
(Dreirite
®
, W.A. Hammond Dreirite Co. Ltd., OH).  Freshly milled samples were 
characterized typically within 5-10 minutes after sample withdrawal.   Water content of 
milled samples was <0.5 wt% up to 100 
o
C by thermogravimetric analysis (TGA Q500, 
TA Instruments, New Castle, DE). 
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6.2.3 Characterization of milled samples 
Thermal studies. The milled samples were studied using Differential Scanning 
Calorimetry (DSC Q1000 and Q2000, TA Instruments, New Castle, DE) to assess their 
crystallinity after milling.  Universal Analysis (Version 4.1D, TA Instruments) was used 
for DSC data analysis.  The baseline of DSC was calibrated using empty cell, followed 
by sapphire discs.  Temperature and enthalpy calibrations were done using high purity 
indium (standard mode, ramp rate of 10 K/min).  Heat capacity was calibrated using 
crystalline sucrose, where the heat capacity constants (ratio of theoretical to actual Cp) 
were 0.988 for the direct signal and 1.049 for the reversing signal (acceptable Cp constant 
range:  0.9 - 1.1).   A low purge flow rate of nitrogen (~5 mL/min) was used to improve 
the accuracy of heat capacity measurements by minimizing thermal fluctuations.  A 
sinusoidal modulation of ±1K was employed every 100 seconds, with a ramp rate of 
2K/min.   Sample weights for heat capacity measurements were on average ~15 mg.  To 
maximize thermal contact of the sample, sample powders were mildly pressed into thin 
compacts to fit inside the bottom of DSC pans.   Glass transition temperatures (Tg) are 
reported as the mid-points of the glass transition events determined from the reversing 
heat capacity (rev Cp) signal.  Crystallization and melting temperatures are reported as the 
extrapolated onset temperatures of the corresponding thermal events.   Enthalpies of 
crystallization and fusion events have been obtained by integrating the peaks using 
sigmoidal baseline.    
 
The amorphous content (φ) of the milled samples was quantified using the enthalpies 
of crystallization (Hc) and melting (Hm) measured using DSC in non-isothermal mode 
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(10K/min), by performing a heat capacity correction for the temperature difference at 
which the melting and crystallization events occur during a non-isothermal ramp  
(equation 1).
20
  All milled samples were handled and DSC pans crimped in glove box 
purged with dry nitrogen.    
)1(
)( cm
c
pm
c
TTCH
H

  
 In this expression, ΔCp
l-c
 is the difference in heat capacities of the liquid and crystal, 
determined by modulated DSC at 2K/min.  The corrected Hm is the total enthalpy 
required to “melt” the crystal at the temperature of crystallization, which is equal to the 
heat of crystallization for a pure amorphous phase.  This heat capacity correction to 
account for the thermal dependence of enthalpy of materials is necessary when 
comparing two thermal events occurring at two widely separated temperatures (like 
crystallization and melting).      
 
 Powder X-ray diffraction studies:  A powder X-ray diffractometer (D8 Advance, Bruker 
AXS, Madison, WI) with CuK  radiation and scintillation counter detector was used to 
examine changes in crystallinity of the samples after milling.  The diffractometer was 
calibrated using corundum standard (SRM 674b, NIST) at d = 2.0852Ǻ.  Diffraction data 
were collected over 5 - 35º 2θ with step size of 0.05º and dwell time of 1s.  Milled 
samples were packed into the sample holder without further treatment.  Melt-quenched 
glasses were mildly ground using mortar and pestle before being packed for PXRD 
studies.  All samples were packed into the sample holder by top filling method.  PXRD 
data were collected using the Diffrac Plus XRD commander software (Bruker, AXS).  
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Data analysis was performed using JADE (version 8, Materials Data Inc., Livermore, 
CA). 
 
6.2.4 Configurational parameters 
The excess thermodynamic parameters of non-equilibrium amorphous phase were 
quantified using the configurational heat capacity (Cp,conf), defined as the difference in the 
measured heat capacities between the amorphous and the crystalline phases (equation 2).    
)2(crystalpamorphouspconfp CCC  
 
To obtain Cp,conf, crystals were melt-quenched and reheated in situ in DSC at 2°C/min 
with modulation.  
 
The configurational entropy barrier to crystallization (∆Sconf) is a measure of 
configurational flexibility of molecules and may be computed by integrating the 
configurational heat capacity as function of temperature (Origin 8.6) and using 
information on fusion enthalpy, ∆Hm of each material (equation 3). 
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Configurational entropy is then correlated with molecular mobility through the Adam-
Gibbs theory,
21
  which will be described later.  For materials that crystallized during 
melt-quenching, configurational entropy was calculated by extrapolating the heat 
capacity of the liquidus phase prior to crystallization onset.  
  148 
 6.2.5 Crystallization activation energy of glass 
Activation energy of non-isothermal crystallization (in DSC) of melt-quenched glass was 
obtained by fitting crystallization data to the Avrami-Erofeev model
22-24
 of the third order 
to a modified Coats-Redfern equation
25, 26
 (equation 4).    
)4(
2
1ln)(.ln
2
TR
E
E
TR
E
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g a
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In this expression, β is the linear heating rate, g( ) is the crystallization model in the 
integral from, Ea is the activation energy, A is frequency factor of Arrhenius equation, R 
is the gas constant, and T is the temperature in Kelvin.   Activation energy was obtained 
from the slope of the linear plot between )(.ln g  and 
T
1
.    Nine kinetic models were 
tested for all compounds, such as Avrami-Erofeev model and diffusion kinetics model of 
different orders.  Avrami-Erofeev model of the third order was found to provide the best 
statistical fit to the crystallization data between 25 - 75% of conversion, consistent with 
previous literature.
27
  At very low and high extents of crystallization, the fit deviated from 
linearity and data from these portions were not used for calculating Ea by model-fitting. 
 
6.2.6 Isothermal microcalorimetry 
As a final step to correlate molecular weight with experimental global molecular 
mobility values of glasses, the structural relaxation times of a few melt-quenched glasses 
were measured using isothermal microcalorimetry with a Thermal Activity Monitor 
(TAM 2277, Thermometric, Jarfalla, Sweden).  The annealing temperature in TAM was 
Tg – 15 for all glasses.  Fixing the annealing temperature allowed us to directly compare 
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the rate of energy loss of different glasses as a function of molecular weight at a fixed 
temperature relative to Tg.   Approximately 250 mg sample was sealed in glass ampoule 
(4 mL—Thermometric) under an atmosphere of dry nitrogen.   The reference used was 
crystalline glycine of approximately the same weight as the sample glass.  The time-
dependent power decay due to structural relaxation of glass sample was fitted to the 
derivative form of a modified stretched exponential (MSE) function (equation 5).
28
 
)5(1exp11
)(
8.772
1
10110
2
ttttH
P r   
 
In this equation, P is the power loss during annealing (in μW/g), 0 is the relaxation time 
constant, 1 is the relaxation time constant at short time limit, is the factor indicating 
distribution of relaxation times, and )(rH  is the enthalpy relaxation at time infinity, 
calculated using equation 6.   
)6()(),( TTCTH gpr  
where, pC is the step change in heat capacity at Tg.   For TAM experiments, the initial 
power-time data at t<0.5 h were not used to eliminate friction effects generated by 
introducing sample vial into the temperature-controlled bath.  The initial 30 min also 
allowed the samples to reach the bath temperature for each annealing experiment. 
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0 , 1 and  were obtained through non-linear curve fitting of power-time data 
(Origin 8.6).  These parameters were then used to compute the relaxation times ( G ) of 
glasses, according to equation 7.    
1
10G       (7) 
 
The use of G , instead of G , as the structural relaxation time is because the 
G value changes with annealing duration as a result of continuous change in glass 
structure.   The scaling of relaxation time with helps to minimize this effect.
28, 29
  Post 
TAM experiment, DSC/PXRD was performed on the tested samples to ensure that no 
crystallization occurred during TAM studies. 
 
 
 
6.3 RESULTS AND DISCUSSION 
6.3.1 Influence of molecular weight on solid-state amorphization 
To reach our goal of identifying key material properties that can be used to predict the 
amorphization behaviors of pharmaceutical crystals during processing, we have explored 
a large number of thermodynamic, structural and molecular factors that can potentially 
influence the process.   A key material property that provides a promising correlation 
with amorphization is molecular weight.  The effect of molecular weight on the 
amorphization potential of materials is shown in Figure 6.1.   Up to 2 hrs of cryomilling, 
crystals of low molecular weight molecules (MW < 260 g/mol) consistently did not show 
detectable amorphization both by powder X-ray diffraction and DSC.  
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Figure 6.1.  Dependence of solid-state amorphization, induced by 2 hr of cryomilling, on 
molecular weight of materials.   
 
 
Table 6.1 summarizes the diverse amorphization behaviors of various model 
crystalline compounds in this study, along with some of their basic molecular parameters.   
There is a clear delineation in the amorphization potential of materials under mechanical 
stress based on their molecular weights.   All materials with molecular weights higher 
than 260 g/mol underwent significant amorphization after 2 hrs of cryomilling, even 
though the extent of amorphization varied among different materials.   
 
  152 
 
 
Table 6.1.   Basic information on some relevant molecular properties of the model compounds and their solid-state 
amorphization behaviors.   Data presented as mean ± one standard deviation of measurements (n = 3).   Only compounds 
belonging to Amorphization Classes II and IV have been included in this work. 
 
Compound 
Molecular 
Weight 
Mw /g-mol
-1 
Amorphized up 
to 2 hrs of 
cryomilling 
Amorphous 
Content 
% 
Melting 
point 
Tm  /K 
Melting 
enthalpy 
Hm/KJ-
mol
-1 
Glass 
transition 
Tg  /K 
ΔCp at Tg 
J-g
-1
K
-1
 ‡ 
  DSC PXRD      
Acetaminophen-I (ACM-I) 151.2 No No 0 439.3±0.2 26.7±1.1 296.7±0.3 0.42±0.16 
Acetaminophen-II (ACM-II) 151.2 No No 0 430.4±0.1 32.1±0.6 296.7±0.3 0.42±0.16 
Phenacetin (PHE) 179.2 No No 0 405.9±0.2 19.7±1.1 - - 
Aspirin (ASP) 180.2 No No 0 401.8±1.2 29.7±4.2 - - 
Sulfacetamide (SCT) 214.2 No No 0 453.1±0.1 17.1±1.7 303.5±0.5 0.42±0.03 
Sulfadiazine (SDZ) 250.3 No No 0 526.1±0.4 55.5±1.4 390.9±0.7 0.26±0.04 
Sulfamethoxazole (SMET) 253.3 No No 0 439.5±0.3 38.8±2.1 302.8±0.9 0.38±0.08 
Sulfamerazine-I (SMZ-I) 264.3 Yes Yes 79.58 ± 4.98 505.4±0.2 40.4±1.1 334.1±2.4 0.43±0.04 
Sulfamethazine (SMT) 278.3 Yes Yes 73.47 ± 4.36 470.0±1.1 60.5±4.5 348.6±0.6 0.46±0.06 
Hydrochlorothiazide (HCT) 297.7 Yes Yes 73.85 ± 5.61 534.8±0.2 34.3±1.0 391.9±1.2 0.34±0.02 
Sulfadoxin (SDOX) 310.3 Yes Yes 61.74 ± 4.56 465.8±0.1 44.2±3.8 330.7±0.2 0.47±0.01 
-piroxicam (PRX) 331.3 Yes Yes 54.54 ± 5.12 473.9±0.1 36.0±1.8 336.0±0.2 0.41±0.01 
Danazol (DNZ) 337.5 Yes Yes 61.11 ± 9.13 494.8±1.3 39.0±1.9 345.6±0.7 0.46±0.01 
Sucrose (SUC) 342.3 Yes Yes 63.24 ± 4.21 Decomposes - 347.2 0.54±0.02 
Nifedipine (NFD) 346.3 Yes Yes 49.23 ± 3.03 443.1±0.5 40.6±4.1 318.9±0.2 0.36±0.02 
Griseofulvin (GRF) 352.8 Yes Yes 79.65 ± 4.51 493.4±0.1 39.2±0.7 363.9±0.8 0.37±0.04 
-Indomethacin (IMC) 357.8 Yes Yes 72.36 ± 2.54 433.2±0.6 39.1±3.5 318.9±1.0 0.37±0.05 
Felodipine (FLD) 384.3 Yes Yes 69.52 ± 2.47 411.5±0.2 30.6±0.7 319.7±0.2 0.30±0.03 
Terfenadine (TFD) 471.6 Yes Yes 98.63 ± 3.31 419.6±0.3 55.4±2.1 332.6±0.3 0.56±0.19 
Dipyridamole (DPD) 504.5 Yes Yes 88.68 ± 7.45 434.5±0.1 31.6±0.7 311.5±0.4 0.28±0.04 
Ketoconazole (KNZ) 531.4 Yes Yes 80.21 ± 4.60 419.4±0.3 57.4±1.7 317.6±0.4 0.46±0.06 
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To illustrate the lack of amorphization of low MW compounds, the powder XRD profiles 
of unmilled and cryomilled acetaminophen (MW = 151 g/mol) are shown in Figure 6.2 .  
The milled material shows high intensity crystalline peaks, and is phase identical to the 
unmilled sample. 
 
 
 
 
 
 
 
 
Figure 6.2. Lack of amorphous generation by cryomilling (CM) for acetaminophen 
(MW = 151 g/mol) is confirmed by powder X-ray diffractometry.   
 
Using co-cryomilling with polymer to hinder crystallization, in Chapter 5, we have 
demonstrated that acetaminophen actually amorphizes under mechanical stress, but rapid 
recrystallization of the generated amorphous phase prevents its direct observation.   
Based on principal component analysis, Baird et al. recently showed that low molecular 
weight molecules tend to crystallize faster, which is linked to the possible molecular 
flexibility in the amorphous phase.
30
   Both these results suggest that the physical stability 
of amorphous phase generated by milling should be carefully considered to explain the 
observed correlation between molecular weight and mechanical amorphization behaviors 
of crystals.   
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6.3.2 Configurational entropy 
It was proposed that amorphous phase stability is related to configurational molecular 
flexibility in the amorphous phase.
31, 32
  The excess configurational entropy, i.e., the 
entropy difference between amorphous and crystal, was evaluated in this study as an 
experimental measure of molecular flexibility in the amorphous phase.  Summarized in 
Table 6.1 are the configurational enthalpies of different crystals at their respective fusion 
temperatures, which can be used to calculate their corresponding configurational 
entropies at fusion.  The configurational entropy at any other temperature below melting 
point can be calculated using equation 3, using fusion entropy and configurational heat 
capacity data.   A representative plot of the dependence of configurational quantities 
(entropy, enthalpy and free energy) on temperature, both below and above the glass 
transition, is shown in Figure 6.3.  These plots for any other molecule can be obtained 
using the same approach.  As expected, the configurational entropy and enthalpy increase 
with increasing temperature, while the configurational free energy decreases as 
temperature gradually approaches melting. The difference in configurational free energy 
is zero at melting temperature since the crystal is in equilibrium with its liquid.   The non-
linear decrease in free energy is attributed to the fact that enthalpy and entropy of 
materials do not change at the same rates with temperature.   For molecules, which could 
not be amorphized by melt-quenching due to fast recrystallization (indicated in Table 
6.1), the configurational parameters were predicted based on the heat capacity difference 
between liquid (instead of amorphous) and crystal. 
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Figure 6.3.  Configurational parameters (enthalpy, entropy, and free energy) as function 
of temperature for amorphous indomethacin, calculated based on configurational heat 
capacity data. 
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Figure 6.4 shows a positive correlation between molecular weight of several 
structurally diverse molecules and their configurational entropy.  This indicates that with 
increasing molecular weight, the configurational entropy increases.   Over the molecular 
weight range of compounds probed in this study (150 - 600 g/mol), the configurational 
entropy increased by approximately 3.5 folds.   Some degree of scatter observed in the 
data is not unexpected given the structural diversity of molecules explored in this study.  . 
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Figure 6.4.  Correlation between molecular weight (Mw) and configurational entropy 
(∆Sconf) of molecules in the disordered phase at roomn temperature.   Data are presented 
as mean ± one standard deviation of DSC measurements (n = 3).   Linear fit correlation  
equation:  85.0;77.9281.0 2RMS wconf . 
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6.3.3 Molecular mobility from configurational entropy 
The significance of configurational entropy in amorphous stability has been a topic of 
interest for some time.
31
   However, contradicting results have been reported regarding 
the true effect of this parameter on crystallization.  It has been argued, using compounds 
such as ritonavir and acetaminophen, that a higher configurational entropy indicates a 
higher number of possible molecular configurations in the amorphous phase, which will 
retard crystallization.  In other words, crystallization is facilitated when molecules easily 
assume proper configurations, i.e., have lower configurational entropy.
31
  However, it 
was also suggested, while evaluating amorphous stability of hexitols,
33
 that molecules 
with higher configurational entropy at fusion crystallized faster.    
 
To address this contradiction and clarify the role  of configurational entropy (hence, 
molecular weight) in crystallization, we correlated entropy with molecular mobility 
(quantified by inverse structural relaxation time, 1/ calc) in the amorphous phase using 
Adam-Gibbs equation (equation 8).
21
    
)8(exp
conf
calc
ST
C
    
 In equation 8, ∞ is the structural relaxation time constant at infinite temperature 
(typically taken as 10
-14
 sec corresponding to the mobility at fusion), C is a temperature 
independent but material dependent constant, and T is the absolute temperature.  First, at 
T=Tg, the Adam-Gibbs theory is evaluated to derive the value of constant C using a 
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mobility value of 100 sec for Tg and ∆Sconf from the configurational heat capacity data.   
Thereafter, the constant C is used to determine the calc values based on the thermal 
variation of ∆Sconf. 
Molecular mobility in amorphous phase involves global mobility (  relaxation), i.e., 
the mobility associated with glass transition, and secondary
34, 35
 and surface
36
 relaxations 
below Tg.  The discussion here is limited to the molecular global mobility in supercooled 
liquids.   The effect of molecular weight on calculated global mobility is investigated by 
comparing 4 amorphous solids with different molecular weights: acetaminophen (MW = 
151 g/mol), sulfamerazine (MW = 264 g/mol), danazol (MW = 338 g/mol) and 
terfenadine (MW = 471 g/mol).   The plot of calculated mobility values as a function of 
T/Tg (Figure 6.5) shows that the molecular mobility (inverse of relaxation time) sharply 
decreases, over several orders of magnitude at a fixed temperature above Tg, with 
increasing molecular weight.   
 
 
 
 
 
 
 
Figure 6.5.  Correlation between calculated global mobility (1/ calc) and molecular 
weight with temperature scaled to Tg.   Polynomial of the fifth order was found to best fit 
the calculated mobility data.  ACM: Acetaminophen, SMZ: Sulfamerazine, DNZ: 
Danazol, TFD: Terfenadine 
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Adam-Gibbs equation allows us to calculate mean relaxation times of molecules in 
the supercooled liquid phase from entropy data.  According to this calculation, we 
observe the inverse rank order of mobility (terfenadine < danazol < sulfamerazine < 
acetaminophen) to their molecular weight (terfenadine > danazol > sulfamerazine > 
acetaminophen).   These data suggest that a molecule with higher MW is likely to be less 
mobile, at least in the supercooled liquid temperature region.  Whether the same can be 
said for temperature below Tg will be investigated using isothermal relaxation studies.    
 
6.3.4 Isothermal relaxation studies 
To check if the mobility rank order holds for amorphous solids below Tg, we 
experimentally determined global relaxation times of freshly melt-quenched glasses of 
these compounds at Tg - 15 using Thermal Activity Monitor (TAM).  A representative 
TAM power decay, with the associated post TAM DSC profile for terfenadine glass, is 
shown in Figure 6.6.   TAM studies were not performed on milled samples, because we 
could not obtain pure amorphous materials by milling for all compounds.  We also must 
preclude the probability of glass crystallizing during the TAM isothermal annealing for 
the TAM data to be meaningful.  However, milled samples tend to crystallize during 
annealing due to facilitated heterogeneous nucleation due to their activated surfaces and 
residual seed nuclei.
6, 17
   
 
 
 
  
 
160 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6.   (A)  Representative power decay plot from isothermal microcalorimetry for 
terfenadine melt-quenched glass at Tg - 15 (~45°C).   The data were fit to the derivative 
of the MSE equation.
28
  Fit parameters:  0 = 1.52 ± 0.1 hr, 1 = 0.11 ± 0.005 hr, = 
0.14 ± 0.002, Reduced 
2
 = 0.42.  (B) Post TAM DSC (10K/min) 
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TAM has been widely used to study the relaxation behavior of amorphous 
pharmaceuticals.
29, 37, 38
   The temperature regime where TAM works is ~25 - 90°C.  
Therefore, acetaminophen could not be tested as its Tg is 24°C.   For the 3 other 
compounds for which calculated mobility analysis was performed, the corresponding 
TAM data at Tg -15 are summarized in Table 6.2, and the rank order of mobility (inverse 
G
β
) is terfenadine < danazol < sulfamerazine, which is the same as that for supercooled 
liquids.   These experimental data confirm the hypothesis that higher MW molecules are 
likely to form more stable amorphous phases driven by the lower molecular mobility. 
 
Table 6.2.  Isothermal relaxation studies using TAM at Tg-15.  Data presented as mean ± 
one standard deviation of measurements (n = 3). 
 
 
 
Glass )(rH  G  
Reduced 
2 
 J/g hr  
Sulfamerazine 6.45 5.96 ± 0.55 0.23 
Danazol 6.72 7.15 ± 0.86 0.72 
Terfenadine 14.4 10.56 ± 0.61 0.41 
 
 
 
 
 
6.3.5 Correlations with crystallization  
Kinetic stability of amorphous materials was quantified using the activation energy of 
non-isothermal crystallization, calculated using model-dependent kinetics at multiple 
heating rates between 2-20 K/min.  Ex situ melt-quenched glass was used in this study, as 
some of the in situ melt-quenched glasses never crystallize in DSC, e.g., felodipine.  
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Among common models, Avrami-Erofeev model of the third order was used for deriving 
activation energy because it gave correlation coefficients closest to unity.  Activation 
energy by this approach was obtained only for model systems that could form a 
reasonably stable glass by quenching melts, which crystallize on heating.  Crystallization 
when quenching a melt, e.g., for phenacetin, precluded several model systems from this 
analysis.    Figure 6.7 shows the dependence of activation energy of crystallization on the 
molecular weight of the compounds, showing a relatively strong relationship.  This 
relationship confirms the earlier hypothesis that higher MW molecules form more stable 
amorphous solids. 
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Figure 6.7.  Correlation between molecular weight and activation energy of non-
isothermal crystallization of glasses, calculated by model-fitting to Avrami-Erofeev
22-24
 
of the third order. 
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Molecular mobility has been recognized as a major factor that influences the 
crystallization of amorphous phase, thus their physical stability, 
34, 35, 39, 40
 along with 
other factors such as secondary relaxations
29, 41
 and surface relaxations
36
 below Tg.  
Studies have shown that the mean global relaxations are either completely or partially 
coupled with amorphous crystallization.
42-44
   This work provides additional evidences to 
such a coupling through the demonstration of correlations among molecular weight, 
configurational entropy, molecular mobility in amorphous phase, and recrystallization 
activation energy.   This insight helps us to evaluate the solid-state amorphization 
behaviors of molecules (Table 6.1).   No low molecular weight crystals showed 
amorphous conversion, while higher molecular weight materials all amorphized after 2 
hrs of cryomilling.   Our data, therefore, suggest that fast crystallization contributes to the 
lack of observed amorphous by milling for crystals of low molecular weight materials.  
The same concept of molecular weight influence on amorphous stability can, in principle, 
be extended to amorphous phase generated through other routes.
30
 
 
6.3.6 Shared glass - different excess entropy:  Polymorphs  
So far we have demonstrated the relationship among MW, configurational flexibility 
of molecules in the amorphous phase, and stability of amorphous solids using chemically 
diverse molecules.  This insight gives rise to an opportunity to answer an outstanding 
question: What determines the amorphization potential of polymorphs of the same 
molecule?  The different configurational entropies of the polymorphs mean different 
barriers to their crystallization from the same amorphous phase, even though the glass is 
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shared.  We attempted to approach this question by studying the amorphization potential 
of polymorphs of molecules of different molecular weights. 
 
Low MW polymorphs:  Amorphization potential of acetaminophen polymorphs I and II 
(MW ~151 g/mol) was investigated by performing 2 hours of cryomilling.  Both 
polymorphs of acetaminophen did not show detectable amorphous conversion up to 2 
hours of milling (Figure 6.8A).      
 
High MW polymorphs:  Amorphization potential of piroxicam polymorphs  and  
(MW ~331 g/mol) was investigated by performing 2 hours of cryomilling.  Both 
polymorphs of piroxicam underwent partial amorphization (Figure 6.8B).      
 
 
 
 
 
 
 
 
 
Figure 6.8.  2 hours cryomilling (CM) of (A) acetaminophen I and II, and (B) piroxicam 
 and 
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Intermediate MW polymorphs:   Amorphization potential of sulfamerazine (SMZ) 
polymorphs I and II (MW ~264 g/mol) was investigated by performing 2 hours of 
cryomilling.  Polymorph II did not amorphize but polymorph I underwent ~76% 
amorphization (Figures 6.9A&B), after 2 hours of milling.  When heated, the amorphous 
SMZ recrystallized into polymorph II, which converted to polymorph I upon further 
heating in DSC.   Summarized in Table 6.3 are lattice strength and amorphous stability 
parameters of polymorphs necessary to evaluate the amorphization potential. 
 
Table 6.3.   Factors relevant for glass formation of polymorphs.  Data presented as mean 
± one standard deviation of measurements (n = 3). 
 
 
Polymorph 
Volume 
expansivity 
Configurational 
entropy 
Amorphization 
Class 
 (x10
-6
 K
-1
)* (J/mol-K)  
Acetaminophen I 150.54 ± 4.36 21.98 ± 2.73 II 
Acetaminophen II 173.67 ± 4.29 24.37 ± 1.67 II 
Sulfamerazine I 152.09 ± 4.18 45.82 ± 5.82 IV 
Sulfamerazine II 95.66 ± 4.24 14.25 ± 2.21 I 
piroxicam Not tested 50.37 ± 2.13 Likely IV 
piroxicam 267.89 ± 6.86 55.32 ± 5.86 IV 
 
* Measured using variable temperature single crystal XRD.  Higher expansivity correlates with weaker 
lattice strength.   
Classification criterion:    I - VT <150×10
-6
 K
-1
, Sc <25 J mol
-1
 K
-1
 
    II - VT >150×10
-6
 K
-1
, Sc <25 J mol
-1
 K
-1
 
    III - VT <150×10
-6
 K
-1
, Sc >25 J mol
-1
 K
-1
 
    IV - VT >150×10
-6
 K
-1
, Sc >25 J mol
-1
 K
-1 
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Figure 6.9.  Cryomilling (CM) of sulfamerazine polymorphs I and II.  (A)  DSC and (B) 
powder XRD overlay.  Form II does not show any amorphous conversion till two hours 
of milling. 
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Results from the polymorph milling studies validate the proposed role of molecular 
weight in stability of amorphous phase.  Our earlier work has shown that both crystal 
lattice strength and amorphous stability influence amorphization potential of 
pharmaceutical crystals.  A lower expansivity indicates stronger lattice, while a lower 
configurational entropy indicates faster amorphous crystallization tendency (Table 6.3). 
Polymorphs differ both in their crystal lattice strength and amorphous stability.   For 
polymorphs of low molecular weight molecules, e.g., acetaminophen, neither polymorph 
can form stable glass irrespective of crystal lattice strength.  This lack of observed 
amorphization is attributed to fast recrystallization of both polymorphs, which is 
indicated by lower configurational entropy values (Table 6.3).   When molecular weight 
is high (piroxicam polymorphs), both polymorphs can amorphize due to slower 
recrystallization of amorphous phase generated, indicated by higher configurational 
entropy (Table 6.3).  Therefore, amorphization behaviors do not appear sensitive to 
crystal packing for these two types of molecules.  However, for polymorphs of molecules 
with intermediate MW (250 - 300 g/mol), amorphization is sensitive to crystal packing.  
Form II sulfamerazine polymorph has stronger lattice and belongs to Class I crystal 
according to the Amorphization Classification System (see chapter 5 for explanation).  
Form I polymorph belongs to Class IV because of its weak crystal lattice.  Form II crystal 
lattice is sufficiently strong to resist significant amorphization by milling.  Crystallization 
into Form II is also easier because of the lower entropic barrier to crystallization (Table 
6.3). That explains why amorphous phase generated from milling Form I crystal 
crystallizes into Form II, despite the abundant Form I seeds in the milled material.   
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6.4 CONCLUSIONS 
Molecular weight is a relatively reliable parameter for predicting amorphization of 
organic crystals, where high molecular weight is required to avoid fast elimination of the 
amorphous phase generated by milling.  This effect of molecular weight is explained 
based on the configurational molecular flexibility in the amorphous phase, as measured 
by excess entropy, and molecular mobility.  It is clear that lower molecular weight 
materials have faster mobility in the amorphous phase, which explains their lower 
activation energy to recrystallize.   
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Chapter 7. 
 
 
Modulating amorphization of drug crystals through 
cocrystallization 
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Based on the knowledge of the concurrent influence of crystal lattice strength and 
amorphous stability on amorphization potential of crystals, in this chapter, our objective 
is to assess the utility of using cocrystals to modify the amorphization potential of drugs. 
The model compounds are sulfamethazine (SMT) and its 1:1 cocrystals with p-
hydroxybenzoic acid (HBA) and benzamide (BZM).  The stability of melt-quenched 
amorphous follows the order of SMT-HBA > SMT-BZM > SMT, based on both 
configurational entropy (ΔSconf) and structural relaxation times calculated using Adam-
Gibbs equation.  The onset of amorphization is the earliest for the SMT-BZM cocrystal 
(~10 min cryomilling) and the most delayed for the SMT-HBA cocrystal (>30 min 
cryomilling), corresponding to the lowest and highest crystal lattice strength, 
respectively.   However, the extent of amorphous conversion after 2hrs of milling follows 
a different rank order of glass stability, i.e., SMT-HBA > SMT-BZM > SMT.   The 
lowest net conversion of the SMT is explained by its faster recrystallization propensity, 
despite an earlier amorphization onset.   This work illustrates that cocrystals may be used 
to either minimize unintended amorphization of crystalline drugs during processing or 
enable the preparation of stable amorphous drug products.    
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7.1 INTRODUCTION 
 An objective of crystal engineering is to create new functional materials having 
desired physicochemical and mechanical properties by modifying the molecular packing 
in crystalline solids.
1, 2
   A useful approach in crystal engineering is cocrystallization, 
where two or more non-volatile components crystallize in stoichiometric ratios within the 
same crystalline structure.
2, 3
   To be distinguished from salts, at least one of the 
components must be neutral, irrespective of the temperature.  Cocrystals have found 
utility in modifying a number of pharmaceutical properties,
4
 such as physical stability,
5
 
chemical stability,
6
 solubility and bioavailability,
7
 and mechanical properties.
8, 9
    
 
The purpose of this work is to demonstrate the feasibility to modify the 
amorphization potential of crystalline drugs by cocrystallization.   Amorphous solids, 
unlike crystals, lack three-dimensional long range molecular order, and possess higher 
free energy.
10, 11
   For pharmaceutical applications, the generation of amorphous phase 
can either be intentional or unintentional.   Intentional amorphous conversion of crystals 
is desired to enhance the 'apparent' solubility, dissolution kinetics, and bioavailability of 
poorly soluble drugs,
11
 which constitute a large number of newer drug molecules.
12, 13
   
Sometimes, amorphous solids may also exhibit better chemical stability than their 
crystalline counterparts.
14
  A key challenge in intentionally developing an amorphous 
drug product is to maintain the physical stability.  On the other hand, mechanical stress 
involved in processing operations, such as milling, can lead to unintended 
amorphization.
15-18
  This usually leads to problems, such as deteriorated physicochemical 
  
 
172 
stability, variable dissolution kinetics, and issues with manufacturing the drug product.
19, 
20
 
 
The amorphization potential of a crystal may be defined as “the ability to form a 
stable amorphous phase within pharmaceutically relevant timescales”.   Our previous 
work with solid-state amorphization (chapters 5 and 6) has revealed that the 
amorphization potential is dependent on both the crystal lattice strength (which dictates 
the ease of amorphous generation) and amorphous stability (which dictates amorphous 
elimination through recrystallization).  In essence, the observed solid-state amorphization 
of a crystal is the net outcome of a balance between the amorphous generation and 
elimination processes.  This differs from other amorphization routes where a liquid 
intermediate is involved, for instance melt-quenching, lyophilization or spray drying,
10
 
where only the stability of glass directs the outcome of the process. 
 
  The solid-state amorphization behaviors of single component crystals, both 
pharmaceutical
15-17, 21-24
 and non-pharmaceutical,
25-27
 have been widely investigated.    In 
this work, we are interested in probing the solid-state amorphization potential of multi-
component cocrystals in an effort to examine the effectiveness of cocrystallization as a 
strategy to alter the amorphization potential of drug crystals by influencing both the 
crystal lattice strength and the stability of the amorphous glass.  The exploration of 
cocrystal glass opens up interesting new opportunities to widen the solid-state landscape 
of drugs. 
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7.2 MATERIALS AND METHODS 
7.2.1 Materials 
Sulfamethazine (SMT), p-Hydroxybenzoic acid (HBA), and benzamide (BZM) were 
purchased from Sigma–Aldrich, Inc. (St. Louis, MO, USA).  Their molecular structures 
are shown in Figure 7.1.  The cocrystals have been previously reported.
28
  Some of the 
basic properties of the drug and cocrystals are summarized in Table 7.1.  SMT is used in 
this study based on the earlier observation that it underwent significant amorphization on 
cryomilling.  
 
 
 
 
 
Figure 7.1.  Molecular structures of sulfamethazine (A) and coformers p-hydroxybenzoic 
acid (B) and benzamide (C) 
 
7.2.2 Preparation of bulk cocrystals and phase identification 
SMT-HBA cocrystal:  2.78 g of SMT and 1.38 g of HBA were suspended in 60 
mL of acetonitrile in a conical flask under ambient conditions (23.6°C, 48.4% RH).  The 
suspension  was stirred under stable vortex using a magnetic stirrer for 3 days.  The flask, 
was covered with parafilm to avoid loss of solvent during the course of stirring. 
SMT-BZM cocrystal:  2.78 g SMT and 1.21 g BZM were suspended in 90 mL of 
acetonitrile in a conical flask under ambient conditions (23.6°C, 48.4% RH).  The 
 
A B C 
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suspension  was stirred under stable vortex using a magnetic stirrer for 5 days.  The flask, 
was covered with parafilm to avoid loss of solvent during the course of stirring. 
   
Table 7.1.   Molecular properties of sulfamethazine (SMT), sulfamethazine-
hydroxybenzoic acid cocrystal (SMT-HBA) and sulfamethazine-benzamide cocrystal 
(SMT-BZM).  Data represented as mean ± standard deviation of measurement in DSC 
(n=3).  A heating rate of 10K/min was used in DSC to estimate the melting point and 
enthalpy.  Heat capacity at Tg was obtained using a heating rate of 2K/min 
 
Material 
Molecular 
weight 
(g/mol) 
Melting 
point 
(K) 
Melting 
enthalpy 
(J/g) 
Glass transition, 
Tg 
(K) 
ΔCp at Tg (J/g-K) 
SMT 278.33 471.6 ± 1.9 111.9 ± 2.1 343.0 ± 0.6 0.783 ± 0.052 
SMT-HBA 416.45 492.4 ± 1.3 201.2 ± 1.2 350.3 ± 1.1 0.338 ± 0.021 
SMT-BZM 399.47 458.4 ± 1.5 165.3 ± 0.9 306.6 ± 0.8 0.554 ± 0.038 
  
Glass transition temperatures (Tg) are reported as the mid-points of the glass transition events determined 
from the reversing heat capacity (rev Cp) signal.  Melting temperatures are reported as the extrapolated 
onset temperatures.   Enthalpies of fusion events have been obtained by integrating the peaks using 
sigmoidal baseline.    
 
 
The conversion of coformers to cocrystals was monitored by examining the phase 
purity of each suspended solid.  For this purpose, an aliquot of the suspension was 
withdrawn, filtered, and vacuum dried at room temperature.  The solid was analyzed 
using powder X-ray diffractometry (PXRD, Bruker AXS D5005, Madison, WI).  
Experimental PXRD pattern was compared against patterns calculated from single crystal 
structures.  The reference codes for the single crystal structures solved at room 
temperature are EXAMUM (SMT-HBA 1:1 cocrystal) and EXAPAV (SMT:BZM 1:1 
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cocrystal). The bulk powder was harvested after a confirmation of complete conversion 
to the cocrystal and the phase purity of the final powder was again verified using PXRD.   
 
7.2.3 Assessment of solid-state amorphization  
Approximately 2g of crystalline powder for each material was cryomilled in a liquid 
nitrogen bath at ~77K (6750 Freezer Mill, SPEX CertiPrep, Metuchen, NJ) for up to 2 
hours, with intermittent sample withdrawal at short (10 min) and long (>30 min) milling 
times.  Samples were milled under the impact of a magnetically-driven cylindrical 
stainless-steel milling bar on to two stainless-steel lids of a polycarbonate tube containing 
the samples.  Before milling started, the milling assembly along with the sample, was 
pre-cooled at liquid nitrogen temperature (~77K) for 2 minutes.  Milling was conducted 
at a rate of 10 impacts per second.  A 2 min cooling period was employed after each 2min 
of milling.  Cryomilled samples were removed from the milling chamber inside a glove 
box purged with dry nitrogen and stored in desiccator containing anhydrous calcium 
sulfate (Dreirite
®
, W.A. Hammond Dreirite Co. Ltd., OH).  Freshly milled samples were 
characterized typically within 5-10 minutes after sample withdrawal.   Water content of 
milled samples was <0.5 wt% measured using thermogravimetric analysis (TGA Q500, 
TA Instruments, New Castle, DE). 
  
A powder X-ray diffractometer (D8 Advance, Bruker AXS, Madison, WI) with CuK  
radiation and scintillation counter detector was used to verify phase purity of the starting 
materials (drug and cocrystals), melt-quenched glasses, and milled samples.  The 
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diffractometer was calibrated using corundum standard (SRM 674b, NIST) at d = 
2.0852Ǻ.  Diffraction data were collected over 5 - 35º 2θ angles, with step size of 0.05º 
and dwell time of 1s.  Milled samples were directly packed into the sample holder.  Melt-
quenched glasses were mildly ground using mortar and pestle before being packed for 
PXRD studies.  All samples were packed into the sample holder by top filling method.  
PXRD data were collected using the Diffrac Plus XRD commander software (Bruker, 
AXS).  Data analysis was performed using JADE (version 8, Materials Data Inc., 
Livermore, CA).   Crystallinity loss of the milled samples, as function of milling time, 
was quantified using powder X-ray diffractometry with step size of 0.02º and dwell time 
of 4s, using specific peaks for each of the three materials:  20.0° 2 (SMT), 19.1° 
2 (SMT-HBA), and 20.4° 2 (SMT-BZM). 
 
7.2.4 Calorimetric assessment of lattice strength 
The lattice strength of crystals has been estimated using the “lattice enthalpy of 
fusion” of crystals at the temperature of milling ( KfH
77
) by performing a heat capacity 
correction between liquid and crystal extrapolated to 77 K assuming linear dependence of 
delta heat capacity on temperature below Tg (equation 1). 
)1(
77
77 dTCHH
mT
K
xl
pf
K
f
 
 
where Tm is the melting temperature of the crystal in Kelvin.  
K
fH
77
 is the energy 
required to covert the crystal to a disordered phase at 77 K.   For crystals with very 
different melting points, the enthalpy of fusion at the melting temperature cannot be 
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reliably used to measure the lattice strength because the heat capacity is temperature and 
material dependent.   The hypothetical “fusion enthalpy” at a fixed temperature, 
described here, is a more appropriate parameter to compare the lattice strength of 
different crystals.  The temperature should be relevant to the process of interest where 
amorphous is generated, which is 77 K in this study. 
 
7.2.5 Amorphous stability  
Amorphous stability is influenced both by thermodynamic and kinetic factors.
29
   In this 
study, the thermodynamic stability was quantified by deriving the configurational entropy  
(ΔSconf) of the amorphous phase using heat capacity data.  Molecular mobility, was 
obtained from entropy data through Adam-Gibbs equation.
30
  Kinetic stability was 
evaluated using activation energy of crystallization during non-isothermal heating in 
DSC. 
 
Configurational parameters:   The excess configurational entropy of non-equilibrium 
amorphous phase (in situ melt-quenched glass) was quantified using the configurational 
heat capacity (Cp conf), defined as the difference in the measured heat capacities between 
the amorphous and the crystalline phases (equation 2).    
)2(crystalpamorphouspconfp CCC  
 
The configurational entropy barrier to crystallization (∆Sconf) is a measure of 
configurational flexibility of molecules and may be computed by integrating the 
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configurational heat capacity as a function of temperature and using information on 
fusion enthalpy, ∆Hm, of each material (equation 3).
31, 32
 
)3(
298298
dT
T
C
T
H
dT
T
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T
confp
meltconf
mm
 
 
Configurational entropy is then correlated with global molecular mobility above Tg 
through the Adam-Gibbs theory for the drug and cocrystal.
30
 Adam-Gibbs theory 
suggests that the mean structural relaxation times of molecules in the supercooled liquid 
phase ( calc) may be calculated using equation 4.  The global molecular mobility above Tg 
is measured by 1/ calc.  Faster mobility, or shorter calc, indicates less stable glass.
29
   
)4(exp
conf
calc
ST
C
 
In this equation, ∞ is the structural relaxation time constant at infinite temperature 
(typically taken as 10
-14
 sec corresponding to the mobility at fusion), C is a temperature 
independent but material dependent constant, and T is the absolute temperature.  First, at 
T=Tg, the Adam-Gibbs theory is evaluated to derive the value of constant C using a 
structural relaxation time of 100 s.  The ∆Sconf at Tg is calculated from the configurational 
heat capacity data according to equation 3.   Once C is determined, the calc values at a 
desired temperature can be calculated based on the corresponding ∆Sconf. 
 
Configurational parameters were calculated using experimental data from differential 
scanning calorimetry (DSC Q1000 or Q2000, TA Instruments, New Castle, DE).   The 
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baseline of DSC was calibrated using empty cell, followed by sapphire disc.  The 
temperature and enthalpy calibrations were done using high purity indium (standard 
mode, ramp rate of 10K/min).  Heat capacity was calibrated using crystalline sucrose, 
where the heat capacity constants (ratio of theoretical to actual Cp) were 0.988 for the 
direct signal and 1.049 for the reversing signal (acceptable Cp constant range:  0.9 - 1.1). 
Hermetically sealed aluminum pans (TA Instruments) without pinholes were used.  The 
DSC cell was purged with nitrogen, at a purge rate of 50 mL/min.   A low purge flow rate 
of nitrogen (~5 mL/min) was used to improve the accuracy of heat capacity 
measurements by minimizing thermal fluctuations.  For modulated DSC, a sinusoidal 
modulation of ±1K was employed every 100 seconds, with a ramp rate of 2K/min.    
 
7.3 RESULTS AND DISCUSSIONS 
7.3.1 Phase nature of the starting materials 
The phase purity of sulfamethazine and the two cocrystal powders was verified using 
powder X-ray diffractometry (Figure 7.2), by matching the bulk powder X-ray diffraction 
profiles with the calculated diffraction patterns obtained from single crystal structures 
solved at room temperature.   
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Figure 7.2.  Phase purity of (A) SMT-HBA cocrystal, and (B) SMT-BZM cocrystal bulk 
powders tested by matching powder X-ray diffraction patterns with those calculated from 
single crystal structures.   
 
 
 
7.3.2 Solid-state amorphization potential of cocrystals 
Sulfamethazine and the two cocrystals were cryomilled separately for up to a total 
milling duration of 2 hours.  Intermittent samples were withdrawn for tracking the 
crystallinity as a function of time.  Figures 7.3 and 7.4 show the powder X-ray diffraction 
patterns of the sulfamethazine cocrystals, milled for various time points, along with their 
melt-quenched glasses.  The SMT-HBA cocrystal is not amorphized up to 30 min of 
cryomilling but partially amorphized after longer milling as shown by the amorphous 
halo in the PXRD patterns and the reduced intensity diffraction peaks (Figure 7.3).   In 
comparison, the melt-quenched cocrystal glass is fully X-ray amorphous. 
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Figure 7.3.   Solid-state amorphization of 1:1 cocrystal of sulfamethazine and 4-
hydroxybenzoic acid (SMT-HBA):  Powder X-ray diffraction overlay of unmilled, 
cryomilled (CM) and melt-quenched samples.  The melt-quenched cocrystal is 
completely X-ray amorphous, while the cryomilled samples milled for greater than 30 
min are partially amorphous.    
 
 
In comparison, the SMT-BZM cocrystal has a much earlier amorphization onset, with 
amorphization clearly detected after 10 min cryomilling (Figure 7.4).   Powders were 
only partially amorphous even after 2 hrs of milling.   
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Figure 7.4.   Solid-state amorphization of 1:1 cocrystal of sulfamethazine and benzamide 
(SMT-BZM):   Powder X-ray diffraction overlay of unmilled, cryomilled (CM) and melt-
quenched samples.  The melt-quenched cocrystal is completely X-ray amorphous, while 
the samples milled for 10 min or greater are partially amorphous.    
 
Table 7.1 summarizes the glass transition temperatures and heat capacity changes at 
Tg of melt-quenched glasses by modulated DSC analysis. Tg of all materials are 
approximately 0.71 - 0.76 times the melting point in Kelvin, consistent with most 
compounds.
33, 34
  The milled samples have smaller ΔCp at Tg than melt-quenched glasses, 
attributed to the partial amorphous nature of the milled samples, indicated by PXRD.  For 
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example, for the 1 hour cryomilled cocrystals, the ratio of ΔCp
Tg
 for milled and melt-
quenched glass are 0.57 (SMT-HBA cocrystal) and 0.41 (SMT-BZM cocrystal).   
 
The solid-state amorphization behavior of sulfamethazine is illustrated in Figure 7.5, 
along with the PXRD profile of melt-quenched glass.   Similar to the two cocrystals. the 
milled samples are only partly amorphous. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5.  Solid-state amorphization of sulfamethazine:  Powder X-ray diffraction 
patterns for unmilled and cryomilled (CM).   Beyond 30 min of cryomilling, 
characteristic features of both amorphous halo and crystal peaks are visible. 
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Figure 7.6 shows the loss in crystallinity as a function of milling duration for SMT 
and the two cocrystals.  At short milling times (<30 min milling), the order of the 
observed amorphization follows SMT-BZM cocrystal > SMT >> SMT-HBA cocrystal.    
However, after 2 hours of milling, the order of amorphization is changed into  SMT-HBA 
cocrystal >  SMT-BZM cocrystal > SMT.    
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Figure 7.6.  Loss of crystallinity on milling for various materials, tracked by powder X-
ray diffractometry (0.02° steps, 4s dwell time). 
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The different amorphization behaviors indicate that the cocrystallization approach is 
effective in modulating the amorphization potential of drugs.  However, the effect 
depends on the level of stress applied (milling duration in this study).  As we have shown 
earlier, crystal amorphization is influenced by crystal lattice strength (affecting the 
amorphous generation) and amorphous stability (affecting amorphous elimination). 
Hence, a mechanistic understanding of the effect of cocrystallization on amorphization 
potential requires simultaneous consideration of these two aspects.. 
 
7.3.3 Crystal lattice strength 
The lattice strength of the three materials may be assessed using 
K
fH
77
, which are 
summarized in Table 7.2.  A higher value of 
K
fH
77
indicates a higher energy requirement 
to completely disrupt the crystal packing and convert the crystal into the disordered 
phase.  The rank orders of 
K
fH
77
 and amorphization onset time are identical: SMT-HBA 
cocrystal >> SMT-BZM cocrystal > SMT.  This confirms that a stronger crystal lattice is 
more resistant to disruption by mechanical means.  The stronger lattice of SMT-HBA is 
also supported by FT-IR data (Table 7.2).  SMT-HBA shows a shift of -86 units in the 
stretching frequency for the amine group (predominant hydrogen bond in both cocrystals 
involve N-H as donor), compared to only -8 units for the SMT-BZM cocrystal, with 
respect to the SMT.   Since a stronger hydrogen bond will produce a larger shift to a 
lower wave number,
35
 the IR data suggest that SMT-HBA structure involves significantly 
stronger hydrogen bonds, which is expected to stabilize its lattice. 
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Table 7.2.  Lattice strength of sulfamethazine, sulfamethazine - hydroxybenzoic acid 
cocrystal, and sulfamethazine - benzamide cocrystal measured by quantifying fusion 
enthalpy extrapolated to the milling temperature.  Data represented as mean ± 1 standard 
deviation of measurement in DSC (n=3).   
 
Crystal 
ΔCp
l-c
 
(J /mol-K) 
Fusion enthalpy at 
77K 
(KJ/mol) 
IR stretching 
frequency 
(NH2) assym 
cm
-1
  † 
SMT 61.15 ± 1.01 13.65 ± 2.41 3443 
SMT-
HBA 
82.01 ± 5.76 55.36 ± 4.13 3357 (-86) 
SMT-
BZM 
146.77 ± 4.98 20.64 ± 2.24 3435 (-8) 
  
 
† The numbers in brackets indicate frequency shifts compared to groups in SMT crystal. 
 
The relative hydrogen bond strength among the cocrystals is further illustrated by an 
analysis of their molecular packing motifs (Figure 7.7).   Sulfamethazine can potentially 
have two hydrogen bond donors, amine -NH2 and sulfonamide –NH.  The hydrogen 
bonding propensity and its ability to tautomerize between amidine and imidine forms 
render sulfamethazine a good cocrystal former.
28
  In the SMT-HBA cocrystal, the 
coformers form a tetramer, with three moderately strong intermolecular hydrogen bonds 
involved.   The hydroxyl moiety from HBA interacts with amine group of SMT through 
an O-H
...
N hydrogen bond (2.83Ǻ, room temperature).  Two other hydrogen bonds are 
formed using the imidine site in SMT with HBA:  O-H
...
N hydrogen bond (2.79Ǻ, room 
temperature) and N-H
...
O hydrogen bond (2.76Ǻ, room temperature).   All possible 
hydrogen bond donors and acceptors are utilized in this structure.  In SMT-BZM 
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cocrystal, there is a dimer formation between the SMT imidine tautomer and benzamide 
via N-H
...O (2.9279Ǻ, room temperature) and N-H...N (2.7Ǻ, room temperature) hydrogen 
bonds.  The stronger H-bonding interaction in SMT-HBA supports the IR data and 
suggests it is more difficult to displace molecules from their original positions in the 
crystal during milling.  This is in agreement with the longer onset time of milling induced 
amorphization.  SMT also forms hydrogen bonded dimers with, but using very weak N-
H
...
N hydrogen bonds (~3.1Ǻ), which explains its faster amorphization onset. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7.   Basic supramolecular motif in crystal lattice of (A)  sulfamethazine-
hydroxybenzoic acid cocrystal tetramer, (B) sulfamethazine-benzamide cocrystal dimer, 
and (C) sulfamethazine dimer. 
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7.3.4 Amorphous stability considerations 
Amorphous stability of sulfamethazine and the two cocrystal glasses was assessed 
using both the thermodynamic (configurational entropy) and kinetic (calculated mobility, 
fragility, and activation energy of crystallization) parameters.  Figure 7.8 illustrates the 
concept of configurational difference between amorphous and crystal, using SMT-BZM 
as an example.   The heat capacity of glass and the supercooled liquid is higher than that 
of the crystal, consistent with the laws of thermodynamics.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8.  Heat capacity versus temperature plot for sulfamethazine-benzamide (SMT-
BZM) cocrystal showing the slope changes in the heat capacities of the crystal, glass, and 
supercooled liquid, along with the step change in heat capacity at the glass transition.  A 
modulated DSC was used at 2K/min heating rate with a modulation of ±1K every 100 
seconds.  Also shown is the configurational heat capacity difference between amorphous 
and crystal. 
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Figure 7.9 shows the configurational entropy, which is calculated based on heat 
capacity, of the three amorphous materials as a function of temperature.  At any given 
temperature the rank order of configurational entropy follows:  SMT-HBA > SMT-BZM 
> SMT.   It has been shown using compounds such as ritonavir and acetaminophen that a 
higher configurational entropy indicates a larger number of possible molecular 
configurations in the amorphous phase, which is expected to retard crystallization.
31
   In 
other words, crystallization is facilitated when molecules can easily assume proper 
configurations, i.e., when they have lower configurational entropy.   Therefore, SMT 
glass can be expected to be the fastest crystallizer, while the crystallization from SMT-
HBA glass is expected to be the slowest.    
 
 
 
 
 
 
 
 
 
 
Figure 7.9.  Thermal variations of configurational entropy (
crystamorph SS ) of 
sulfamethazine (SMT), sulfamethazine-benzamide cocrystal (SMT-BZM), and 
sulfamethazine-hydroxybenzoic acid cocrystal (SMT-HBA) glasses.   The dotted line 
indicates the glass transition temperature. 
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The influence of configurational entropy on amorphous stability can be explained 
from the viewpoint of global molecular mobility.  Studies have shown that the mean 
global mobility can be either completely or partially coupled with amorphous 
crystallization, with a faster mobility indicating faster crystallization.
36-38
  Mean 
molecular mobility above Tg can be calculated using Adam-Gibbs theory,
30
 which allows 
us to connect the configurational entropy with the structural relaxation times.   The 
calculated structural relaxation times, on logarithmic scale, are plotted for the three 
materials in Figure 7.10A.  This plot, known as the Angell plot,
39
 indicates the deviation 
of the structural relaxation times from the Arrhenius relationship above Tg,
40
 and may be 
used to classify materials into strong or fragile glass formers.   A strong glass former will 
show a longer relaxation time (more stable glass) with less deviation from Arrhenius 
relationship as Tg is approached.   By this measure, SMT glass is the most fragile, while 
SMT-HBA glass is the least.  A higher ΔCp at the glass transition for SMT also indicates 
higher fragility.
41
   
 
Based on the structural relaxation times, the global molecular mobility is calculated 
as the inverse of relaxation time.  The general term, “molecular mobility” includes global 
mobility (  relaxation), i.e., the mobility associated with glass transition, and 
secondary
42, 43
 and surface
44
 relaxations below Tg.  Global mobility has shown promising 
correlations with crystallization in many cases.
42, 43, 45, 46
   In this work, the material with 
the lowest configurational entropy, SMT, has the fastest calculated global mobility 
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(Figure 7.10B).  In fact, there are orders of magnitude differences in the mobility between 
the different glasses.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10.  (A) Structural relaxation (fragility), and (B) global molecular mobility 
above the glass transition for sulfamethazine (SMT), sulfamethazine - benzamide 
cocrystal (SMT-BZM), and sulfamethazine - hydroxybenzoic acid cocrystal (SMZ-
HBA).  Mobility calculated based on Adam-Gibbs theory using configurational entropy 
data.  
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This significantly different mobility suggests the potentially different crystallization 
tendency of the three materials.  To assess crystallization tendency, the activation 
energies (Ea) of non-isothermal crystallization were calculated for the three materials, 
using Avrami-Erofeev kinetic model of the third order.
47-49
  Ea shows the following order 
of SMT (4.9 KJ/mol) < SMT-BZM (7.9 KJ/mol) < SMT-HBA (16.8 KJ/mol).  This 
suggests that crystallization tendency follows the order of SMT > SMT-BZM > SMT-
HBA, which is the same as that predicted based on configurational entropy or molecular 
mobility. 
 
7.3.5 Explaining amorphization using lattice and amorphous stability data 
The solid-state amorphization of the drug and the cocrystals has been found to depend 
on milling duration in our study.  At short milling times, amorphization propensity 
follows the order of SMT-BZM > SMT >> SMT-HBA.  SMT-HBA cocrystal has a much 
stronger lattice compared to the other two materials.   This correlates well with the long 
amorphization onset of SMT-HBA and its low degree of amorphization at short milling 
times.  The drug, SMT, has the weakest lattice, and is expected to amorphize the most at 
short milling times, contrary to the rank order observed.  This apparent contradiction may 
be explained by the faster crystallization of amorphous SMT, which reduces the net 
amorphous conversion compared to that in the SMT-BZM cocrystal glass. 
 
The amorphization behaviors after longer cryomilling can be explained in a similar 
manner.  Here, SMT-HBA cocrystal shows the highest amorphous conversion, despite 
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the delayed onset.   At longer milling times, the stress input is sufficient to disrupt the 
lattice packing in all three crystals (Figure 7.6).   However, the amorphous SMT-HBA  
forms a kinetically more stable glass than the other two materials.  Consequently, the 
amorphous generated for this material by milling can more easily accumulate with longer 
milling.   This leads to its highest net amorphization after 2 hours of milling.   The faster 
crystallization of SMT eliminates amorphous more effectively.  Hence, its net amorphous 
conversion is lower despite its weaker crystal lattice and faster generation of amorphous 
phase.  Thus, the seemingly complicated milling duration dependent amorphization 
behaviors of the three materials can be well explained by considering the interplay 
between crystal lattice strength and amorphous phase stability. 
 
7.4 CONCLUSIONS 
We have shown that cocrystallization is effective in modulating the amorphization 
potential of a drug.   The relative ranking of amorphization potential of the SMT and two 
of its cocrystals depends on the milling duration.   At short milling times (<30 min), the 
order of amorphization is SMT-BZM cocrystal > SMT >> SMT-HBA cocrystal.  
However, at long milling times (~2 hr), the amorphous conversion follows the rank order 
of SMT-HBA cocrystal > SMT-BZM cocrystal > SMT.  The complex amorphization 
behaviors are explained by considering the concurrent influence of crystal lattice strength 
and amorphous phase stability of these materials. SMT-HBA cocrystal exhibits the 
longest onset time to amorphization because of its strongest crystal lattice.  However, the 
amorphous phase of this material also has the highest configurational entropy and the 
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slowest molecular mobility, both favor slower recrystallization.  This helps to kinetically 
stabilize the SMT-HBA amorphous phase that may be generated during milling.  As a 
result, higher amorphous conversion is observed with longer milling.    Systematic test of 
this concept using more cocrystal systems will be valuable to further elucidate the 
amorphization behavior of cocrystals. 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
  
 
195 
Chapter 8. 
 
 
Origin of two modes of non-isothermal crystallization of 
glasses generated by milling:  Calorimetric assessment 
of role of amorphous surface structure in crystallization 
 
 
 
 
 
 
 
 
 
 
This chapter is based on the following published research article: Chattoraj et al.,  
Pharmaceutical Research, 29, 1020–1032, 2012. 
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The purpose of this work is to mechanistically investigate the role of amorphous surface 
structure of milled materials in facilitating earlier crystallization onset, to explain the 
origin of two distinct non-isothermal crystallization modes, single-peak (unimodal) and 
two-peak (bimodal).   Glasses of ten organic molecules were prepared by melt-quenching 
and cryogenic milling of crystals.   Non-isothermal crystallization of glasses was 
monitored using differential scanning calorimetry and powder X-ray diffractometry.    
The non-isothermal crystallization of glass, generated by milling, is either unimodal or 
bimodal, while that of melt-quenched glass without being milled is always unimodal.   
The mode of crystallization of amorphous phase depends on the relative position of the 
crystallization onset (Tc) with respect to glass transition temperature (Tg), and can be 
explained by a surface crystallization model.  Bimodal crystallization event is observed 
when Tc is below or near Tg, due to the fast crystallization onset at milled glass surfaces.  
Unimodal crystallization is observed when Tc is well above Tg.  We have verified this 
model by intentionally inducing flip between the two crystallization modes for several 
compounds through manipulating glass surface area and Tc.     Thus, the appearance of 
the two modes of non-isothermal crystallization of organic glasses is a result of the 
combined effects of faster surface crystallization and variation in specific surface area by 
milling.   
 
  
 
197 
8.1 INTRODUCTION 
The crystallization of glasses is a topic of considerable interest to diverse research 
fields such as pharmaceuticals,
1, 2
 food sciences,
3, 4
 biochemicals 
5
 and inorganic material 
sciences.
6-8
  Amorphous glasses can be generated either by evading crystallization 
through quenching of melts, vapor deposition, and freeze drying,
1, 2
 or by mechanical 
activation of crystalline solids through processes such as milling,
9-12
 which cause lattice 
disruption due to accumulation of crystal dislocations resulting from mechanical stress.
13
  
Irrespective of the route of amorphous generation, the amorphous phase of a solid lacks 
the three-dimensional long range molecular order characteristic of crystals and possesses 
higher free energy compared to corresponding crystalline states.
1, 14, 15
  As a consequence 
of the higher free energy, amorphous solids are thermodynamically unstable and tend to 
reorder into a crystalline state.
1, 16
  The physical instability of amorphous solids and their 
crystallization tendency are of particular importance in drug product development.
17-19
    
 
The crystallization during heating of a glass usually emerges as a well-defined single 
exothermic event in DSC, i.e., unimodal crystallization.  However, two distinct 
exotherms or bimodal events have also been observed, especially during heating of 
amorphous phase generated through mechanical milling.
20, 21
  Currently, there are 
different views in the literature regarding the possible physical origin of the appearance 
of bimodal exotherms.  In one view, the bimodal exotherms were attributed to reordering 
of a milling-induced high energy mesophase (or a defective crystalline state), which is a 
phase thermodynamically distinct from the true amorphous glass.
20, 22
  Others suggested 
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that the phenomenon may be a result of nuclei-induced glass surface crystallization 
followed by crystallization of bulk and amorphous particles free from crystal nuclei.
23
 In 
addition, bimodal crystallization of melt-quenched D-mannitol 
24
 and nifedipine 
25
 
glasses have been attributed to crystallization into two different polymorphs.      
 
It appears that, despite considerable efforts in recent years, the physical basis of the 
bimodal phenomena remains elusive.  This hinders the proper understanding of the nature 
of the instability of organic glasses displaying such a phenomenon and the development 
of effective strategies to stabilize them.  In this work, we describe a model that can 
explain both the unimodal and bimodal crystallization behaviors of glasses, taking into 
consideration the relative positions of their crystallization and glass transition 
temperatures.   
 
8.2 MATERIALS AND METHODS 
8.2.1 Materials 
A total of 10 crystalline drugs were selected as model compounds for this study (Table 
8.1).  Model compounds were selected on the basis of properties commonly thought to 
influence the amorphization tendency of crystals, such as the melting temperature and 
enthalpy of fusion (crystal lattice stability), and glass transition temperature (glass 
stability).  All model compounds were used as received for amorphous preparation, and 
subsequent calorimetric and X-ray diffraction studies. 
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Table 8.1.  Information on crystal forms of APIs milled, their melting points, enthalpies 
of fusion and glass transition temperatures (Tg).  Reported Tg values are from the 
reversing Cp signal of modulated DSC.  Other parameters have been obtained at a DSC 
heating rate of 10ºC/min.  Standard deviations are for three DSC measurements using 
independent samples. 
 
Model compound 
Form 
milled 
Melting point  
(ºC)
 
Enthalpy 
of fusion 
(J/g) 
Tg (ºC) Supplier 
Dipyridamole (DPD) Form I 161.5±0.13 65.4±2.2 40.2±0.4 Aldrich 
Ketoconazole (KNZ) NA
a
 145.9±0.16 102.5±2.1 42.4±0.3 PHHA Assoc. 
Indomethacin (IMC) Form  160.2±0.69 109.1±1.2 46.2±0.3 Sigma-Aldrich 
Sulfamethazine (SMT) Form I 196.2±0.33 111.9±2.1 74.3±0.3 AK Scientific 
Terfenadine (TFD) Form I 151.0±0.25 109.8±0.6 58.6±0.3 Sigma-Aldrich 
Felodipine (FLD) Form I 140.5±0.75 74.5±1.4 46.9±0.2 Aldrich 
Sulfamerazine (SMZ) Form I 235.9±0.73 149.4±2.3 62.5±3.1 Sigma-Aldrich 
Piroxicam (PRX) Form  200.6±0.37 118.2±3.0 63.0±0.2 Sigma 
Griseofulvin (GRF) NA
a 
219.6±0.42 111.8±1.2 91.3±0.1 Sigma-Aldrich 
Hydrochlorothiazide 
(HCT) 
Form I 267.6 ± 0.19 
97.2±2.1 
118.9±1.1 Sigma-Aldrich 
     a
 No known polymorph. 
 
8.2.2 Preparation of amorphous phase 
Amorphous glass for each model compound was prepared by cryogenic milling of 
crystals and quenching of melts.  For cryomilling, approximately 2g of crystalline powder 
was milled in a polycarbonate tube submerged in liquid nitrogen bath (6750 Freezer Mill, 
SPEX CertiPrep, Metuchen, NJ).  In this technique, a sample is milled when a 
magnetically-driven cylindrical stainless-steel milling bar impacts two stainless-steel lids 
of a polycarbonate tube within which the sample is enclosed.  Before milling, the whole 
milling assembly was pre-cooled in liquid nitrogen (~77K) for 2 minutes.  Milling was 
conducted at a rate of 10 impacts per second.  A 2min cooling period was employed after 
every 2min of milling.   Samples were withdrawn inside a glove box under a dry nitrogen 
purge at various time points during milling, and stored in a desiccator containing 
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anhydrous calcium sulfate (Dreirite
®
, W.A. Hammond Dreirite Co. Ltd., OH).  Thermal 
and X-ray characterization on freshly milled samples were performed typically within 5-
10 minutes after sample withdrawal.   Amorphous glasses were also prepared by ex situ 
melt-quenching. Samples were melted in aluminum pans inside a glove box purged with 
dry nitrogen.  Care was taken to ensure complete melting of the powders while avoiding 
decomposition of samples.  Once the sample melted, it was quenched by placing the 
sample pan on a steel surface (~10ºC) inside the glove box.  This melt-quenching 
technique was suitable for preparing amorphous phase for all compounds in this study.       
 
8.2.3 Non-isothermal crystallization studies 
Crystallization studies were done using a differential scanning calorimeter (DSC, either 
Q1000 or Q2000, TA Instruments, New Castle, DE) equipped with a refrigerated cooling 
system.  The DSC cell was purged with nitrogen at a rate of 50 mL/min.  The baseline of 
DSC was initially calibrated using an empty DSC cell, followed by placing sapphire 
discs, without pans, directly on the reference and sample positions.  The temperature and 
enthalpy calibrations were done using indium.  Hermetically sealed aluminum pans 
without pinholes were used for all studies.  To enhance thermal contact with samples, 
pans were hermetically sealed by crimping the pan lids upside down to minimize 
headspace within the sealed pans.  For standard DSC runs, ramp rate of 10ºC/min was 
used.  For temperature-modulated DSC (MDSC), heat capacity was calibrated using 
crystalline sucrose, where the heat capacity constants were 0.988 for the direct signal and 
1.049 for the reversing signal.  A sinusoidal modulation of ±1ºC was employed every 100 
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seconds, with a ramp rate of 2ºC/min.  For DSC runs, average sample weight was 
approximately 4 – 8 mg.  Universal Analysis (Version 4.1D, TA Instruments) was used 
for DSC data analysis.  Glass transition temperatures (Tg) were reported as the mid-points 
of the glass transition events determined from the reversing heat capacity (rev Cp) signal.  
Crystallization and melting temperatures were the extrapolated onset temperatures of the 
corresponding thermal events.  Enthalpy of the exothermic events was obtained by 
integrating the peaks using a sigmoidal baseline.  For bimodal events, enthalpy of each 
exotherm was obtained by drawing a perpendicular line from the valley between the two 
peaks onto the baseline.   
 
8.2.4 Estimation of amorphous content 
The amorphous content of the milled samples was quantified using equation 1.
26, 27
  
)1(
)( cm
c
pm
c
TTCH
H

  
Where, Hc and Hm are the crystallization and melting enthalpies of the sample.  For 
bimodal events, Hc was obtained by integrating both exotherms together because both 
exothermic peaks correspond to crystallization of glass as we will discuss later.  ΔCp
l-c
 is 
the difference in heat capacities of the super-cooled liquid and crystal, determined by 
MDSC for each material.  The heat capacity term accounts for the temperature difference 
between melting and crystallization events.  Standard DSC at 10ºC/min heating rate was 
used to measure other parameters in equations 1.   
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8.2.5 Powder X-Ray Diffraction (PXRD) 
A powder X-ray diffractometer (D8 Advance, Bruker AXS, Madison, WI) with CuK  
radiation and scintillation counter detector was used to examine changes in crystallinity 
of the samples with milling.  The diffractometer was calibrated using corundum standard 
(SRM 674b, NIST) at d = 2.0852Ǻ.  The angular range studied was 5 - 35º 2θ, with step 
size of 0.05º and dwell time of 1s.  Milled samples were directly packed into the sample 
holder.  Melt-quenched glasses were mildly ground using mortar and pestle before being 
packed for PXRD studies.  All samples were packed into the sample holder by top filling 
method.  PXRD data were collected using the Diffrac Plus XRD commander software 
(Bruker, AXS).  Data analysis was performed using JADE (version 8, Materials Data 
Inc., Livermore, CA).  Variable temperature XRD was conducted using D8 Advance 
diffractometer, fitted with temperature-controlled stage, using a heating rate of 0.167ºC/s 
(~10ºC/min).   
 
8.2.6 Particle morphology and surface area 
A thermally activated field emission gun type scanning electron microscope (FEG-SEM, 
JEOL 6500F, Tokyo, Japan) was used to characterize particle size and morphology of the 
milled samples.  Before SEM analysis, a thin layer of platinum (thickness ~50 Ǻ) was 
sputter-coated on the particle surfaces using an Ion Beam Sputter (IBS/TM200S, VCR 
Group Inc., CA, USA).  The SEM sample chamber was maintained under a high vacuum 
(10
-4
 to 10
-5
 Pa) during the imaging process.  Specific surface area of milled and unmilled 
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particles was estimated by BET nitrogen gas adsorption (ASAP 2000 v3.03, 
Micromeritics, Norcross, Georgia). 
 
8.3 RESULTS AND DISCUSSION 
For compounds in this study, the non-isothermal crystallization of cryomilled samples 
is either unimodal or bimodal, while that of unmilled melt-quenched glasses is always 
unimodal.  Table 8.2 summarizes the crystallization behaviors of milled compounds at 
two different milling time points, using 10 ºC/min DSC heating rate. 
 
8.3.1 Unimodal crystallization of cryomilled crystals 
The crystallization behavior of -indomethacin glass illustrates the unimodal 
crystallization phenomenon (Figure 8.1).  Similar to a previous observation,
16
 the 
cryomilled samples show Tg comparable to its melt-quenched glass at 42–44°C, 
determined using 10ºC/min DSC heating rate, followed by a single crystallization 
exotherm that corresponds to the crystallization of -indomethacin polymorph.  The 
crystallization event of the milled samples, however, progressively shifts to a higher 
temperature with longer milling.   
The up-shift in the crystallization temperature (Tc) may be attributed to the decreasing 
proportion of crystal seeds in milled samples with longer milling.  The milled samples are 
verified by PXRD to be partially crystalline.  Longer duration of milling is expected to 
reduce the concentration of crystal seeds in the milled samples, which can explain an 
elevation in Tc due to slower crystallization kinetics.    
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Table 8.2.  Summary of various parameters of equation 1 used to calculate amorphous content ( ) of milled samples.  Also reported 
are the non-isothermal crystallization modes.  ∆Cp
l-c values are determined from MDSC.  Other parameters are obtained with DSC 
heating rate of 10ºC/min.  Standard deviations are for three DSC measurements using independent samples. 
 
Model 
API 
∆Cp
l-c
 
(J/g-ºC) 
60 min CM 120 min CM 
Cryst. 
enthalpy 
(J/g) 
Tm – Tc 
(ºC) 
 (%) Cryst. 
mode 
Cryst. 
enthalpy 
(J/g) 
Tm – Tc 
(ºC) 
 (%) Cryst. 
mode 
DPD
 
0.29±0.02 22.6±1.2 117.8±2.6 71.2±4.1 Unimodal 31.4±1.9 105.0±1.5 88.7±6.0 Unimodal 
KNZ 0.51±0.03 36.6±1.4 93.4±1.8 67.3±3.1 Unimodal 46.2±1.1 87.0±2.0 80.1±2.9 Unimodal 
IMC 0.47±0.07 27.9±1.6 94.6±2.2 42.9±3.1 Unimodal 42.5±2.1 85.8±1.4 61.4±3.5 Unimodal 
SMT
 
0.32±0.02 32.2±1.0 114.1±2.4 41.9±0.7 Unimodal 56.9±2.3 108.1±2.3 73.5±5.5 Unimodal 
TFD 0.66±0.03 70.2±0.9 55.8±1.3 95.9±2.8 Unimodal 79.6±1.6 44.0±3.0 98.5±1.3 Unimodal 
FLD 0.34±0.03 21.3±3.2 93.5±0.9 49.8±3.8 Bimodal 30.8±0.6 89.0±1.8 70.3±1.8 Unimodal
 
SMZ 0.45±0.05 34.3±2.7 194.7±2.4 56.1±5.5 Bimodal 69.9±2.3 190.9±0.7 79.3±2.4 Bimodal 
PRX 0.29±0.02 29.9±1.9 157.1±2.3 41.6±2.7 Bimodal 34.6±1.4 154.2±1.5 47.5±2.6 Bimodal 
GRF 0.42±0.01 30.0±1.7 150.8±0.8 62.7±5.5 Bimodal 38.5±1.3 148.2±1.1 78.6±3.2 Bimodal 
HCT 0.32±0.03 24.4±2.5 163.5±1.5 53.6±6.2 Bimodal 37.8±1.3 145.3±1.0 73.7±2.4 Unimodal
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Figure 8.1.  Non-isothermal crystallization of cryomilled (CM) indomethacin and 
melt-quenched indomethacin glass under standard DSC (10ºC/min). 
 
 
The crystallization temperature is the highest for melt-quenched glass, which is free 
from detectable crystal seeds, verified by polarized light microscopy (Nikon Eclipse 
E200 POL, Japan).  The seeding effect also explains why the cryomilled polymorph 
sample, containing polymorph seeds, always crystallizes into pure polymorph, while 
a mixture of  (melting point ~151ºC) and polymorphs (melting point ~161ºC) 
crystallize from the melt-quenched glasses where no seed for either polymorph is present.  
This effect of seeding on crystallization has been further supported by ex situ controlled 
seeding studies described later. 
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8.3.2 Bimodal exotherms of cryomilled crystals 
Five of the ten model compounds, after 60 min cryomilling, display bimodal exotherms 
when a 10ºC/min DSC heating rate is used to heat the milled samples (Table 8.2).  The 
widespread occurrence of the bimodal phenomenon highlights the necessity of 
mechanistically understanding its physical origin.  As an illustration of this behavior, the 
bimodal crystallization of milled piroxicam is described here.  The piroxicam samples, 
cryomilled for different durations, show two exothermic thermal events in the total heat 
flow signal of standard DSC (Figure 8.2A).  However, for these milled samples showing 
bimodal behavior, Tg cannot be observed from the standard DSC traces.  Instead, the first 
broad exothermic peak covers the temperature range where the glass transition event is 
expected (~60ºC).  However, we can readily identify glass transition of the milled 
piroxicam samples at ~55-59
o
C from the reversing signal of modulated DSC (Figure 
8.2B), once the contribution from the non-reversing crystallization event is separated.  
The Tg observed for the melt-quenched piroxicam glass is ~62-63
o
C by modulated DSC 
at 2
o
C/min.  Similarly, Tg of milled samples can also be identified from the reversing Cp 
signal for other compounds that display bimodal crystallization. The observation of Tg in 
the milled samples suggests that they do contain amorphous domains.  The partially 
amorphous nature of the milled piroxicam samples is further verified by PXRD overlay 
shown in Figure 8.2C, in which both the crystalline diffraction peaks and amorphous 
halos are visible.   There is a slight drop in Tg of the milled samples, compared to melt-
quenched glass.  While the exact reason for this observation is not yet clear, moisture 
likely does not cause the drop in Tg because all samples were handled in a dry 
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environment following the same procedure, and water content of freshly milled samples 
was <0.5%.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2.  Cryomilling of crystalline piroxicam polymorph : (A) Characterization of 
cryomilled (CM) and melt-quenched piroxicam using standard DSC (heating rate 
10ºC/min), (B) reversing Cp signals by modulated DSC (heating rate 2ºC/min), (C) 
PXRD patterns of milled and unmilled piroxicam, (D) variation of crystallization 
enthalpies of milled piroxicam with milling duration.  Error bars represent one standard 
deviation of DSC measurements (n = 3). 
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Similar to the behavior of indomethacin, the Tc of amorphous piroxicam generated 
through milling is significantly lower than corresponding melt-quenched glass.  Similar 
observations of depressed Tc on milling have previously been made for compounds such 
as sucrose 
28
 and dipyridamole.
29
  Some of the key factors causing depression in Tc of 
milled samples will be discussed in the later sections. Interestingly, the enthalpy of the 
first exothermic event increases with milling time up to 2 hours, while that of the second 
exotherm decreases (Figure 8.2D).  This indicates that the physical process, responsible 
for the first exotherm, becomes more dominating with longer milling.  Longer milling 
beyond 2 hours does not result in appreciable change in enthalpy ratio between the two 
exotherms.  These changes in ratio between the two crystallization exotherms correlate 
well with change in particle size, which decreases with longer milling within the first two 
hours but is approximately constant subsequently (Figure 8.3).  As will be discussed later, 
particle size is a key factor that leads to the observation of bimodal crystallization 
phenomenon in milled glasses. 
 
2hr cryomilled
4hr cryomilled
0.5hr cryomilled
 
Figure 8.3.  SEM data providing an estimate of particle size distribution for cryomilled 
piroxicam.  Reduction in particle size occurs up to 2 hours of milling beyond which 
average size remains approximately constant.  The changes in particle size correlate with 
change in crystallization enthalpy shown in Figure 8.2D. 
B 
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8.3.3 A surface crystallization model for bimodal crystallization 
In examining the crystallization behaviors of different model compounds, we find that 
when the crystallization onset temperature of the milled samples is very close to or below 
Tg, bimodal crystallization is always observed.  On the other hand, when the Tc is well 
above the corresponding Tg of glasses, single crystallization exotherms are observed 
(Figure 8.4).   This definite dependence of the mode of crystallization of glass on the 
position of Tc relative to Tg indicates that two separate crystallization mechanisms are 
active below and above Tg that contribute to the two types of non-isothermal 
crystallization behaviors in DSC.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4.  Crystallization mode, unimodal or bimodal, depends on the location of Tc 
relative to Tg.  The dotted box shows two examples where the mode of crystallization 
flips depending on milling duration. Data obtained at 10ºC/min heating rate has been 
used for plotting this graph.  Error bars represent one standard deviation of DSC 
measurements (n = 3). 
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 Faster crystallization on glass surfaces, by several orders of magnitude, compared to 
bulk glass, has been reported for several organic glasses at temperatures below and 
slightly above Tg.
30-33
  This faster surface crystallization phenomenon has been explained 
on the basis of fast surface mobility.
30, 34
   An alternative explanation to this phenomenon, 
based on the density difference between the growing crystal and glass, 
35
  was recently 
challenged.
36
   At temperatures well above Tg, surface and bulk crystallization rates of a 
supercooled liquid are similar due to similar molecular mobility throughout.   Thus, if Tc 
occurs well beyond Tg, only a single crystallization exotherm is expected during DSC 
non-isothermal experiments.  However, when the amorphous crystallization commences 
near or below Tg, the surface first crystallizes at a significantly faster rate, which is 
followed by bulk glass crystallization at higher temperatures.   
 
 The clear dependence of the mode of crystallization on Tc-Tg relationship, as 
shown in Figure 8.4, suggests that the faster surface crystallization below Tg may be a 
key factor leading to the bimodal crystallization behavior of the cryomilled materials.   
Assuming the surface layer thickness for the same glass is constant at a constant 
temperature below Tg, the fraction of the material in the surface layer will increase with 
decreasing particle size, as illustrated in a hypothetical model schematic (Figure 8.5A).  
For an unmilled melt-quenched glass, the percentage of fast crystallizing surface portion 
is negligible since the surface layer is very thin.  Consequently, unmilled melt-quenched 
glasses display only single crystallization exotherm in DSC studies, corresponding to 
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bulk glass crystallization at a crystallization temperature well above Tg.  However, with 
decreasing particle size on longer milling, the fraction of the glass in the surface layer is 
expected to increase, corresponding to the increase in surface area as milling proceeds.  
For example, the specific surface area of griseofulvin is enhanced by almost ~4-fold after 
1 hr of milling.  With increasing surface proportion, the faster surface crystallization 
should become more predominant and, at some point, detectable by DSC as a distinct 
exothermic event, followed by a second exotherm attributed to the crystallization of 
remaining glass.  When particle size is sufficiently reduced, the second exotherm may 
eventually disappear as the amount of slower crystallizing bulk glass is negligible.   
 
These expected changes in crystallization behaviors, based on the surface 
crystallization model, are well demonstrated with cryomilled piroxicam glass (Figure 
8.5B).  The crystallization of the unmilled piroxicam glass (prepared by melt-quenching) 
is initially unimodal, but becomes bimodal when the same glass is cryomilled for 1 
minute.  The first peak gains in enthalpy with longer milling, as particle size is reduced 
(Figure 8.5C) while the second peak diminishes.  The second peak eventually disappears 
after 10 minutes of milling.  If this model is valid, it should be possible to control the 
mode of crystallization of a glass by controlling the surface area and Tc, as discussed in 
the following sections.   
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Figure 8.5.  (A) Schematic showing the relative change in proportion of surface to bulk 
with longer milling (B) DSC curves (10ºC/min heating rate) for melt-quenched (Mq) 
piroxicam glass which was thereafter cryomilled (CM) for different durations.  The 
crystallization exotherm shows a time dependent evolution from unimodal (unmilled 
glass) to bimodal (milled <10 min) and then unimodal again (milled ≥ 10 min).  (C) SEM 
images of melt-quenched piroxicam glass cryomilled for different durations.     
 
 
8.3.4 Changing Tc of a glass by grinding 
Reduction in particle size of glass during milling introduces more sites for heterogeneous 
nucleation and enhances the probability of faster surface crystallization, which should 
favor an earlier crystallization onset in the milled samples compared to unmilled glass.  
This effect of milling on Tc of glass is demonstrated for griseofulvin glass in Figure 8.6A.  
1 MIN 2 MIN 10 MIN
C
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The crystallization onset of glass is significantly reduced with increasing milling 
duration.  Similar observations were previously reported on indomethacin glass.
37
     
 
When the depressed Tc
 
of the milled glass reaches the temperature of glass transition 
(visible only from reversing Cp signal), the crystallization mode switches from unimodal 
to bimodal, which may be explained by the activation of surface crystallization as 
discussed earlier.   In Figure 8.6B, the variation of enthalpies of crystallization of the two 
peaks with milling is shown.  The total enthalpy of the bimodal crystallization of milled 
glasses is essentially independent of the milling duration and is very close to the enthalpy 
of unmilled glass after correcting for the difference in crystallization onset between the 
unmilled and milled glasses doing a heat capacity correction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6.  Cryomilling of melt-quenched griseofulvin glass:  (A) Effect of milling on 
crystallization mode of melt-quenched griseofulvin glass tested at 10ºC/min heating rate.  
The arrow indicates that Tc is depressed with longer milling. (B) Dependence of 
crystallization enthalpies of the two exotherms on milling duration.  Also plotted is the 
total crystallization enthalpy for the milled samples, which match closely with the 
crystallization enthalpy of unmilled melt-quenched glass, after performing the heat 
capacity corrections according to equation 1.  Error bars represent one standard deviation 
of DSC measurements (n = 3). 
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8.3.5 Effects of crystal seeds and heating rate on Tc 
In addition to particle size reduction, another factor that significantly contributes to 
depression in Tc of milled crystals is the presence of crystal nuclei or seeds in the milled 
samples, which survive vitrification under mechanical stresses of milling.  Figure 8.7A 
shows the correlation between the extent of Tc depression, ΔTc (Tc of unmilled melt 
quenched glass – Tc of 1-hr cryomilled sample), and the amorphous content of milled 
samples for ten model compounds.  Despite the scatter in the plot, there is a trend that 
milled materials having more seeds exhibit larger ΔTc.    
 
To further test the effect of seeding on Tc depression of glass, we have performed ex 
situ DSC seeding experiments by sprinkling indomethacin crystal seeds on the surface 
of melt-quenched indomethacin glass.  The non-isothermal crystallization behavior of 
indomethacin glass at various seed concentrations of indomethacin at 2 ºC/min heating 
rate are shown in Figure 8.7B.   At this slow heating rate, Tc of seeded indomethacin 
glass is lower than that observed at 10
o
C/min, which is expected due to the well-
established effect of heating rate on crystallization onset.
38
  With increasing 
indomethacin seed added, the Tc of indomethacin glasses decreases and crystallization 
of the polymorph also becomes more predominant at the expense of indomethacin.  
This is consistent with the observations we have made in Figure 8.1, where pure 
indomethacin crystallizes from cryomilled samples that contain large proportions of 
indomethacin crystal seeds.   
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Figure 8.7.  (A)  Correlation between depression in Tc of milled crystals, relative to melt-
quenched glass (ΔTc= Tc
melt-quenched
 - Tc
1 hr milled
) and amorphous content of milled samples 
(10
o
C/min heating rate).  (B)  Effect of ex situ seeding on crystallization onset of 
indomethacin glass (2
o
C/min heating rate).  (C) Comparison of ΔTc, at 10ºC/min heating 
rate, of indomethacin cryomilled (CM) (■, n = 3) with ex situ seeded melt-quenched glass 
(□, n=1).   
 
 
The effect of Tc depression of glass by ex situ seeding is, however, not as drastic as 
observed for cryomilled materials at the same seed concentration (>45%) (Figure 8.7C).  
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concentrations >30%.  However, for milled samples, Tc depression continues to be 
observed at higher seed concentrations.  This is not surprising because, for ex situ seeded 
samples, the contact between crystal seeds and glass is expected to reach a maximum 
once a layer of crystals completely covers the top layer of the glass surface.  On the 
contrary, for cryomilled samples, the glass generated through milling is intimately in 
contact with crystal seeds at all available glass surfaces, which will promote a greater 
drop in Tc in milled samples. 
 
8.3.6 Kinetic flip of crystallization modes 
So far, we have shown that milling duration, seeding, and heating rate can all affect Tc of 
a glass. If Tc of a cryomilled sample can be kinetically controlled through these 
parameters to be either below or above Tg, we should observe flip between the unimodal 
and bimodal crystallization behaviors for the same glass if the surface crystallization 
model is valid.    
 
In fact, we do observe kinetic flip between unimodal and bimodal crystallization by 
modifying milling duration.  For example, Tc of the indomethacin crystals milled for 2 
hours at 2
o
C/min heating rate (~43
o
C) is slightly lower than its Tg (~46ºC determined 
from rev Cp) and bimodal crystallization occurs (Figure 8.8).  At the same heating rate, 
however, Tc of indomethacin after 4 hours of cryomilling (76ºC) is 30ºC beyond Tg and 
only a single crystallization peak is observed.   
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Figure 8.8.  Effect of milling duration on crystallization modes of cryomilled (CM) -
indomethacin crystals tested at 2ºC/min heating rate in DSC.  Also shown are the Tgs of 
the milled and melt-quenched samples from the reversing Cp signal.   
 
Similar milling-induced flipping behavior can also be observed for felodipine and 
hydrochlorothiazide.  Provided faster surface crystallization is universal, our model 
predicts that any organic glass can display either crystallization behaviors depending on 
kinetics of crystallization.  When felodipine crystals are milled for 1 hr, the Tc (46
o
C) is 
approximately the same as Tg (~46.2ºC) and bimodal crystallization behavior is observed 
(Figure 8.9A).  However, longer milling duration (4 hr) shifts the crystallization onset to 
a temperature (66ºC) much higher than its Tg .  Consequently, only a single crystallization 
peak is observed. 
 
At a heating rate of 10 ºC/min, the Tc of the 2 hr milled felodipine (51ºC) is ~5 
o
C 
higher than Tg (~46 
o
C).  For this sample, a small leading shoulder can still be observed 
before the main crystallization event (Figure 8.9A), indicating faster surface 
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crystallization remains active at slightly above Tg.  This is consistent with the observation 
that the faster surface crystallization process remains active up to a few degrees above Tg 
instead of being abruptly turned off at Tg.
30
  However, when the same 2hr milled 
felodipine sample is heated at a slower heating rate at 2ºC/min during the MDSC 
experiments, the Tc (46ºC) is below its Tg (~47.2ºC determined at 2 ºC/min from 
reversing Cp) and we observe a clear bimodal crystallization behavior (Figure 8.9B).  The 
heating rate-induced kinetic flip in crystallization mode for the same sample effectively 
excludes the possibility that the bimodal thermal behavior is simply a consequence of the 
presence of two size populations of particles in the cryomilled samples.  Such an 
explanation cannot explain the unimodal crystallization behavior of some cryomilled 
samples anyway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.9.  Non-isothermal crystallization of cryomilled (CM) felodipine crystals, 
showing flip between unimodal and bimodal crystallization under (A) standard DSC 
(10ºC/min), and (B) modulated DSC (non-reversing heat flow, 2ºC/min).   
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Similar to felodipine, heating rate-induced flipping in crystallization mode is also 
observed for indomethacin.  Indomethacin, cryomilled for 2 hours, shows unimodal 
crystallization behavior (Tc of 71ºC and Tg of ~44ºC), when tested at a heating rate of 
10ºC/min in DSC.  However, the same sample shows bimodal crystallization when a 
slower heating rate of 2ºC/min is used (Tc of 42.9ºC and Tg of ~46ºC from reversing Cp) 
(Figure 8.10).   
 
For some materials, an increase in heating rate from 2
o
C/min to 10
o
C/min does not 
cause a sufficient change in Tc to switch from bimodal crystallization to unimodal 
behavior.  However, the relative sizes of the two crystallization exotherms in the bimodal 
event vary according to the proposed surface crystallization model.  For instance, when a 
sample of crystalline piroxicam, cryomilled for 2 hrs, is subjected to a slower heating rate 
of 2ºC/min during modulated DSC experiments, the ratio of the area of the first 
crystallization peak to that of the second peak is 26:1.  However, at a faster heating rate 
of 10
o
C/min, the ratio reduces to 4.4:1 for the same sample.  This is expected because 
more time is available for the surface to crystallize completely at a slower heating rate, 
which increases the first exotherm area at the expense of the second exotherm.   
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Figure 8.10.  Effect of heating rate on the crystallization behaviors of crystalline 
indomethacin cryomilled for 2 hours.  Crystallization is unimodal at 10
o
C/min but 
bimodal at 2
o
C/min for the same glass prepared by 2 hr milling, due to faster 
crystallization onset at slower heating rate.   
 
 
8.3.7 Flip induced by polymer 
The phenomenon of kinetic flipping between unimodal and bimodal behaviors by 
simply changing the heating rate or milling duration supports the surface crystallization 
model, which well explains the two crystallization behaviors.  The validity of this model 
can also be further tested if we can flip the crystallization from bimodal to unimodal, by 
raising the Tc to above Tg of a glass using crystallization inhibitors.  To test this, 
crystalline griseofulvin was cryomilled for 30 minutes in presence of crystallization 
inhibitor polyvinyl pyrrolidone vinyl acetate (PVPVA, Kollidon VA 64 Fine, BASF 
Corporation).  Milling of griseofulvin alone for 30 minutes yields an amorphous phase 
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that exhibits bimodal crystallization, with Tc approximately 25ºC below Tg (90ºC).  The 
presence of polymer slows down the crystallization and hence elevates Tc as expected but 
does not affect Tg of griseofulvin (~90ºC), as seen from the reversing Cp signal in Figure 
8.11.  This is likely because griseofulvin does not form strong hydrogen bond interactions 
with PVPVA, due to lack for strong hydrogen bond donor moieties. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.11.  Effect of polymer on crystallization onset and mode of crystallization of 30 
min cryomilled griseofulvin.  Also shown is the reversing Cp signal for 20% PVPVA 
loading that confirms that Tg of griseofulvin (~90ºC) is unchanged in presence of the 
polymer. 
 
When cryomilled with 20% PVPVA, the Tc of griseofulvin almost coincides with Tg 
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Tc (~106ºC) is well beyond Tg (~90ºC) at 30% PVPVA loading, only unimodal 
crystallization behavior is observed.  This experiment further supports that the bimodal 
exothermic event is caused by faster glass crystallization below Tg. 
 
8.3.8 Flip induced by surface elimination 
We have shown that size reduction of glasses can induce bimodal crystallization 
(Figure 8.6A).  An excellent further test of our model is to convert bimodal crystallization 
to unimodal by eliminating surface area that was originally generated by milling.  
Cryomilled griseofulvin glass was compressed into thin discs (4 mm diameter) at the 
pressures of 100 and 300 MPa.  It is expected that consolidation of a powder diminishes 
powder porosity, hence, total surface area.
39, 40
 We therefore expect reduced size of the 
first exotherm, which is attributed to surface crystallization, after compaction.  As-milled 
griseofulvin glass displays clear bimodal crystallization, with the first exotherm 
accounting for ~70% of the total enthalpy (Figure 8.12).  For the disc compressed at 100 
MPa, surface proportion accounts for ~24% of overall crystallization.  With 300 MPa 
pressure, the surface crystallization peak is eliminated (Figure 8.12), and crystallization 
behavior resembles that of the unmilled melt-quenched glass.  The total enthalpy of 
crystallization (including two peaks), for milled and compacted samples, match closely 
with that of melt-quenched glass that has not been subjected to any mechanical stress.  
This experiment confirms that surface crystallization of milled samples is indeed 
responsible for the first exothermic event in bimodal crystallization, which can be 
eliminated by compaction. 
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Figure 8.12.  Effect of compaction on crystallization behavior of griseofulvin glass 
(prepared by melt-quenching followed by cryomilled for 10 min).  For uncompacted 
cryomilled glass, crystallization is clearly bimodal, with surface proportion (i.e. the first 
exotherm) accounting for 70% of total enthalpy.  After compaction at 100 MPa pressure, 
the surface proportion accounts for ~24% of overall crystallization.  With 300 MPa 
pressure, the first exotherm (surface) is eliminated and the crystallization is unimodal at 
T>Tg. 
 
 
8.3.9 Possibility of crystallization into different polymorphs 
Crystallization into two distinct polymorphs can result in bimodal crystallization, when 
crystallization onset is higher than Tg for some organic glasses.
24, 25
  However, the 
possibility of different polymorphs crystallizing can be ruled out for molecules, such as 
griseofulvin, which exhibit bimodal crystallization behavior despite having no known 
polymorphs.  Figure 8.13A shows that only a single crystalline phase crystallizes during 
the entire process of crystallization of cryomilled griseofulvin over a temperature range 
covering both exotherms.  In the temperature range of the bimodal events (10
o
C/min was 
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used for both VTPXRD and DSC experiments), we only observe a progressive increase 
in fraction of the same crystalline form of griseofulvin, estimated by integrating the area 
of peak maxima at 16.6º 2θ (Figure 8.13B).  Both exothermic events, therefore, 
correspond to crystallization of the amorphous phase into the same crystal form.   
Moreover, all model compounds that exhibit bimodal crystallization in this work have 
only a single melting endotherm following crystallization during DSC experiments.  
Thus, the possibility of bimodal events corresponding to crystallization of different 
polymorphs may be excluded for these compounds.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.13.  (A) Overlay of variable temperature XRD and (B) integrated area of X-ray 
diffraction peak at 16.6º 2θ as a function of temperature, along with the DSC trace 
showing the bimodal behavior, for 30 min cryomilled griseofulvin.  The arrow indicates 
the room temperature X-ray peak area for the milled sample. 
 
 
It is possible that a polymorphic transition may be exothermal (e.g. transition from 
polymorph III to II in acetaminophen).  If so, two exotherms may be observed for a glass 
that undergoes unimodal crystallization.  However, the two exotherms (crystallization of 
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the glass and polymorphic transition) are usually well separated.  It is also possible that a 
glass may crystallize into two polymorphs at different temperatures (e.g. nifedipine).  In 
both cases, crystallization events take place at temperatures above Tg and can be readily 
distinguished from the bimodal crystallization phenomenon discussed in this report.     
 
8.4 CONCLUSIONS 
In this work, we have described a surface crystallization model that can be used to 
explain both unimodal and bimodal crystallization of organic glasses prepared by 
different routes.   We have shown that the modes of crystallization of all molecules in this 
study are determined by the relative position of crystallization onset, Tc, and glass 
transition temperatures, Tg.  Unimodal crystallization occurs when Tc is at least several 
degrees higher than Tg.  Bimodal crystallization takes place when Tc is lower than or 
close to Tg.  This model clearly explains the otherwise perplexing effects of milling 
duration, heating rate, particle size, crystallization inhibition, and compaction on the 
thermal behavior of organic glasses.  
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Chapter 9. 
 
 
Thesis Summary 
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The overall objective of this research work was to investigate the relationships between 
the structure of pharmaceutical solids, both crystalline and amorphous, with their 
properties relevant for processing, such as mechanical, flow, and solid-state 
amorphization.  The key message from the various aspects of this endeavor are 
summarized here. 
 
Chapter 2. 
In chapter 2, the correlations between the crystal structure, crystal plasticity, and powder 
compaction properties were probed using the model system of theophylline anhydrate, 
methyl gallate, and their 1:1 cocrystal.  Theophylline showed exceptionally high 
plasticity, indicated by very low crystal hardness measured using nanoindentation, which 
led to its superior powder compaction properties. The plasticity was, however, 
deteriorated on cocrystallizing the drug with the co-former methyl gallate.  This resulted 
in deterioration in powder compaction properties after cocrystallization.  This illustrates 
the importance of analyzing the effect of changing solid forms of drugs on their 
mechanical properties, as that will directly influence their manufacturing potential 
downstream. Another point of interest in this work was the observation that 
theophylline's compactibility was relatively insensitive to changes in particle size or 
morphology.  This suggests that when a material's plasticity is very high, then particulate 
property alteration may not necessarily lead to an effect on powder compaction.   Finally, 
we showed that the different plasticity and powder compaction properties could be well 
explained by the consideration of the crystal packing in different materials.  The presence 
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of an extremely dense three-dimensional hydrogen bonded network structure lowered the 
plastic deformation in the methyl gallate crystal, leading to its poor compaction.  In 
contrast, the cocrystal structure exhibited a two-dimensional hydrogen bonded layered 
structure, which improved its plasticity and compaction properties relative to methyl 
gallate by facilitating slip.  Theophylline underwent the highest plastic deformation due 
to multiple slip layers conferred by hydrogen bonded columns.   
 
Chapter 3. 
In chapter 3, we further extended our analysis on the effect of structure on the mechanical 
properties of organic crystals by performing a thorough quantitative analysis of the 
mechanical property landscape of the model system of piroxicam-saccharin cocrystal, 
using single crystal nanoindentation.  In addition to more widely used mechanical 
properties, such as hardness and modulus, we were able to experimentally measure the 
crystal yield strength, i.e. the onset of plastic deformation, by performing partial loading-
unloading experiments at small strain levels (<50 nm).  Using mechanical property 
hierarchy of crystal hardness and yield strength, we successfully explained the observed 
rank order of powder compaction in this system:  saccharin > piroxicam > cocrystal.  
This work is very significant as such an in-depth analysis of crystal mechanical properties 
for molecular organic solids have rarely been attempted.  This endeavor provided a direct 
quantitative correlation between the mechanical properties of single crystals, and bulk 
powder compaction behavior. 
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Chapter 4. 
In chapter 4, we studied the effect of changing the surface structure of cohesive powders 
on their flow properties.  Using a very cohesive and poorly flowing grade of 
microcrystalline cellulose (Avicel PH105) as substrate, we established the utility of using 
comilling technique to coat the substrate surfaces with nano-sized silica particles.  This 
surface coverage with discrete silica particles, verified by SEM, helped to increase the 
interparticulate separation between adjacent MCC substrates, thereby minimizing 
cohesion.  The flow properties of the optimized nanocoated batch were comparable to the 
gold standard material for assessing adequate flow, i.e., Avicel PH102.   In addition, the 
nanocoated batch exhibited far superior compaction properties compared to PH102.  
Therefore, this nanocoated composite is potentially useful for direct compression 
applications.  This approach of using comil to dry coat the surfaces of cohesive powders 
is industrially very attractive, due to its efficacy, simplistic instrument set-up, and lack of 
appreciable stress levels that ensure no amorphization of substrates during the comil 
operation. 
 
Chapter 5. 
From chapter 5 onwards, the thesis focuses exclusively on milling-induced mechanical 
amorphization of crystals.  In chapter 5, we established the concurrent influence of 
crystal lattice strength (LS) and amorphous phase stability (AS) on the amorphization 
potential of crystals.  LS governed amorphous generation (crystal → amorphous), while 
AS governed amorphous elimination (amorphous → crystalline).   An amorphization 
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classification map was constructed to categorize the model compounds into four classes:  
I (high LS, low AS), II (low LS, low AS), III (high LS, high AS), and IV (low LS, high AS).  
Amorphous phase of classes I and II materials were highly unstable (indicated by lower 
activation energy of crystallization) and underwent fast recrystallization.  Materials in 
these two classes, therefore, had low propensity to undergo processing-induced 
amorphization due to rapid amorphous elimination.   On the contrary, materials in class 
IV were more suitable for amorphization, both due to weaker lattice favoring amorphous 
generation, and better amorphous stability than other classes.   This knowledge of 
different amorphization classes of crystals is expected to facilitate the drug development 
process by an early identification of 1) the suitability of drugs for developing stable 
amorphous product, or 2) potential problems of unexpected processing-induced 
amorphization if the crystalline phase is used for development. 
 
Chapter 6. 
In chapter 6, the role of molecular weight (MW) in solid-state amorphization was 
investigated, using 21 model compounds.  Low MW materials (<260 g/mol) did not show 
amorphous conversion after milling operation, while all materials with higher MW 
amorphized.  The effect of MW was connected to the amorphous phase stability.  Lower 
MW compounds showed lower crystallization activation energies, indicating faster 
crystallization.  This effect is due to the connection between MW and molecular 
flexibility in the amorphous phase, estimated by measuring the configurational entropy 
( confS ) of materials.  Low MW materials had low confS , which was connected to faster 
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molecular mobility using Adam-Gibbs theory.  In summary, the lack of observable 
amorphization of low MW crystals was shown to be a result of fast elimination of 
amorphous phase at ambient conditions prior to sample characterization.      
 
Chapter 7. 
In chapter 7, we investigated the utility of cocrystals to modulate the amorphization 
potential of drugs, by manipulating both the crystal lattice strength and amorphous phase 
stability.  Using the model system of sulfamethazine (SMT) and its 1:1 cocrystals with p-
hydroxybenzoic acid (HBA) and benzamide (BZM), we showed that the amorphization 
of cocrystals depended on milling duration.  The onset of amorphization was the earliest 
for the SMT-BZM cocrystal (~10 min cryomilling) and the most delayed for the SMT-
HBA cocrystal (>30 min cryomilling), corresponding to the lowest and highest crystal 
lattice strength, respectively.  However, the extent of amorphous conversion after 2hrs of 
milling followed a different rank order, i.e., SMT-HBA > SMT-BZM > SMT.  The extent 
of amorphization appeared to be linked with the stability of amorphous, which followed 
the order of SMT-HBA > SMT-BZM > SMT, based on both configurational entropy 
(ΔSconf) and structural relaxation times calculated using Adam-Gibbs equation.  The 
lowest net conversion of the SMT was explained by its faster recrystallization propensity, 
despite an earlier amorphization onset.   This work illustrates that cocrystals may be used 
to either minimize unintended amorphization of crystalline drugs during processing or 
enable the preparation of stable amorphous drug products.    
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Chapter 8. 
In chapter 8, we investigated the role of activated surface in milled amorphous glasses on 
their recrystallization under non-isothermal conditions.  Two crystallization modes were 
identified:  unimodal and bimodal.  The mode of crystallization of amorphous phase was 
found to depend on the relative position of the crystallization onset (Tc) with respect to 
glass transition temperature (Tg), and was explained by a surface crystallization model.  
Bimodal crystallization event was observed when Tc was below or near Tg, due to the fast 
crystallization onset at milled glass surfaces due to facilitated heterogeneous nucleation.  
Unimodal crystallization was observed when Tc  was well above Tg where there was no 
distinction in surface and bulk crystallization rates.  We verified this model by 
intentionally inducing flip between the two crystallization modes for several compounds 
through manipulating several kinetic factors that influence crystallization, such as glass 
surface area, heating rate, polymer doping, and surface elimination through compaction.     
Thus, the appearance of the two modes of non-isothermal crystallization of organic 
glasses was found to be a result of the combined effects of faster surface crystallization 
and variation in specific surface area by milling.   
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Future work 
Powder compaction 
The research described in chapters 2 and 3 has clearly demonstrated the association 
between crystal structure, crystal mechanical properties (mainly, plastic deformation), 
and bulk powder compaction of pharmaceutical solids.   In these chapters, we have 
demonstrated that changing the solid form of a crystalline drug can alter the  powder 
compaction properties.  However, all studies described here have been restricted to the 
pure, "neat" form of the drug.  The next step would be to correlate the mechanical 
properties of the drug or its alternate solid form with the powder compaction behaviors of 
formulated drug products, containing both drugs and excipients.  Here, the role of drug 
loading is expected to play a significant role.   At a higher drug loading, the mechanical 
properties of the drug will likely be more consequential to the powder compaction 
properties of the formulated product.  A systematic analysis of the influence of 
mechanical properties of the solid drug on the compaction properties of formulations, as 
function drug loading, will be a logical next step. 
 
Another aspect worth further exploration is the utility of using nanoindentation to 
quantify the yield strength of crystals, following the process of partial loading and 
unloading cycles.  Yield strength is a fundamental property of materials that describes the 
ease of plastic deformation onset.  A lower yield strength indicates easier onset of 
plasticity, which means the material will likely compact well under pharmaceutically 
relevant stress levels.  While such analyses for non-pharmaceutical crystals have been 
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frequently attempted, studies on molecular organic materials are relatively rare, despite 
the significance of this parameter in pharmaceutical research.  Nanoindentation provides 
the opportunity to accurately quantify the yield strength of materials.  A systematic 
determination of the yield strengths of common pharmaceutical solids with appropriate 
correlation to their bulk powder compaction properties will be useful. 
 
Dry surface coating for powder flow enhancement 
Our work described in Chapter 4 shows that by simple surface dry coating using a 
common laboratory tool, such as comilling, the flow properties of highly cohesive 
powders can be substantially enhanced.  This approach is attractive because of it does not 
significantly impact average particle size of the powder, unlike granulation.  Therefore, a 
significant portion of tabletability of the powders is preserved after nanocoating.  This 
comilled composite displays both good flow and compaction properties, making the 
material potentially amenable to direct compression.  The next step in this study would be 
to apply the same concept to enhance the flow of poorly flowing drugs.  A large fraction 
of drug powders have very fine average particle sizes (<~30 m) and are, therefore, 
highly cohesive and poorly flowing.  This leads to a substantial challenge during powder 
compaction, as the powder does not flow from hopper under gravity.  A successful 
demonstration of the nanocoating approach in enhancing the flow properties of cohesive 
drugs, without affecting their compaction, will justify its widespread use during drug 
development. 
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Another potential aspect that requires further evaluation is the impact of dry surface 
coating with hydrophobic silica on drug dissolution.  Even though the silica levels 
required for flow enhancement are low, the effect on dissolution remains to be 
investigated.  
 
Mechanical amorphization of crystals 
A significant portion of our amorphization studies have focused on single component 
crystals.  We also have briefly demonstrated that some of the concepts can potentially be 
extended to multi-component crystals, such as cocrystals.  A useful next step would be to 
systematically investigate the amorphization potential of more structurally diverse 
cocrystals and salts to validate the concurrent influence of crystal lattice strength and 
amorphous stability on amorphization.  Another interesting aspect to further investigate is 
the amorphization of solvates and hydrates.  There can be several possibilities when a 
solvate is milled.  The solvent molecule can potentially stabilize the crystal lattice to 
increase the resistance to amorphization.  In such a scenario, a delayed amorphization 
onset is expected, relative to the parent desolvate.  However, it is also possible that the 
solvent molecule actually leaves the lattice under milling stress resulting in lattice 
collapse.  However, in this case, the evolved solvent will act as a plasticizer to potentially 
facilitate recrystallization.  The interpretation of solvate amorphization can potentially be 
very challenging, but can provide fresh insight into the amorphization problem. 
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Finally, it would be interesting to see if there is any correlation between the 
Amorphization Classification System developed here with the Biopharmaceutical 
Classification System of drugs.  Based on very preliminary analysis, I have observed that 
drugs in Class II and IV of BCS classification (low solubility) actually fall in Class IV of 
ACS classification (good amorphous candidates).  This might be attributed to 
configurational flexibility of molecules that influence both solubility and amorphization.  
If such a correlation between the two classification systems is confirmed, it will imply 
that amorphous phase preparation is inherently appropriate as a drug solubilization 
approach. 
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Appendix I 
Regression model development for predicting amorphization 
Statistical regression models for amorphization prediction were developed using Arc 
statistical software ver 1.06 (Department of Statistics, University of Minnesota, 2004).  
The initial linear regression model (L1) was developed with amorphization rate constant 
(KA) as the response variable, and 8 model terms - configurational entropy (SC), volume 
expansivity (VT), molecular weight (MW), molar volume (MV), fusion enthalpy (HM), 
glass transition temperature (TG) and kinetic fragility (FRAG).   The initial model had F 
of 3.73 and p value of 0.04, indicating an acceptable model at 95% confidence level. 
Initial Model (L1) with 8 predictors 
Data set = Amorphization, Name of Fit = L1 
Normal Regression 
Kernel mean function = Identity 
Response      = KA 
Terms         = (SC VT MW MV HM TG FRAG) 
Coefficient Estimates 
Label       Estimate          Std. Error      t-value     p-value 
Constant    0.00134602       0.0312723        0.043      0.9667 
SC          0.0000727903     0.0000447961     1.625      0.1428 
VT          0.0000204566     0.0000217847     0.939      0.3752 
MW          0.0000355063     0.0000640200     0.555      0.5943 
MV        -7.544806E-6      0.0000848906    -0.089      0.9314 
HM         -0.0000619598     0.000126251     -0.491      0.6368 
TG          0.0000384571     0.0000438011     0.878      0.4055 
FRAG       -0.0375301        0.0501962        -0.748      0.4761 
 
R Squared:                0.765506     
Sigma hat:                0.0034452    
Number of cases:              16 
Degrees of freedom:          8 
 
Summary Analysis of Variance Table 
Source          df        SS              MS             F      p-value 
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Regression      7   0.000309982    0.0000442831    3.73      0.0424 
Residual         8   0.0000949555   0.0000118694 
 
However, we further attempted to refine the model by minimizing the number of 
predictors to the most influential ones.   For this purpose, a forward subset model 
selection was performed, where we first start with the intercept as the base model.  Then 
progressively, fresh terms are added to expand the model and a submodel is selected that 
results in small value of Mallow's CI statistic, which is a total mean squared error.   
nk
RSS
C II 2
ˆ 2
 
where, kI are the number of terms in the model and n are the number of model 
compounds.  The criterion for submodel selection is to minimize error CI to <kI 
 
Model parameter optimization by forward selection 
Data set = Amorphization, Name of Fit = L1 
Normal Regression 
Kernel mean function = Identity 
Response      = KA 
Terms         = (SC VT MW MV HM TG FRAG) 
Forward Selection:  Sequentially add terms 
that minimize the value of C_I. 
All fits include an intercept. 
 
Base terms: Intercept 
              df   RSS            |   k    C_I 
Add: SC       14  0.000164422     |   2    1.853 
Add: MW       14  0.000169702     |   2    2.297 
Add: MV       14  0.000194052     |   2    4.349 
Add: VT       14  0.000280893     |   2   11.665 
Add: FRAG     14  0.000294263     |   2   12.792 
Add: TG       14  0.000349909     |   2   17.480 
Add: HM       14  0.00039117      |   2   20.956 
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Base terms: (SC) 
              df   RSS            |   k    C_I 
Add: MW       13  0.000131365     |   3    1.068 
Add: VT       13  0.000135335     |   3    1.402 
Add: TG       13  0.000139541     |   3    1.756 
Add: MV       13  0.000143891     |   3    2.123 
Add: HM       13  0.000162742     |   3    3.711 
Add: FRAG     13  0.000164176     |   3    3.832 
 
Base terms: (SC MW) 
              df   RSS            |   k    C_I 
Add: VT       12  0.000108887     |   4    1.174 
Add: TG       12  0.000121368     |   4    2.225 
Add: MV       12  0.000128813     |   4    2.852 
Add: FRAG     12  0.000129288     |   4    2.893 
Add: HM       12  0.000131034     |   4    3.040 
 
Base terms: (SC MW VT) - selected submodel 
              df   RSS            |   k    C_I 
Add: TG       11  0.000105994     |   5    2.930 
Add: FRAG    11  0.00010602      |   5    2.932 
Add: HM       11  0.000108095     |   5    3.107 
Add: MV       11  0.000108871     |   5    3.172 
 
Base terms: (SC MW VT TG) 
              df   RSS            |   k    C_I 
Add: FRAG    10  0.0000984951    |   6    4.298 
Add: HM       10  0.000102799     |   6    4.661 
Add: MV       10  0.000105645     |   6    4.901 
 
Base terms: (SC MW VT TG FRAG) 
             df   RSS            |   k    C_I 
Add: HM      9     0.0000950492    |   7    6.008 
Add: MV      9     0.0000978142    |   7    6.241 
 
Base terms: (SC MW VT TG FRAG HM) 
             df   RSS            |   k    C_I 
Add: MV      8  0.0000949555    |   8    8.000 
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Using the submodel terms, the final predictive model is created using linear regression 
analysis (model L2).  The final model has F of 10.88 and p =0.001 (<<0.05).  The model 
is highly significant at 95% confidence level. 
 
Final model 
Data set = Amorphization, Name of Fit = L2 
Normal Regression 
Kernel mean function = Identity    
Response      = KA 
Terms         = (SC VT MW) 
Coefficient Estimates 
Label       Estimate          Std. Error      t-value     p-value 
Constant   -0.0130138        0.00363158       -3.584      0.0038 
SC          0.0000533407     0.0000314765     1.695      0.1159 
VT          0.0000271099     0.0000172244     1.574      0.1415 
MW          0.0000284464     0.0000166620     1.707     0.1135 
 
R Squared:               0.731102     
Sigma hat:               0.00301229   
Number of cases:              16 
Degrees of freedom:          12 
 
Summary Analysis of Variance Table 
Source          df        SS             MS             F      p-value 
Regression      3   0.00029605     0.0000986835   10.88     0.0010 
Residual        12   0.000108887   9.073920E-6 
 
Reference for Appendix 
Cook, R.D. & Weisberg, S.  Applied Regression Including Computing and Graphics.  
Wiley, New Jersey, 1999. 
